Cytogen - Endlich Neuigkeiten - 500 Beiträge pro Seite

[CaptainChaos]

Quartalszahlen kommen am 13. November laut HP von Cytogen ( www.cytogen.com).
Darüber hianus hat CYTO das alleinige Vermarktungsrecht in den USA für das Medikament Brachy Seed in den USA erhalten, das zusammen mit Draxis Health Corp. entwickelt worden ist. Die Zulassung der FDA und der kanadischen Gesundheitsbehörde für BrachySeed liegen bereits vor.

DRAXIS Health Reports Third Quarter Results

Canadian Corporate News
November 7, 2000 7:12am
MISSISSAUGA, ONTARIO--(CCN Disclosure, November 7, 2000)--DRAXIS Health Inc. (TSE: DAX; NASDAQ: DRAX) today reported results for the third quarter of 2000. Total operating revenues for the quarter were $11,887,000, an increase of 13.0% from the correspoter EBITDA of $422, 000 compares with $399,000 last year while earnings per share of $(0.04) compares with $(0.03) for 1999.

In commenting on the third quarter results, Dr. Martin Barkin, President and CEO of DRAXIS stated: "DRAXIS has recently achieved a number of important milestones including: receiving all U.S. and Canadian regulatory approvals for BrachySeed(TM), entering into a U.S. distribution agreement with CYTOGEN Corporation (NASDAQ:CYTO) for BrachySeed(TM), priority review for Ziconotide, expanded indication for Permax(R), Brazilian approval for Anipryl(R) and new pharmaceutical manufacturing contracts. Operationally, the Company`s financial results showed solid improvement over 1999. Third quarter results were affected by the annually scheduled, mid-summer plant maintenance shutdown."





FINANCIAL HIGHLIGHTS1
(thousands of Canadian dollars except per share amounts and in
accordance with Canadian GAAP)
(unaudited)




2000 1999
------------------------------------------------------------------------
Q3 Q2 Q1 Q4 Q3
------------------------------------------------------------------------




Revenues
Canadian Pharmaceuticals $3,536 $ 4,208 $ 3,518 $ 3,674 $ 3,307
Radiopharmaceuticals 2,171 2,617 2,389 2,324 1,846
Companion Animal Health 1,747 1,679 1,583 1,545 1,714
Manufacturing 4,889 6,497 5,052 5,960 3,831
Intercompany (456) (1,081) (685) (116) (177)
------------------------------------------------------------------------
11,887 13,920 11,857 13,387 10,521
------------------------------------------------------------------------

EBITDA(2) (pre-R&D and
restructuring costs) 1,120 2,114(3) 1,836 1,108 791
R&D (net) (698) (723) (400) (575) (392)
------------------------------------------------------------------------
EDITDA(2)(pre restructuring
costs) 422 1,391(3) 1,436 533 399
------------------------------------------------------------------------

Net Income (Loss) (1,437) (548) 1,509 (81) (1,219)
Net Income (Loss)
Per Share $ (0.04) $ (0.01) $ 0.04 $ (0.00) $(0.03)

Cash and Cash
Equivalents $ 10,099 $ 9,432 $ 9,199 $ 2,927 $ 6,002

Weighted Average Number
of Shares 36,510,051 35,788,318 34,895,573
36,408,792 35,557,366
------------------------------------------------------------------------
1 In 2000, the Company changed its policy with respect to the accounting for non-refundable, up-front payments. This change has been applied retroactively and prior periods have been restated.

2 Earnings (loss) before depreciation and amortization, financial income (expense), other income (expense), income taxes and non-controlling interest

3 Before restructuring charges of $792,000

FINANCIAL REVIEW

Third quarter revenues increased by 13.0% over 1999 levels with all operating units contributing to this growth. Revenues declined as compared with the second quarter due to shipment delays at DRAXIMAGE andDRAXIS Pharma as a result of scheduled summer maintenance and impact of non-recurring sales in respect of divested product lines in Q2.

Cost of sales increased to 63.8% of operating revenues compared with 58.5% last year, in part reflecting higher costs associated with temporary off-site lyophilization production for DRAXIMAGE. Selling, general and administration expenses of $3,181,000 in the third quarter decreased 11.1% as compared with last year.

Income from operations before depreciation and amortization (EBITDA) of $422,000 for the third quarter compares with $399,000 last year.

Net research and development expenditures totalled $698,000 for the current quarter as compared to $392,000 incurred in 1999.

Depreciation and amortization of $2,094,000 during the third quarter compares with $1,943,000 for 1999. The increase is due to depreciation commencing on capital expenditures incurred in 1999 and the amount, in total, is equal to the amount incurred in the second quarter.

Loss before income taxes and non-controlling interest includes a $190, 000 gain on the sale of product rights relating to the divestiture of the Kerasal(R) product line.

Loss per share for the third quarter of $0.04 compares with a $0.03 loss reported in 1999.

Cash and cash equivalents at September 30 were $10,099,000 as compared to June balances of $9,432,000. Working capital decreased by $1,793,000 and was offset by capital expenditures of $340,000 and repayment of long-term debt in the amount of $275,000.

In October 2000, the Company purchased for cancellation 100,000 of its shares pursuant to its share buyback program at an average purchase price of $3.97. All purchases were completed through open market transactions on the Toronto Stock Exchange.

UNITED STATES GAAP INFORMATION

The following table summarizes DRAXIS` results under both United States and Canadian Generally Accepted Accounting Principles (GAAP):





2000 1999
------------------------------------------------------------------------
Q3 Q2 Q1 Q4 Q3
------------------------------------------------------------------------
(thousands of Canadian dollars except per share amounts - unaudited)




US GAAP1
Net Income (Loss) $ (625) $ 248 $ 339 $ (296) $(1,435)
Net Income (Loss)
Per Share $ (0.02) $ 0.01 $ 0.01 $(0.01) $ (0.04)
Canadian GAAP1
Net Income (Loss) $ (1,437) $ (548) $ 1,509 $ (81) $(1,219)
Net Income (Loss)
Per Share $ (0.04) $(0.02) $ 0.04 $(0.00) $ (0.03)
------------------------------------------------------------------------

1 In 2000, the Company changed its policy with respect to the accounting for non-refundable, up-front payments. In accordance with U.S. GAAP, this change has been applied prospectively commencing in Q1 2000. In accordance with Canadian GAAP, this change has been applied retroactively and prior periods have been restated.

RADIOPHARMACEUTICALS

Third quarter revenues from the Company`s radiopharmaceutical line of $2,171,000 increased 17.6% as compared to the same period last year but declined 17.0% versus the second quarter due to production related delays. Off-site lyophilized (cold kit) production continues to be constrained due to capacity issues. This situation is expected to improve significantly once the Company`s own lyophilization capacity comes on line.

Segment EBITDA for the third quarter of $118,000 compares with $451, 000 earned last year, the reduction partly due to increased R&D expenditures incurred with respect to products under development and also caused by higher fixed costs associated with temporary off-site lyophilization production.

In October 2000, the Company announced that it had received Canadian nuclear regulatory approval for BrachySeed(TM). With that approval obtained, the Company is cleared for the launch of BrachySeed(TM) in both the U.S. and Canada commencing in the fourth quarter.

In the U.S., CYTOGEN Corporation (NASDAQ:CYTO) will market and distribute BrachySeed(TM). CYTOGEN has developed and markets Prostascint(TM), used to pre-screen and select patients for brachytherapy.

CANADIAN PHARMACEUTICALS

Despite the divestiture of the Company`s dermatology product lines earlier this year, third quarter revenues of $3,536,000 were 6.9% ahead of last year`s level due to sales of new products Zanaflex(R), Diastat(R) and Mysoline(R) and growing revenues for Alertec(R) and Permax(R).

During the quarter, the Company completed the divestitures of the rights to its Kerasal(R) product line and realized a pre-tax gain of $190,000.

Segment EBITDA for the third quarter of $1,226,000 compares with $724, 000 last year. The increase reflects higher neurology product sales and favourable timing of certain expenses.

MANUFACTURING

Third quarter total revenues of $4,889,000 were 27.6% ahead of 1999 due mainly to new contract manufacturing volumes.

Segment EBITDA loss of $481,000 for the third quarter compares with a loss of $829,000 incurred in the corresponding quarter last year. The scheduled plant shutdown for maintenance occurred during the third quarter and resulted in temporary lower shipments and a corresponding increased loss as compared to the previous quarter.

During the quarter, the Company announced the signing of a five-year supply agreement with Virco Pharmaceuticals for the production of Lanoxin(R), used in the treatment of heart failure and disturbances in heart rhythm.

COMPANION ANIMAL HEALTH

Revenues derived from the Company`s collaboration agreement with Pfizer with respect to Anipryl(R) increased 1.9% in the third quarter over 1999, which included royalty income of $578,000 as compared with $545,000 last year. Third quarter royalties increased 13.3% over second quarter results and represented the third consecutive quarter of increase.

Segment EBITDA for the third quarter of $1,380,000 compares with $1, 456,000 for 1999 due to increases in expenses.

In October, the Company announced that Brazilian approval for Anipryl(R) had been obtained. Brazil represents the fifth jurisdiction to approve Anipryl(R) following approvals in Canada, U.S., Australia and New Zealand.

RESEARCH AND DEVELOPMENT

Research and development expenditures increased in the third quarter to $698,000 (net), almost double the amount for the same period last year. This reflects increased activity in development work with respect to Fibrimage(R) the Company`s deep venous thrombosis imaging agent now in Phase III, the completion of Phase I studies with Amiscan(R), an imaging agent for heart attacks, and regulatory work in relation to BrachySeed(TM).

YEAR 2000 ISSUE (Y2K)

The Company completed and adopted a detailed systems plan in July 1998. The central focus of this plan was the implementation of a state-of-the-art ERP system. This project was completed in the third quarter of 1999. Certain process control systems at DRAXIS Pharma were identified as having potential exposure to the Year 2000 risk. Rectification and testing of these systems were substantially completed by December 31, 1998. The Company believes that it is fully Year 2000 compliant for internal systems. Based on its evaluation and remediation efforts to date the Company does not believe that its products or mission critical databases, software and hardware systems will be substantially affected by Year 2000 issues.

CHANGE IN ACCOUNTING POLICY

The Company has adopted the new guidelines issued by the U.S. Securities and Exchange Commission (SEC) and contained in its Staff Accounting Bulletin # 101 (SAB 101) dated December 1999 with respect to the accounting for non-refundable up-front fees received in connection with collaboration agreements. Adoption of these guidelines constitutes a change in the Company`s accounting policies and, in accordance with Canadian Generally Accepted Accounting Principles (GAAP), the changehas been applied retroactively with results of prior periods being restated.

The new policy has been applied to the accounting for DRAXIS` global alliance with Pfizer Inc. with respect to Anipryl(R) as if it had been in place from the time the transaction was entered into in 1997. Accordingly, a portion of the US$28 million in milestone payments already received from Pfizer and previously reflected in revenue and income will be deferred and recognized on a straight-line basis over the period to December 31, 2006. $25 million of intangible asset values originally written off in 1997 as part of the transaction will be partially re-established and amortized over the same future period. For fiscal years 1999 and 2000, the impact of the change in policy has been an increase in quarterly revenues and net income by $1,168,000 and $330,000, respectively.

The collaboration with CYTOGEN includes up-front milestone payments, royalties and a supply agreement. In accordance with the Company`s new accounting policy, the milestone payments will be established as deferred revenue and amortized over the 10-year term of the agreement.

OUTLOOK

Revenues and EBITDA at DRAXIMAGE over the next 12 months are expected to increase reflecting increased sales of existing products following the commissioning of new manufacturing capacity as well as new product introductions expected to take place late this year. Until DRAXIMAGE`s new lyophilization line enters production, the Company will remain affected by the availability of outsourced production.

Anipryl(R) is expected to continue to contribute to earnings albeit at a slower rate of growth than originally expected.

New third party manufacturing volume is expected to continue to come on line and will add additional throughput to the DRAXIS Pharma facility, helping this division move towards profitability. Following the completion of scheduled plant maintenance, shipments are expected to return to normal levels commencing in Q4.

Following the sale of the Company`s dermatology product lines, DRAXIS Pharmaceutica`s revenues are expected to show a modest increase over 1999. Profitability is expected to be constrained in the short term by marketing costs associated with new product launches and higher R&D expenditures related with bringing DRAXIS Pharmaceutica`s pipeline through to regulatory approval.






Copyright (c) 2000, Canadian Corporate News, all rights reserved.



Source: Canadian Corporate News

[CaptainChaos]

Und hier noch die Meldung hinsichtlich der Veröfentlichung der Quartalszahlen:

Cytogen Corporation Invites You to Join a Live Conference Call For Third Quarter 2000 Results

PR Newswire
November 7, 2000 1:15pm
PRINCETON, N.J., Nov 7, 2000 /PRNewswire via COMTEX/ -- Cytogen Corporation (Nasdaq: CYTO) will announce third quarter 2000 results live over the Internet on a conference call. You are invited to listen during the live cybercast on Monday, November 13 at 10:00 a.m. EST.



What: Cytogen Corporation Third Quarter 2000 Results

When: Monday, November 13 at 10:00 a.m. EST

Where: HTTP://WWW.VIDEONEWSWIRE.COM/CYTOGEN/111300/

How: Live over the Internet -- Simply log on to the web at the
address above

Contact: Mary Coleman, for Cytogen, 609-750-8223
Cytogen Corporation is a biopharmaceutical company in Princeton, NJ, whose mission is setting new standards in cancer care. Its two principal lines of business, proteomics and oncology, are built upon its expertise in antibodies and molecular recognition and are directed principally to development of novel products for the diagnosis, imaging, staging and treatment of prostate cancer and a proteomics-driven drug discovery platform.

*If you are unable to participate during the live webcast, the event will be archived on the web site HTTP://WWW.PRNEWSWIRE.COM for 90 days. To access the replay, click on archive under multimedia to view a listing of events then click the Cytogen Corporation event headline dated 11/13/00.

(Minimum Requirements to listen to broadcast: The RealPlayer software, downloadable free from WWW.REAL.COM/PRODUCTS/PLAYER/INDEX.HTML, and at least a 14.4Kbps connection to the Internet. If you experience problems listening to the broadcast, send an email to [e-mail].)

SOURCE Cytogen Corporation



CONTACT: Mary Coleman, for Cytogen, 609-750-8223

URL: HTTP://WWW.CYTOGEN.COM
HTTP://WWW.PRNEWSWIRE.COM

(C) 2000 PR Newswire. All rights reserved.
KEYWORD: New Jersey INDUSTRY KEYWORD: MTC SUBJECT CODE: ERN



Source: PR Newswire

[CaptainChaos]

Aktuelle Kaufempfehlung für Cytogen:

Quelle. Bloomberg.com


Cytogen Corp. Raised to Long-Term `Buy` at Granite Financial
By Sybil Carlson
Princeton, New Jersey, Nov. 15 (Bloomberg Data) -- Cytogen Corp. (CYTO US) was raised to long-term ``buy`` from ``accumulate`` by analyst David N. Allen at Granite Financial Group.

[Dummschwaezer]

Und noch eine Kaufempfelung!!!!!!

CYTO will be $10.00 by 10/17/2000
(CYTO was $5.12 on 4/17/2000)
A PROFITABLE BIOTECH FOR UNDER $5!!!!
It`s important to find gems among the garbage when the market turns ugly. Cytogen appears to be just such a gem. 1997 reported a net loss of $.63/shr; 1998 saw a net loss of $.24/shr; and 1999 reported a PROFIT of $.02/shr. Obviously, we have a company going in the right direction. So what do they do? "Biopharmaceutical company CYTOGEN develops and markets products to improve the diagnosis and treatment of cancer and other diseases. Its products include ProstaScint, a diagnostic imaging agent for prostrate cancer; Quadramet, a bone pain treatment for cancers that have spread to the skeleton and can be seen on a bone scan; and OncoScint CR/OV, a diagnostic agent for colorectal and ovarian cancer. ProstaScint, Quadramet, and OncoScint are distributed worldwide by the company or through agreements with Bard, CIS Biointernational, and DuPont Pharmaceuticals." The charts suggest that there should be good support at the $5 level. Of course, should the market sell-off continue, lower levels may be reached. The worst case scenario could see $1 1/2. I don`t think this is likely given the company`s profitability. Look for a quick rebound to the $8-9 level.

Quelle:
http://www.iexchange.com/ii/sl?sidii=7al0sfj4tp.s31be&s=1966…

Kann man mit diesem Wert noch etwas falsche machen??????

[CaptainChaos]

Und wider CYTO - Neuigkeiten:

Independent Studies Underscore Clinical Utility of Cytogen`s ProstaScint Imaging Agent For Prostate Cancer
PRINCETON, N.J., Nov 16, 2000 /PRNewswire via COMTEX/ -- In two retrospective studies scheduled for presentation at the upcoming Annual Meeting of the Radiological Society of North America (RSNA) in late November in Chicago, independent researchers plan to report on clinical advantages using ProstaScint(R), Cytogen Corporation`s (Nasdaq: CYTO ) imaging agent for the detection of metastatic prostate cancer. Reported benefits of using ProstaScint included:


* improved treatment outcomes in those prostate cancer patients who were
imaged with ProstaScint prior to selection of treatment,
* enhanced diagnostic efficacy for metastatic disease with ProstaScint
compared to bone scans in men with rising PSA (prostate specific
antigen) after primary treatment for their cancer.

"The results of these studies, along with previously published studies, reinforce the benefits of using ProstaScint in the diagnosis and treatment selection of prostate cancer patients," said Terry Novak, Cytogen`s Vice President of Sales and Marketing. "In both newly diagnosed and recurrent disease patients, the benefits of ProstaScint are clear."
"ProstaScint scan was associated with different therapeutic decisions and more frequent successful patient outcome," concluded Yu Liu, MD, MSc, Department of Radiology, and colleagues at the Medical College of Wisconsin. Their findings were based on a retrospective study of 142 prostate cancer patients treated at the institution. Patients who received a ProstaScint scan typically received combination therapies more frequently (radical prostatectomy followed by radiation therapy or hormonal therapy, or radiation therapy as primary treatment combined with hormonal therapy) when ProstaScint- detected cancer localized to lymph nodes. Results of the study showed that a "successful outcome was found in 92% in the ProstaScint group compared with 70% in the control group." Findings were based on a durable PSA response at the time of follow-up twelve months after treatment. PSA is a biochemical marker whose increase suggests the recurrence of the cancer. "Results of the study indicate ProstaScint can provide additional information to oncologists in making a decision regarding the choice of effective treatment," said Dr. Liu, regarding his presentation entitled, "The effectiveness of ProstaScint scanning on prostate cancer outcome."

Another retrospective study compared the rate of detection of prostate cancer metastases by ProstaScint and by bone scan. ProstaScint "identified 46 positives that bone scan did not, while the bone scan only found two positives that the In-mab [ProstaScint] scan did not." The study, led by Cherie T. Thomas, MD, Fellow in Radiation Oncology at the University of Michigan Medical Center, examined ProstaScint imaging results in 155 men, who had rising PSA levels, out of a total of 195 who had undergone primary therapy for prostate cancer. The report stated that "the findings ... are statistically significant and indicate that the indium-111-capromab pendetide [ProstaScint] scan results in more positive tests than radionuclide bone scintigraphy ... in the evaluation of disease recurrence." No correlation between PSA and positive ProstaScint scan was seen, a finding in keeping with the fact that ProstaScint provides information that is independent of and complementary to PSA. "ProstaScint scan, in conjunction with other diagnostic evaluation, can provide additional information useful in the selection of patients who may benefit from salvage therapy after failing primary treatment," said Dr. Howard S. Sandler, Associate Professor of Radiation Oncology at the University of Michigan Medical Center and co-author of the paper. "Dr. Thomas` presentation is entitled, "Evaluation of agreement rates between radionuclide bone scintigraphy and radioimmunoscintigraphy with indium-111-capromab pendetide (ProstaScint) in patients with rising PSA after definitive prostrate cancer treatment."

Four additional papers regarding ProstaScint are scheduled to be presented at the RSNA meeting and their abstracts were published in a recent supplement of Radiology, Volume 217. These other presentations are entitled, "In-111 ProstaScint imaging in prostate cancer," "Evaluation of false positives during In-111 ProstaScint immunoscintigraphy," "ProstaScint imaging in metastatic evaluation of patients cancer and assessment of post-prostatectomy recurrence," and "Combined CT/SPECT with dual-energy attenuation correction for quantitative ProstaScint imaging."

Presentations mentioned in this press release reflect independent research and the view of the authors of such presentations.

Cytogen Corporation is a biopharmaceutical company in Princeton, NJ, whose mission is setting new standards in cancer care. Its two principal lines of business, proteomics and oncology, are built upon its expertise in antibodies and molecular recognition and are directed principally to development of novel products for the diagnosis, imaging, staging and treatment of prostate cancer and a proteomics-driven drug discovery platform. The Company`s cancer management franchise currently comprises four FDA-approved products: ProstaScint(R), used to image the extent and spread of prostate cancer; BrachySeed(TM) implants for prostate cancer therapy, OncoScint CR/OV(R), a diagnostic imaging agent for colorectal and ovarian cancer; and Quadramet(R), for the relief of cancer-related bone pain. The Company has established a pipeline of product candidates based on its proprietary antibody and prostate specific membrane antigen, or PSMA, technologies, and holds worldwide exclusive license to PSMA. Cytogen and its joint venture partner, Progenics Pharmaceuticals, are developing in-vivo immunotherapies for prostate cancer based on PSMA. The Company also has U.S. marketing rights to the late-stage product candidate Combidex(R), a magnetic resonance imaging agent being developed by Advanced Magnetics for the detection of lymph node metastases. The Company`s subsidiary, AxCell Biosciences Corporation, is developing a proprietary protein pathway database as a drug discovery and development tool for the pharmaceutical and biotechnology industries. For additional information on Cytogen, visit the Company`s web sites at www.cytogen.com and www.axcellbio.com .

This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Information in this press release, which is not historical, is forward looking and involves a number of risks and uncertainties. Investors are cautioned not to put any undue reliance on any forward-looking statement. The Company`s actual results may differ materially from the Company`s historical results of operations and those discussed in the forward-looking statements for various reasons, including, but not limited to the Company`s ability to carry out its business plan, to successfully develop and commercialize acceptance of its products, ability to fund development necessary for existing products and for the pursuit of new product opportunities, the risk of whether products result from development activities, protection of its intellectual property portfolio, ability to integrate in-licensed products, ability to establish and successfully complete clinical trials where required for product approval, the risk associated with obtaining the necessary regulatory approvals, dependence on its partners for development of certain projects, the ability to obtain foreign regulatory approvals for products and to establish marketing arrangements in countries where approval is obtained, and other factors discussed in the Company`s 1999 Form 10-K and from time-to-time the Company`s other filings with the Securities and Exchange Commission.

SOURCE Cytogen Corporation


CONTACT: Richard W. Krawiec, Ph.D., Vice President Investor Relations
and Corporate Communications of Cytogen Corporation, 609-750-8289

URL: http://www.axcellbio.com
http://www.prnewswire.com

(C) 2000 PR Newswire. All rights reserved.

-0-


KEYWORD: New Jersey
Illinois
INDUSTRY KEYWORD: MTC
BIO

[CaptainChaos]

Hier eine auszugsweise Babelfish Übersetzung des zuvor geposteten Beitrags. Leider hat das Übersetzungsprogramm Probleme mit der deutsche Grammatik. Man kann sich den postiven Inhalt der Meldung aber sehr wohl herausfiltern:

Unabhängige Studien unterstreichen klinisches Hilfsprogramm des Mittels Belichtung Cytogen`s ProstaScint für ProstatakrebscPrinceton, N.J., Nov. 16, 2000 / PRNewswire über COMTEX / -- in zwei zurückblickenden Studien, die für Darstellung bei der upcoming jährlichen Sitzung der radiologischen Gesellschaft von Nordamerika (RSNA) eingeplant werden in spätem November in Chicago, unabhängiger Forscherplan zum Bericht über klinische Vorteile mit ProstaScint(R), Cytogen Corporation`s (Nasdaq: CYTO-) Belichtung Mittel für die Abfragung des metastatic Prostatakrebses. Berichtet Nutzen von, der ProstaScint umfaßt verwendet: * verbesserte Behandlungresultate bei jenen Prostatakrebspatienten, die mit ProstaScint vor Auswahl der Behandlung abgebildet waren-, * erhöhte Diagnosewirksamkeit für metastatic Krankheit mit ProstaScint verglich mit Knochenscans in den Männern mit steigendem PSA (Prostataspezifisches Antigen) nach Primärbehandlung für ihren Krebs. " die Resultate dieser Studien, zusammen mit vorher erschienenen Studien, verstärkt den Nutzen des Verwendens von ProstaScint in der Diagnose und Behandlungauswahl der Prostatakrebspatienten, ", sagte Terry Novak, Vizepräsident Cytogen`s von Verkäufen und von Marketing. " bei beiden, die eben und rückläufigen Krankheitpatienten bestimmt werden, ist der Nutzen von ProstaScint klar. ", " ProstaScint-Scan bezog sich auf unterschiedliche therapeutische Entscheidungen und häufigeres erfolgreiches geduldiges Resultat, " folgerte Yu Liu, MD, MSc, Abteilung der Radiologie und Kollegen an der medizinischen Hochschule von Wisconsin. Ihre Entdeckungen basierten auf einer zurückblickenden Studie von 142 Prostatakrebspatienten, die an der Anstalt behandelt wurden. Patienten, die einen ProstaScint-Scan gewöhnlich empfingen, empfingen Kombination Therapien häufiger (radikale prostatectomy gefolgt von der Strahlentherapie oder von der hormonalen Therapie oder Strahlentherapie als Primärbehandlung kombiniert mit hormonaler Therapie) als ProstaScint- den Krebs ermittelte, der zu den Lymphknoten beschränkt wurde

[börsenfüxlein]

was war den heute bei cytogen los? +40 % , weiß jemand etwas???

füxlein

[CaptainChaos]

Auf der HP von CYTO und in den News - Programmen keine Nachrichten. Ich denke, dass es teilweise eine technische Reaktion war, zum anderen Teil bei vielen Biotech - Anlegern die Erkenntnis gekommen ist, dass ein Investment in hochbewertete Biotech - Titel, die nur von Fantasie leben, gefährlich sein kann.

Ich glaube der Trend geht klar zu den Biotech - Titeln, die Produkte von der FED genehmigt bekommen haben und bereits vermarkten oder kurz vor der Vermarktung stehen.
(Cytogen, Sciclone, Curis) und noch Fantasie durch ihre Produktpipeline mitbringen.

[CaptainChaos]

Noch purzelt der Kurs, aber ich bin guter Dinge. Cytogen will expandieren und hat heute mitgeteilt, dass folgende FDA - genehmigte Produkte vermarktet werden:

ProstaScint(R) Prostata Krebs;
OncoScint(R) CR/OV, Krebs ;
Quadramet(R), Schmerzbehandlung Krebs
BrachySeed(TM) Prostata Krebs ( Vermarktungsrechte wurden von Draxis Health erworben)

und neu !!!!

Vermarktungsrechte in den USA für
Combidex(R), Lymphknotenkrebs





Cytogen Announces Initiation of Research Coverage by Granite Financial
CYTO


RELATED QUOTES

CYTO 3.16 - 3/16
DRAX 2 1/8 - 1/16
PGNX 23 13/16 - 5/8
AVM 2 13/16 0
RELATED TOPICS
prn
acquisition
agricultural
biotechnology
business
california
cancer
clinical
commercial
conference
equity
executive
expansion


PRINCETON, N.J., Nov 29, 2000 /PRNewswire via COMTEX/ -- Cytogen Corporation (Nasdaq: CYTO ) today announced the recent initiation of research coverage by Granite Financial Group, Inc., San Diego, California. In his report, Granite research analyst, David N. Allen initiated coverage of Cytogen with a "long-term buy" recommendation.

"We believe that Cytogen`s stock has the potential to be a superior performer within the biopharmaceutical sector," said Mr. Allen. Granite Financial Group is a NASD member firm that offers research, market making, merger and acquisition advisory services, institutional sales, and investment banking services to the middle market. Granite focuses its efforts on companies seeking capital for expansion, acquisitions and various other growth activities.

"We are increasing our efforts to create a better balance between long- term institutional and retail shareholders," said H. Joseph Reiser, Ph.D., Cytogen`s Chief Executive Officer. "In that regard, in September, Acqua Wellington North American Equities Fund, Ltd., purchased over 900,000 shares of Cytogen stock directly from Cytogen and in October entered into a $70 million equity line of credit with the Company. In the coming months, we are concentrating on the top-line growth of our business units: oncology, with an emphasis on prostate cancer, and proteomics. As we discussed during our recent conference call, we have a number of important upcoming milestones, which we believe have the potential to increase shareholder value: launch of BrachySeed(TM) therapy for prostate cancer, launch of AxCell Bioscience`s InterFunctional Proteomics Database(TM), proof of principal for an ultra- sensitive serum assay for the detection of prostate cancer, and initiation of clinical studies for prostate cancer immunotherapy."

Cytogen Corporation is a biopharmaceutical company in Princeton, NJ, whose mission is setting new standards in cancer care. Its two principal lines of business, proteomics and oncology, are built upon its expertise in antibodies and molecular recognition and are directed principally to development of novel products for the diagnosis, imaging, staging and treatment of prostate cancer and a proteomics-driven drug discovery platform. The Company`s cancer management franchise currently comprises three FDA-approved products: ProstaScint(R), used to image the extent and spread of prostate cancer; OncoScint(R) CR/OV, a diagnostic imaging agent for colorectal and ovarian cancer; and Quadramet(R), for the relief of cancer-related bone pain. The Company has signed a binding letter of intent with Draxis Health, Inc., to market and distribute BrachySeed(TM) implants for prostate cancer therapy in the U.S. The Company has established a pipeline of product candidates based on its proprietary antibody and prostate specific membrane antigen, or PSMA, technologies, and holds worldwide exclusive license to PSMA. Cytogen and its joint venture partner, Progenics Pharmaceuticals, are developing in vivo immunotherapies for prostate cancer based on PSMA. The Company also has U.S. marketing rights to the late-stage product candidate Combidex(R), a magnetic resonance imaging agent being developed by Advanced Magnetics for the detection of lymph node metastases. For additional information visit www.cytogen.com .

AxCell Biosciences, a subsidiary of Cytogen, is using its high-throughput technology to chart protein signaling pathways in the human proteome as a means of discovering new drug tar gets. AxCell is developing a proprietary protein-pathway database, the Inter-Functional Proteomic Database(TM), as a discovery and development tool for subscribers in the pharmaceutical, biotechnology and agricultural industries. AxCell`s bioinformatics platform is designed to identify drug targets for optimization and development through the application of novel, innovative and rapid techniques for deriving intracellular protein-pathway data. For additional information on AxCell Biosciences, visit www.axcellbio.com .

This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Information in this press release, which is not historical, is forward looking and involves a number of risks and uncertainties. Investors are cautioned not to put any undue reliance on any forward looking statement. The Company`s actual results may differ materially from the Company`s historical results of operations and those discussed in the forward-looking statements for various reasons, including, but not limited to the Company`s ability to carry out its business plan, successful development and commercial acceptance of its products, ability to fund development necessary for existing products and for the pursuit of new product opportunities, the risk of whether products result from development activities, protection of its intellectual property portfolio, ability to integrate in-licensed products, ability to establish and successfully complete clinical trials where required for product approval, the risk associated with obtaining the necessary regulatory approvals, dependence on its partners for development of certain projects, the ability to obtain foreign regulatory approvals for products and to establish marketing arrangements in countries where approval is obtained, and other factors discussed in the Company`s 1999 Form 10-K and from time-to-time the Company`s other filings with the Securities and Exchange Commission.

SOURCE Cytogen Corporation

[CaptainChaos]

Viel Text für die CYTO - Interessierten.
Kurzum : Der Vertrag zwischen CYTO und DRAXIS hinsichtlich der Vermarktung von BrachySeed ist unter Dach und Fach.
Hinzu kommen innovative Förderungen in Höhe von 1,6 Mio. USD an CYTO durch den Staat New Jersey.


Cytogen and Draxis Finalize Agreement for Prostate Cancer BrachySeed Therapy in U.S.
CYTO
http://investor.stockpoint.com/quote.asp?Mode=CHART&Symbol=C…

RELATED QUOTES

CYTO 3 3/16 1/4
DRAX 2.09 -0.03
RELATED TOPICS
prn
agricultural
animal
biotechnology
business
canada
cancer

PRINCETON, N.J. and MISSISSAUGA, Ontario, Dec 6, 2000 /PRNewswire via COMTEX/ -- Cytogen Corporation (Nasdaq: CYTO ) and Draxis Health, Inc. (Toronto: DAX; Nasdaq: DRAX) have finalized license, distribution and supply agreements for BrachySeed(TM) implants for prostate cancer therapy. Under the terms of the 10-year arrangement, Cytogen will market and distribute BrachySeed implants in the U.S. and Draxis` wholly owned subsidiary, Draximage, will supply radioactive seeds to Cytogen for sale in the U.S. Cytogen has agreed to certain minimum sales targets during the period of exclusivity and a non-compete provision.
"Given our existing sales force coverage and established relationships with radiation oncologists and urologists, we believe that we are positioned to competitively participate in this growing brachytherapy seed market with BrachySeed," said Terence S. Novak, Cytogen`s Vice President of Marketing and Sales. "We believe that many brachytherapy centers in the U.S. will be early adopters of BrachySeed, and we look forward to introducing this product to new users. With BrachySeed, we plan to offer a second-generation, technologically advanced therapeutic product to complement ProstaScint(R), our prostate cancer imaging agent. This week Cytogen and Draxis are hosting a BrachySeed symposium for key opinion leaders in preparation for launching the product by year`s end."
Brachytherapy is the fastest-growing treatment for early stage prostate cancer and offers a number of potential benefits compared to alternative treatments such as radical prostatectomy, including: rapid patient recovery, lower costs and reduced incidence of complications such as impotency and incontinence. Given this improved side-effect profile, the market for brachytherapy seeds has grown by 95% over the last three years. By 2003, the companies estimate that approximately half of all prostate cancer patients will opt for brachytherapy, while radical prostatectomies will be performed on less that 15% of patients. Independent estimates place the current brachytherapy market at $220 million in the U.S. and growing by approximately $100 million in three years.
The Companies believe that the patented BrachySeed product demonstrates a number of important innovations over currently available technology, including double encapsulation for additional patient safety and a more uniform dosimetry to reduce "cold spots," areas within the target organ not reached by the radiation. Such cold spots may occur when seeds do not provide symmetrical and spherical fields of radiation. Next year Draxis plans to supply Cytogen with second-generation palladium-based seeds. The more energetic radiation from palladium is thought to be suitable for certain aggressive forms of prostate cancer. The original binding letter of intent between Cytogen and Draxis was announced in September.
Cytogen Corporation is a biopharmaceutical company in Princeton, NJ, whose mission is setting new standards in cancer care. Its two principal lines of business, proteomics and oncology, are built upon its expertise in antibodies and molecular recognition and are directed principally to development of novel products for the diagnosis, imaging, staging and treatment of prostate cancer and a proteomics-driven drug discovery platform. The Company`s cancer management franchise currently comprises four FDA-approved products: ProstaScint(R), used to image the extent and spread of prostate cancer; OncoScint(R) CR/OV, a diagnostic imaging agent for colorectal and ovarian cancer; Quadramet(R), for the relief of cancer-related bone pain, and BrachySeed(TM) implants for prostate cancer therapy. The Company has established a pipeline of product candidates based on its proprietary antibody and prostate specific membrane antigen, or PSMA, technologies, and holds worldwide exclusive license to PSMA. Cytogen and its joint venture partner, Progenics Pharmaceuticals, are developing in vivo immunotherapies for prostate cancer based on PSMA. The Company also has U.S. marketing rights to the late-stage product candidate Combidex(R), a magnetic resonance imaging agent being developed by Advanced Magnetics for the detection of lymph node metastases. For additional information visit www.cytogen.com .
AxCell Biosciences, a subsidiary of Cytogen, is using its high-throughput technology to chart protein signaling pathways in the human proteome as a means of discovering new drug targets. AxCell is developing a proprietary protein-pathway database, the Inter-Functional Proteomic Database(TM), as a discovery and development tool for subscribers in the pharmaceutical, biotechnology and agricultural industries. AxCell`s bioinformatics platform is designed to identify drug targets for optimization and development through the application of novel, innovative and rapid techniques for deriving intracellular protein-pathway data. For additional information on AxCell Biosciences, visit www.axcellbio.com .
Draximage, based in Kirkland, Quebec, is Canada`s leading manufacturer of radio-pharmaceuticals and its products are available in many countries around the world. Draximage specializes in the discovery, development, manufacturing and marketing of diagnostic and therapeutic products for use in Nuclear Medicine and Oncology. Fibrimage(R), the Company`s diagnostic agent for deep-vein thrombosis, is undergoing Phase III clinical trials in Canada.
Draxis Health, Inc. is a diversified specialty pharmaceutical company operating in three niche markets: Radiopharmaceuticals (Draximage), Canadian sales and marketing (Draxis Pharmaceutica) and Companion Animal Health (through its global alliance with Pfizer Inc.). Draxis supports its own as well as third party manufacturing requirements through its subsidiary, Draxis Pharma, located in Kirkland, Quebec.
This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Information in this press release, which is not historical, is forward-looking and involves a number of risks and uncertainties. Investors are cautioned not to put any undue reliance on any forward-looking statement. The Company`s actual results may differ materially from the Company`s historical results of operations and those discussed in the forward-looking statements for various reasons, including, but not limited to the Company`s ability to carry out their business plan, successful development and commercial acceptance of its products, ability to fund development necessary for existing products and for the pursuit of new product opportunities, the risk of whether products result from development activities, protection of its intellectual property portfolio, ability to integrate in-licensed products, ability to establish and successfully complete clinical trials where required for product approval, the risk associated with obtaining the necessary regulatory approvals, dependence on its partners for development of certain projects, the ability to obtain foreign regulatory approvals for products and to establish marketing arrangements in countries where approval is obtained, and other factors discussed in the Company`s 1999 Form 10-K and from time-to-time the Company`s other filings with the Securities and Exchange Commission.
SOURCE Cytogen Corporation
CONTACT: Lawrence R. Hoffman, Vice President and Chief Financial Officer
of Cytogen, 609-750-8205; or Richard W. Krawiec, Ph.D., Vice President,
Investor Relations and Corporate Communications of Cytogen, 609-750-8289; or
Paul Lee, Director of Investor Relations of Draxis Health, 877-441-1984

URL: http://www.axcellbio.com
http://www.cytogen.com
http://www.prnewswire.com

(C) 2000 PR Newswire. All rights reserved.



Cytogen Receives Approval to Sell NJ Tax Credits
CYTO
http://investor.stockpoint.com/quote.asp?Mode=CHART&Symbol=C…

RELATED QUOTES

CYTO 3 3/16 1/4
RELATED TOPICS
prn
agricultural
biotechnology
business
cancer
clinical
commercial
fda
health
joint venture
market
marketing

PRINCETON, N.J., Dec 5, 2000 /PRNewswire via COMTEX/ -- Cytogen Corporation (Nasdaq: CYTO ) announced today that it has received notification from the State of New Jersey of the amount of tax benefits it may sell for the current tax year under the State`s Technology Tax Certificate Transfer Program. The amount of tax benefits approved for sale is $1.95 million, which may be sold by the Company for not less than 75 cents on the dollar. The Company is arranging for the sale of the credits and anticipates concluding the transaction for net proceeds of approximately $1.6 million during the fourth quarter.
"We are pleased that this innovative program continues to move forward," said Lawrence R. Hoffman, Cytogen`s Vice President and Chief Financial Officer. "The anticipated sale of approximately $1.95 million in benefits in the fourth quarter should further strengthen our balance sheet. Our next step is to enter into an agreement with a buying business for the sale of the authorized tax benefits. We anticipate participating in the program again next year."
Cytogen Corporation is a biopharmaceutical company in Princeton, NJ, whose mission is setting new standards in cancer care. Its two principal lines of business, proteomics and oncology, are built upon its expertise in antibodies and molecular recognition and are directed principally to development of novel products for the diagnosis, imaging, staging and treatment of prostate cancer and a proteomics-driven drug discovery platform. The Company`s cancer management franchise currently comprises three FDA-approved products: ProstaScint(R), used to image the extent and spread of prostate cancer; OncoScint(R) CR/OV, a diagnostic imaging agent for colorectal and ovarian cancer; and Quadramet(R), for the relief of cancer-related bone pain. The Company has signed a binding letter of intent with Draxis Health, Inc., to market and distribute BrachySeed(TM) implants for prostate cancer therapy in the U.S. The Company has established a pipeline of product candidates based on its proprietary antibody and prostate specific membrane antigen, or PSMA, technologies, and holds worldwide exclusive license to PSMA. Cytogen and its joint venture partner, Progenics Pharmaceuticals, are developing in vivo immunotherapies for prostate cancer based on PSMA. The Company also has U.S. marketing rights to the late-stage product candidate Combidex(R), a magnetic resonance imaging agent being developed by Advanced Magnetics for the detection of lymph node metastases. For additional information visit www.cytogen.com .
AxCell Biosciences, a subsidiary of Cytogen, is using its high-throughput technology to chart protein signaling pathways in the human proteome as a means of discovering new drug targets. AxCell is developing a proprietary protein-pathway database, the Inter-Functional Proteomic Database(TM), as a discovery and development tool for subscribers in the pharmaceutical, biotechnology and agricultural industries. AxCell`s bioinformatics platform is designed to identify drug targets for optimization and development through the application of novel, innovative and rapid techniques for deriving intracellular protein-pathway data. For additional information on AxCell Biosciences, visit www.axcellbio.com .
This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Information in this press release, which is not historical, is forward-looking and involves a number of risks and uncertainties. Investors are cautioned not to put any undue reliance on any forward-looking statement. The Company`s actual results may differ materially from the Company`s historical results of operations and those discussed in the forward-looking statements for various reasons, including, but not limited to the Company`s ability to carry out their business plan, successful development and commercial acceptance of its products, ability to fund development necessary for existing products and for the pursuit of new product opportunities, the risk of whether products result from development activities, protection of its intellectual property portfolio, ability to integrate in-licensed products, ability to establish and successfully complete clinical trials where required for product approval, the risk associated with obtaining the necessary regulatory approvathe Company`s 1999 Form 10-K and from time-to-time the Company`s other filings with the Securities and Exchange Commission.
SOURCE Cytogen Corporation
CONTACT: Lawrence R. Hoffman, Vice Pr Corporation

http://www.prnewswire.com

(C) 2000 PR Newswire. All rights reserved.

-0-


KEYWORD: New Jersey
INDUSTRY KEYWORD: MTC

[Dummschwaezer]

Da haben wohl einige hier kräftig
in die Scheiße gegriffen!!!!!!!!!
Fankfurt - 13%
NASDAQ + 15%
Woran liegts?

[CaptainChaos]

@ Dummschwaezer,

der Rebound von CYTO entstand erst nach Börsenschluss in Europa.
Ich habe ganz und gar nicht das Gefühl in die Sch.... gegriffen zu haben. Immerhin beginnt nun die Vermarktung von -3- FDA- genehmigten Medikamenten, dazu die Vermarktung eines Medikamentens in Lizenz (Draxis).

Es wird sich sicherlich noch herausstellen, ob die Kasse klingelt und damit gute Quartalszahlen erreicht werden.
CYTO hat in der Vergangenheit durch Investitionen hohe Verluste geschrieben. Ich denke zukünftig wird geernet. Ich halte CYTO mit der Pipeline an genehmigten Produkten auf dem derzeitigen Kursniveau hinsichtlich des Kursrisikos für wesentlich kalkulierbarer, als eine Firma mit mehreren Produkten in der Phase III ( siehe Maxim Pharmaceutical).

[CaptainChaos]

Die Story beginnt.

Cytogen and Draxis Announce First Clinical Use of BrachySeed for Prostate Cancer Therapy in U.S. and Canada; ProstaScint Images Used to Guide Placement of Second-Generation Radiation Implants
CYTO


RELATED QUOTES

CYTO 3.03 0.41
DRAX 2.03 -0.03
RELATED TOPICS
prn
agricultural
animal
biotechnology
business
canada
cancer
clinical
commercial
computer
connecticut
delaware


PRINCETON, N.J., and MISSISSAUGA, Ontario, Dec 18, 2000 /PRNewswire via COMTEX/ -- Cytogen Corporation (Nasdaq: CYTO ) and Draxis Health, Inc. (Nasdaq: DRAX ; Toronto: DAX) announced today the first clinical use of BrachySeed(TM), a new type of iodine-125 brachytherapy implant, in both the U.S. and Canada. For the first time, physicians at major medical centers in both countries implanted the second-generation radioactive-iodine seeds in patients with prostate cancer.

"Our first case with BrachySeed went very well," said Rodney J. Ellis, M.D., Director of Brachytherapy, University Hospitals of Cleveland. Dr. Ellis used two Cytogen products to perform the implant procedure. He combined ProstaScint images with CT (computer tomography) scans to locate the areas of highest tumor burden within the prostate gland and implanted additional BrachySeeds areas as required. "The implants provided superior coverage of the target volume of the prostate, with fewer required millicuries of radioactivity. The seed design is excellent, with good visualization by both ultrasound and fluoroscopy. Additionally, the cost for the procedure was reduced through a decrease in the required number of seeds."

The first implantation in Canada was carried out by Eric Vigneault, M.D. at the Centre Hospitalier Universitaire de Quebec. Dr. Vigneault stated, "BrachySeed permitted the use of 11% lower activity seeds to achieve the same therapeutic dose." The use of BrachySeed permits either a reduction in seed activity or seed quantity, which is an advantage over the current market leader.

"BrachySeed now makes it possible for patients to receive a second- generation product for the treatment of their prostate cancer," said Terence S. Novak, Cytogen`s Vice President of Marketing and Sales. "The use of image- guided therapy employing both ProstaScint and BrachySeed underscores the complementary nature that our products play in the diagnosis and treatment of prostate cancer."

"As part of the pre-launch plan, Cytogen recently hosted an opinion leader workshop to introduce BrachySeed and image-guided therapy to radiation oncologists, physicists and urologists," continued Mr. Novak. "We were excited by the interest BrachySeed received from the key thought leaders in prostate cancer therapy. We believe that our implants will become a popular choice for many prostate cancer patients and their physicians and that ProstaScint will play an increasingly important role in prostate cancer therapy."

Under the terms of a 10-year arrangement with DRAXIMAGE, a wholly owned subsidiary of Draxis, Cytogen will market and distribute BrachySeed in the U.S. DRAXIMAGE will supply radioactive seeds to Cytogen for sale in the U.S. and will market the product in Canada.

Dr. Martin Barkin, President and Chief Executive Officer of Draxis Health stated, "We are very encouraged by the early feedback regarding BrachySeed, which serves to confirm Draximage`s position as a quality provider of innovative radiopharmaceutical products, both diagnostic and therapeutic, to the global marketplace. BrachySeed I-125 is the first of the major new products under development to emerge from DRAXIMAGE`s pipeline, and over the next few years the Company expects to bring other products to commercialization."

BrachySeed is a second-generation implant therapy that the companies believe demonstrates a number of important innovations over currently available technology, including double encapsulation for additional patient safety and near perfect dosimetry to reduce "cold spots." Cold spots are areas within the target organ not reached by radiation, that may occur when seeds do not provide symmetrical and spherical fields of radiation.

While brachytherapy has been available since the 1970s, it has only started to gain prominence and greater acceptance within recent years, coinciding with the development of advanced technologies to aid seed placement. Brachytherapy is the fastest growing treatment for early stage prostate cancer and offers a number of potential benefits compared to alternative treatments such as prostatectomy, including: rapid patient recovery, lower costs and reduced incidence of complications such as impotency and incontinence. Given this improved side-effect profile, the market for brachytherapy seeds has grown by 95% over the last three years. By 2003, the companies estimate that approximately half of all newly diagnosed prostate cancer patients will opt for brachytherapy, while radical prostatectomies will be performed on less than 15% of patients. Independent estimates place the current brachytherapy market at $220 million in the U.S. and growing by approximately $100 million in three years.

Cytogen Corporation is a biopharmaceutical company in Princeton, NJ, whose mission is setting new standards in cancer care. Its two principal lines of business, proteomics and oncology, are built upon its expertise in antibodies and molecular recognition and are directed principally to development of novel products for the diagnosis, imaging, staging and treatment of prostate cancer and a proteomics-driven drug discovery platform. The Company`s cancer management franchise currently comprises four FDA-approved products: ProstaScint(R), used to image the extent and spread of prostate cancer; OncoScint(R) CR/OV, a diagnostic imaging agent for colorectal and ovarian cancer; Quadramet(R), for the relief of cancer-related bone pain, and BrachySeed(TM) implants for prostate cancer therapy. The Company has established a pipeline of product candidates based on its proprietary antibody and prostate specific membrane antigen, or PSMA, technologies, and holds worldwide exclusive license to PSMA. Cytogen and its joint venture partner, Progenics Pharmaceuticals, are developing in vivo immunotherapies for prostate cancer based on PSMA. The Company also has U.S. marketing rights to the late- stage product candidate Combidex(R), a magnetic resonance imaging agent being developed by Advanced Magnetics for the detection of lymph node metastases. For additional information visit www.cytogen.com .

AxCell Biosciences, a subsidiary of Cytogen, is using its high-throughput technology to chart protein signaling pathways in the human proteome as a means of discovering new drug targets. AxCell is developing a proprietary protein-pathway database, the Inter-Functional Proteomic Database(TM), as a discovery and development tool for subscribers in the pharmaceutical, biotechnology and agricultural industries. AxCell`s bioinformatics platform is designed to identify drug targets for optimization and development through the application of novel, innovative and rapid techniques for deriving intracellular protein-pathway data. For additional information on AxCell Biosciences, visit www.axcellbio.com .

DRAXIMAGE, based in Kirkland, Quebec, is Canada`s leading manufacturer of radio-pharmaceuticals and its products are available in many countries around the world. DRAXIMAGE specializes in the discovery, development, manufacturing and marketing of diagnostic and therapeutic products for use in Nuclear Medicine and Oncology. Fibrimage(R), the Company`s diagnostic agent for deep- vein thrombosis is undergoing Phase III clinical trials in Canada.

Draxis Health, Inc. is a diversified specialty pharmaceutical company operating in three niche markets: Radiopharmaceuticals (Draximage), Canadian sales and marketing (Draxis Pharmaceutica) and Companion Animal Health (through its global alliance with Pfizer Inc.). Draxis supports its own as well as third party manufacturing requirements through its subsidiary, Draxis Pharma, located in Kirkland, Quebec.

This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Information in this press release, which is not historical, is forward looking and involves a number of risks and uncertainties. Investors are cautioned not to put any undue reliance on any forward looking statement. The Company`s actual results may differ materially from the Company`s historical results of operations and those discussed in the forward-looking statements for various reasons, including, but not limited to the Company`s ability to carry out their business plan, successful development and commercial acceptance of its products, ability to fund development necessary for existing products and for the pursuit of new product opportunities, the risk of whether products result from development activities, protection of its intellectual property portfolio, ability to integrate in-licensed products, ability to establish and successfully complete clinical trials where required for product approval, the risk associated with obtaining the necessary regulatory approvals, dependence on its partners for development of certain projects, the ability to obtain foreign regulatory approvals for products and to establish marketing arrangements in countries where approval is obtained, and other factors discussed in the Company`s 1999 Form 10-K and from time-to-time the Company`s other filings with the Securities and Exchange Commission.

SOURCE Cytogen Corporation


CONTACT: Lawrence R. Hoffman, Vice President and Chief Financial
Officer, 609-750-8205, or Richard W. Krawiec, Ph.D., Vice President, Investor
Relations and Corporate Communications, 609-750-8289, both of Cytogen; or Paul
Lee, Director of Investor Relations of Draxis, 877-441-1984

URL: http://www.axcellbio.com
http://www.cytogen.com
http://www.prnewswire.com

(C) 2000 PR Newswire. All rights reserved.

[Dummschwaezer]

@CaptainChaos
Ich meine damit die jenigen die zu 2,90 an Freitag ihre
Cyto`s abgegeben haben. Ich selber bin und bleib drin.
Übrigens MAXM hatte ich auch mal, bin aber Gott sei Dank
im August bei 60$ raus.
Mir selber gefällt bei Cyto die Produktpalette die
Prokukt Pipeline (Phase III) und die Story um AxCell.
MFG DS

[CaptainChaos]

CYTO`s Tochtergesellschaft kooperiert mot Compaq

AxCell Biosciences Strengthens Its Strategic Relationship With Compaq
CYTO


RELATED QUOTES

CYTO 2 7/16 - 1/16
CPQ 14.70 -0.78
RELATED TOPICS
prn
agricultural
architecture
biotechnology
business
cancer
clinical
commercial
computer
expansion
fda
joint venture


PRINCETON, N.J., Dec 19, 2000 /PRNewswire via COMTEX/ -- AxCell Biosciences Corporation, a subsidiary of Cytogen Corporation (Nasdaq: CYTO ) today announced that it has strengthened its strategic relationship with Compaq Computer Corporation (NYSE: CPQ ). Last December, AxCell began using Compaq`s high performance Tru64 UNIX Alpha systems to deliver the speed, scalability and performance required to chart the signaling pathways within the human proteome. Due to increasing laboratory data output, AxCell`s computing requirements have more than doubled. Compaq`s AlphaServer cluster technology has made the required expansion seamless. AxCell is developing the InterFunctional Proteomics Database(TM) as a means of discovering new drug targets, and determining the functional role of single nucleotide polymorphisms, or SNPs in pharmacogenomics.

"After working with Compaq for nearly a year, we are pleased to expand our development relationship with them," said Brian R. Bullard, Vice-President and Chief Information Officer of AxCell. "With increased data production from our laboratories, we will need additional enhanced computing power to support the data analysis capabilities that are so critical to our research work. Compaq`s Tru64 UNIX scalable architecture will allow AxCell to build on its existing computer systems adding needed computational power."

"Compaq has intensified its commitment to the life sciences industry in the past year, and we are pleased to expand our relationship with AxCell," said Patrick Chassaigne, Director, Life Sciences at Compaq. "Compaq provides high-performance computing solutions and services to assist AxCell in charting the proteome, and our relationship with AxCell demonstrates Compaq`s continued commitment to the application of computing solutions to life sciences with emphasis on proteomics."

AxCell Biosciences, a subsidiary of Cytogen, is using its high-throughput technology to chart protein signaling pathways in the human proteome as a means of discovering new drug targets. AxCell is developing a proprietary protein-pathway database, the Inter-Functional Proteomic Database(TM), as a discovery and development tool for subscribers in the pharmaceutical, biotechnology and agricultural industries. AxCell`s bioinformatics platform is designed to identify drug targets for optimization and development through the application of novel, innovative and rapid techniques for deriving intracellular protein-pathway data. For additional information on AxCell Biosciences, visit www.axcellbio.com .

Cytogen Corporation is a biopharmaceutical company in Princeton, NJ, whose mission is to set new standards in cancer care. Its two principal lines of business, proteomics and oncology, are built upon its expertise in antibodies and molecular recognition and are directed principally to development of novel products for the diagnosis, imaging, staging and treatment of prostate cancer and a proteomics-driven drug discovery platform. The Company`s cancer management franchise currently comprises four FDA-approved products: ProstaScint(R), used to image the extent and spread of prostate cancer; BrachySeed(TM) implants for prostate cancer therapy; OncoScint(R) CR/OV, a diagnostic imaging agent for colorectal and ovarian cancer; and Quadramet(R), for the relief of cancer-related bone pain. The Company has established a pipeline of product candidates based on its proprietary antibody and prostate specific membrane antigen, or PSMA, technologies, and holds worldwide exclusive license to PSMA. Cytogen and its joint venture partner, Progenics Pharmaceuticals, are developing in vivo immunotherapies for prostate cancer based on PSMA. The Company also has U.S. marketing rights to the late-stage product candidate Combidex(R), a magnetic resonance imaging agent being developed by Advanced Magnetics for the detection of lymph node metastases. For additional information visit www.cytogen.com .

This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Information in this press release, which is not historical, is forward looking and involves a number of risks and uncertainties. Investors are cautioned not to put any undue reliance on any forward looking statement. The Company`s actual results may differ materially from the Company`s historical results of operations and those discussed in the forward-looking statements for various reasons, including, but not limited to the Company`s ability to carry out its business plan, successful development and commercial acceptance of its products, ability to fund development necessary for existing products and for the pursuit of new product opportunities, the risk of whether products result from development activities, protection of its intellectual property portfolio, ability to integrate in-licensed products, ability to establish and successfully complete clinical trials where required for product approval, the risk associated with obtaining the necessary regulatory approvals, dependence on its partners for development of certain projects, the ability to obtain foreign regulatory approvals for products and to establish marketing arrangements in countries where approval is obtained, and other factors discussed in the Company`s 1999 Form 10-K and from time-to-time the Company`s other filings with the Securities and Exchange Commission.

SOURCE Cytogen Corporation


CONTACT: Larry Hoffman, Vice President and CFO, 609-750-8205; or Richard
W. Krawiec, Ph.D., Vice President, Investor Relations and Corporate,
609-750-8289, both of Cytogen

URL: http://www.axcellbio.com
http://www.cytogen.com
http://www.prnewswire.com

(C) 2000 PR Newswire. All rights reserved.

-0-


KEYWORD: New Jersey
INDUSTRY KEYWORD: MTC
BIO
CPR
SUBJECT CODE: JVN

STOCK SYMBOLS: [(cyto)] [(cpq)]

[CaptainChaos]

Hallo liebe Cytogen - Fans,

am gestrigen Handelstag wurde ein enormes Handelsvolumen von über 2 Millionen CYTOS verteilt. Ich bin guter Dinge, dass am gestrigen Tage institutionelle Anleger eingestiegen sind.
Nachfolgend poste ich einen Beitrag aus clearstation.com. Tradergirl 527 bringt es auf den Punkt:

From : tradergirl527 Dec 29 2000 10:32PM
Replying To : tagman (post 679)
Title : Interesting Post


I can`t wait to see a turnaround here. I think things will look good soon also. Did anyone happen to watch CNBC just after the market closed today? They mentioned CYTO as having increased volume during the last half hour of trading. It seems there were fund managers out bargain shopping this afternoon--and CYTO was one of the bargains! Best Wishes to all for a Happy, Healthy and Prosperous New Year! L.

Euch allen ein frohes neues Jahr und steigende Kurse in 2001.

Gruss


CC

[Dummschwaezer]

Hey ihr Cyto`s
RT an der Nasdaq +25% bei 3,125 $
Bei dem Marktumfeld Wahnsinn, oder?
Und hier immer noch bei 2,55 €.
Jetzt zugreifen!!!!!!!!!!!!!!!!!!!!

Gruß DS

[CaptainChaos]

Jetzt ist klar, warum die Cytogen - Tochter letzte Woche eine Kooperation mit dem PC - Hersteller COMPAQ eingegangen ist. Ich vermute, dass der Verkauf von Komplettsystemen ansteht.

AxCell Biosciences Completes First-Ever Map of a Human Protein Family
CYTO


RELATED QUOTES

CYTO 2.66 -0.41
RELATED TOPICS
prn
agricultural
biology
biotechnology
business
cancer
cardiovascular
cellular
clinical
commercial
diabetes
disease
drugs
family
health

PRINCETON, N.J., Jan 9, 2001 /PRNewswire via COMTEX/ -- Scientists at AxCell Biosciences Corporation, a subsidiary of Cytogen Corporation (Nasdaq:CYTO), have successfully mapped all of the interactions of the known proteins found in one of the estimated 60 to 80 protein domain families in the human body. This achievement represents the first domain map to be completed in the effort to develop a chart of all of the protein pathways in the human body, which medical scientists believe will have applications for the development of drug therapies for a wide range of diseases.

Using advanced robotic screening techniques and data made available through the Human Genome Project (HGP), AxCell scientists have successfully identified more than 69,000 different protein interactions of the "WW domain," the name for one of the human body`s specific family of proteins. A domain is a structural site on a protein where interaction occurs with another protein.

"This milestone in the effort to map the interaction of human proteins is extremely important for two reasons. First, it will provide important data for research right away. Second, it reinforces our strong belief that AxCell Biosciences will be able to complete the entire human protein interaction model using our robotic screening technique," said John D. Rodwell, Ph.D., acting president and chief technical officer of AxCell Biosciences.

Proteins in the human body interact using signaling pathways that, in turn, regulate cellular activity such as the transmission of nerve impulses, secretion of hormones or the triggering of cell replication. Aberrations in protein interactions play a role in the progress of diseases including cancer, diabetes, cardiovascular and neurological disorders, among many others. Aberrations in the WW protein domain family specifically have been implicated in health problems ranging from hypertension and muscular dystrophy to immunodeficiency.

"AxCell has provided an interesting dataset for understanding protein signaling pathways," said Leroy Hood, M.D., Ph.D., founder, president and director of the Institute for Systems Biology in Seattle, WA, and one of the earliest advocates of the Human Genome Project. "This achievement, a systems analysis of the WW domain family, provides important new information on protein signaling pathways which could have implications for their role in a broad range of diseases."

Because protein signaling pathways play a role in many diseases, scientists are working to develop drugs that specifically target these pathways. While some interactions are likely to have positive clinical results, others can lead to unwanted drug side effects and toxicity. By referring to a chart of the body`s protein interactions, researchers may be better able to identify drugs that target pathways related to a specific disease while avoiding those pathways associated with unwanted side effects.

"By charting all of the protein pathways within human cells, AxCell will be able to offer medical researchers a better understanding of protein interactions and their role in human health. Our human protein map promises to change the way pharmaceuticals are developed in the years ahead, with significant benefits for researchers and patients," Dr. Rodwell said.

In addition to the completion of the WW domain family map, research at AxCell has also led to several other important findings, including the identification of a significant number of previously unrecorded protein interactions. In 1999 AxCell was awarded a U.S. patent for the identification of previously undiscovered proteins in the WW domain family. The company expects to make substantial progress toward complete mapping of two additional protein domains -- the PDZ and SH3 domains -- in 2001. The PDZ and SH3 domains have been implicated in cancer, inflammatory disease, cardiovascular disease and stroke.

"The completion of the map of the WW domain is very exciting, but it`s also just a first step in our ongoing effort to complete the entire map of human protein signaling interactions. We expect many more important discoveries along the way, and are on target to complete this project and make these data available to medical researchers and healthcare companies around the world," said Brian R. Bullard, vice president and chief information officer at AxCell.

To make these findings available to researchers, AxCell, along with partner InforMax, Inc., a leading global provider of bioinformatics software solutions, plan to conduct pre-launch and market activities of the InterFunctional Proteomics(TM) (IFP) Database early in 2001. The IFP Database will be designed to make these important findings available to subscribing medical and scientific researchers around the world on a commercial basis.

As more data from the HGP are made public, information related to the WW domain and all other protein domain families will continue to expand. The robotic screening process developed by AxCell makes it possible to incorporate new data quickly and update information available through the IFP Database.

AxCell Biosciences, a subsidiary of Cytogen Corporation, is a leader in the effort to chart protein signaling pathways in the human proteome as a means of discovering new drug tar gets. In conjunction with InforMax, AxCell is developing a proprietary protein-pathway database, the Inter-Functional Proteomic Database(TM) (IFP Database), as a discovery and development tool for subscribers in the pharmaceutical, biotechnology and agricultural industries. For additional information on AxCell Biosciences, visit http://www.axcellbio.com .

Cytogen Corporation is a biopharmaceutical company based in Princeton, NJ. The company`s two principal lines of business, proteomics and oncology, are built upon its expertise in antibodies and molecular recognition and are directed principally to development of novel products for the diagnosis, imaging, staging and treatment of prostate cancer and a proteomics-driven drug discovery platform. For additional information, visit http://www.cytogen.com .

This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Information in this press release, which is not historical, is forward looking and involves a number of risks and uncertainties. Investors are cautioned not to put any undue reliance on any forward-looking statement. The Company`s actual results may differ materially from the Company`s historical results of operations and those discussed in the forward-looking statements for various reasons, including, but not limited to the Company`s ability to carry out its business plan, successful development and commercial acceptance of its products, ability to fund development necessary for existing products and for the pursuit of new product opportunities, the risk of whether products result from development activities, protection of its intellectual property portfolio, ability to integrate in-licensed products, ability to establish and successfully complete clinical trials where required for product approval, the risk associated with obtaining the necessary regulatory approvals, dependence on its partners for development of certain projects, the ability to obtain foreign regulatory approvals for products and to establish marketing arrangements in countries where approval is obtained, and other factors discussed in the Company`s 1999 Form 10-K and from time-to-time the Company`s other filings with the Securities and Exchange Commission.

SOURCE Cytogen Corporation


CONTACT: Lawrence Hoffman, Vice President and CFO of Cytogen
Corporation, 609-750-8204; or Jim Wetmore of Berry & Co., 212-279-2060URL: http://www.cytogen.com
http://www.prnewswire.com(C) 2001 PR Newswire. All rights reserved.
-0-

KEYWORD: New Jersey
INDUSTRY KEYWORD: MTC
BIO
SUBJECT CODE: PDT
STOCK SYMBOLS: [(cyto)]

[Dummschwaezer]

@CaptainChaos
Das ganze hier steigt für meinen
Geschmack ein wenig zu schnell
bei gerade einmal 1,3 Mio. gehandelte
Aktien an der NASDAQ. Ich glaube
wenn ich richtig gelesen habe das
73 Mio. an Aktien im Umlauf sind.
Hoffentlich bleiben alle Cool!
Wie wird sich deiner Meinung nach
die CYTO bis Jahresmitte entwickeln?

DS

[CaptainChaos]

@ Dummschwaezer,

ich gebe Dir recht, ca. 45 % in zwei Tagen ist schon beängstigend. Ich hoffe, dass institutionelle Anleger eingestiegen sind ( ca. 2,3 Mio. Aktien an zwei Börsentagen).

Ich bin bei CYTO zuversichtlich, da neben der Vermarktung von - 4 - erfolgversprechenden Produkten, die Meldungen
vom 22.12.2000 und vom gestrigen TAge hinsichtlich der Protein - Maps von CYTO`s Tochtergesellschaft und der Kooperation mit Proteonics und Compaq für Fantasie sorgt.

[Wunram]

Fängt vorbörslich ja schon ganz gut an!!

island $ 4,7
nasdaq $ 4,7031

allerdings bei ganz kleinen Umsätzen.

[Wunram]

geht aber lustig weiter
9:38:39

island $ 5,3125

einige größere buy orders > $5,.

[Wunram]

CYTO Nasdaq-NM
Sale $5
Net Change 0.9687
%Change 24.03%
Share Volume 831,700

As of 1/11/2001 10:37 ET Open

[Dummschwaezer]

Von unseren Amerikanischen Kollegen!

From yesterday`s Boston Globe:
John Sullivan, a research analyst with investment bank Stephens Inc. in Boston, said he believes the big winners of 2001 will be companies specializing in proteomics, the science of proteins. While sequencing of the human genome fueled enthusiasm for biotech, understanding proteins is what will allow companies to turn gene-related discoveries into drugs.

Kann man gut mit AxCell und Cytogen in Verbindung setzen!
Auf weiterhin gute Aussichten.
Gruß DS

[CaptainChaos]

75 % in drei Tagen -- so kann es weiterlaufen.

Nachbörslich liegt CYTO bei 5,35 $ und es bestehen (island.com) weitere Kauforders knapp unterhalb dieser Marke.

[Wunram]

Vorbörslich bis island $ 5,3125
allerdings praktisch keine Umsätze
9:02 ET

[Dummschwaezer]

Quelle:ragingbull.com

http://home.flash.net/~motoxcat/cytomissle.html

Gruß DS

[Dummschwaezer]

Hey ihr Jungs und Mädels,
morgen früh wird CYTO bei 6€ eröffnet.
Das sind nach den Tiefständen +200%!!!
Ist das erst der Anfang einer erfolg-
versprechenden Story? Wenn ich mir die
US Boards so anschaue, liest man durchweg
nur positives über CYTO & Axcell.
@CC & Wunram
Euere erwartungen?

[CaptainChaos]

@ Dummschwaezer,

Deine Frage ist derzeit schwierig zu beurteilen. Der Biotech - Index ist immer noch nahe dem Abwärtstrend. Sollte dieser nach unten durchbrochen werden, wird es auch mit CYTO wieder abwärts gehen.

Grundsätzlich zeichnet sich ab, dass BIOS aus der 2. und 3. Reihe stärker aufholen als die Blues. Das liegt m.E. zum einen an dem starken Rückschlagpotential der Werte aus der 1. Reihe, zum zweiten daran, dass sich viele Anleger darüber im klaren sind, dass die heutigen Kandidaten der 1. Reihe vor einem JAhr da waren, wo heute eine CYTO, SCLN, Avan, Xoma , Curis etc. steht.

Viele BIOS der 2. und 3. Reie haben eine prall gefüllte Pipeline.


Cytogen will expandieren und hat mitgeteilt, dass folgende FDA - genehmigte Produkte vermarktet werden:

ProstaScint(R) Prostata Krebs;
OncoScint(R) CR/OV, Krebs ;
Quadramet(R), Schmerzbehandlung Krebs
BrachySeed(TM) Prostata Krebs ( Vermarktungsrechte wurden von Draxis Health erworben)

und neu !!!!

Vermarktungsrechte in den USA für
Combidex(R), Lymphknotenkrebs


Dazu dürften aus der Axcell - Forschung Einnahmen aus dem Verkauf der Katalogisierung der Protein - Ketten kommen. Da eine Kooperation diesbezüglich mit Proteonics und Compaq geschlossen wurde, ist zu vermuten, dass die Protein-Maps als Komplettsystem verkauft werden.

Aus all den o.g. Medikamenten sind noch keine (oder fast keine) Einnahmen in die Earnings eingeflossen. Nun könnte es im Laufe 2001 eine Überraschung geben, indem CYTO den Breakeven erreicht. Die US - Boards sind hinsichtlich CYTO fast euphorisch. DIe Umsätze sind derzeit auch ok.

Mein persönliches KZ bis Mitte 2001 liegt - positive Marktlage vorausgesetzt bei 12 Euro. Das sind zwar nur 50 % des 52 - Wochen - Hochs, jedoch waren die Kurse von Februar, März 2000 m.E. übertrieben.

Gruss

CC

[Wunram]

@Dummschwaezer

.. würde man das nicht eigentlich "Dummschwätzer" schreiben?

aber zur Frage. Im board von clearstation.com steht ein Beitrag, den ich voll und ganz teilen kann:

Topic : Cytogen Corp (CYTO)
Forum : Individual_Stocks

From : Chartpicker Jan 17 2001 12:09AM
Title : Potential Of CYTO

If everyone recalls when computers were first invented and how stock prices of computer companies sky rocketed you can now see where genomics and proteomics are at. This is the hottest technology in the biotech field and it`s future is tremendous. This is going to be the awnser according to most experts to medical cures in the areas of cancer and other diseases. I have never felt so confident in the future of this science that you could say I put my money where my mouth is. Momentum continues in the stock price as more and more investors are learning about this exciting field and what it`s going to do for the medical field. For these reasons I would be a strong buyer of the stock.

Ich glaube allerdings, dass jetzt kurzfristig einige Gewinnmitnahmen stattfinden werden, denn zumindest am amerikanischen Markt ist die Aktie stark überkauft. Ich bleib aber auf jeden Fall drin.

Positiv ist natürlich, dass die "Kleinen" an der Nasdaq notierten, den Index hochhalten trotzdem die "Dicken" nicht so gut laufen.


good trades
Gruss Wunram

[CaptainChaos]

CYTO vorbörslich im Plus ( 6,25 USD)

[Wunram]

Cytogen Corporation CYTO
Jan. 17, 2001 11:54 ET Market Open

Last Sale: $ 5.7813 Net Change: 0.2187 Today`s High: $ 6.5625 Today`s Low: $ 5.7813
Best Bid: $ 5.7813 Best Ask: $ 5.8438
Volume: 1,241,500 Previous Close: $ 6
Market: Nasdaq-NM Common Stock

[Wunram]

Cytogen Corporation CYTO
Jan. 17, 2001 11:54 ET Market Open

Last Sale: $ 5.7813 Net Change: 0.2187 Today`s High: $ 6.5625 Today`s Low: $ 5.7813
Best Bid: $ 5.7813 Best Ask: $ 5.8438
Volume: 1,241,500 Previous Close: $ 6
Market: Nasdaq-NM Common Stock

[Dummschwaezer]

@Wunram
Ja ich weiss habe bei meiner Anmeldung
in der Eile ein t vergessen, was soll`s.
Bin halt der Dummschwaezer ohne t!!!!!
Unsere Cyto bis jetzt leicht im Minus,
kann mir aber gut vorstellen das wir so
gegen 19.30 Uhr wieder + Kurse sehen.
Gruß
DS ohne t

[Wunram]

@alle

die neue Woche startet ja vorbörslich ganz gut, 8:20 ET.

$ 6.125 auf island

Für island- Verhältnisse ziemliche Nachfrage, aber best bid derzeit $ 5,5

Gruss Wunram

[Wunram]

moin, moin

es ist ja ein bisschen ruhiger geworden; wenn man sich aber
mal den Verlauf im Januar an der Nasdaq anschaut, bin ich
doch noch sehr positiv gestimmt und glaube, das dass Kursziel von CC passt.

01/23/2001 5.250 591700
01/22/2001 5.250 1018400
01/19/2001 5.250 767300
01/18/2001 5.750 1193400
01/17/2001 5.969 1822300
01/16/2001 6.000 1786400
01/12/2001 5.125 1329800
01/11/2001 5.250 2504800
01/10/2001 4.031 1374900
01/09/2001 3.375 1028100
01/08/2001 2.656 589900
01/05/2001 3.063 473700
01/04/2001 3.250 648300
01/03/2001 3.438 1255200
01/02/2001 2.500 685500

Höhere Umsätze bei steigenden Kursen und geringe Umsätze bei
fallenden Kursen zeigen kurzfristig doch Stärke für den Kurs.

Schaun mer mal wie´s weiter geht.

Wunram

PS: Wer kann mir eigentlich mal ein paar Formatierungstips geben?
siehe Tabelle oben??? Im Editorfenster siehts immer ganz toll aus!

[Wunram]

Cytogen Appoints Kevin G. Lokay to Its Board of Directors
PRINCETON, N.J., Jan. 24 /PRNewswire/ --

Cytogen Corporation (Nasdaq: CYTO) today announced the appointment of Mr. Kevin G. Lokay to its Board of Directors. Mr. Lokay has over 20 years of experience in the pharmaceutical industry and is currently head of the Oncology Business unit of GlaxoSmithKline plc, one of the world`s leading research-based pharmaceutical and healthcare companies.

Prior to being appointed to his current position in the recently merged GlaxoSmithKline plc, Mr. Lokay spent over three years with SmithKline Beecham as Vice President and Director, Oncology and Specialty Products. Mr. Lokay`s experience also includes 16 years with Merck & Co. Inc., where he was the Vice President, Worldwide Sales, Marketing and Development for its Vaccine Division. In this position he had sales and marketing responsibility for vaccines in North America and other parts of the world, while serving on steering committees for European and Pacific Rim joint ventures regarding strategic marketing and development.

"We are pleased to welcome Kevin as a member of the Board of Directors, and anticipate that he will contribute his many talents and continue to champion our developments in proteomics and oncology," said James A. Grigsby, Chairman of Cytogen Corporation. "His experience in the pharmaceutical industry and marketing and sales will be invaluable and we look forward to having him join us."

Mr. Lokay holds a MBA with a concentration in Marketing from the Krannert School of Management at Purdue University. He obtained his BA in Economics from Lafayette College.

Cytogen Corporation is a biopharmaceutical company based in Princeton, NJ. The company`s two principal lines of business, proteomics and oncology, are built upon its expertise in antibodies and molecular recognition and are directed principally to development of novel products for the diagnosis, imaging, staging and treatment of prostate cancer and a proteomics-driven drug discovery platform. For additional information, visit www.cytogen.com.

AxCell Biosciences, a subsidiary of Cytogen Corporation, is a leader in the effort to chart protein-signaling pathways in the human proteome as a means of discovering new drug tar gets. In conjunction with InforMax, AxCell is developing a proprietary protein-pathway database, the Inter-Functional Proteomic Database(TM) (IFP Database), as a discovery and development tool for subscribers in the pharmaceutical, biotechnology and agricultural industries. For additional information on AxCell Biosciences, visit www.axcellbio.com.


/CONTACT: Mary Coleman of Cytogen Investor Relations, 609-750-8223/

[Wunram]

Symbol CYTO
Market Nasdaq-NM
Last Sale $5.625
Net Change 0.375
%Change 7.14%
Share Volume 196,100

As of 1/24/2001 10:13 ET Open

[Wunram]

haaaalllooo ist eigentlich keiner mehr da???


Symbol CYTO
Market Nasdaq-NM
Last Sale $ 5.75
Net Change 0,5
% Change 9.52%
Share Volume 393000

As of 1/24/2001 11:15 ET Open

[Dummschwaezer]

@Wunram
Kein Sorge mein Freund ich bin noch da und drin!
RT +11% an der NASDAQ. Sah eigendlich zu beginn
der Woche doch recht ärmlich aus. Um so erfreulicher
der unerwartete Anstieg heute.

Gruß DS

[CaptainChaos]

Der ehemalige Vize - Präsident von Merck&Co.Inc. und von
GlaxoSmithKline plc im Vorstand von Cytogen. Also bei mir geht die Fantasie schon ein bischen durch.
Der Mann wird wohl die Absatzmärkte kennen.
Warten wir die nächsten Quartalszahlen ab.

[Dummschwaezer]

@CC&Wunram
Habt ihr ein wenig Ahnung in sachen
Charttechnik und so!?!?
Es sieht danz danach aus das wir die
6$ in den nächsten zwei Wochen hinter uns lassen.
Es ist schön zu beobachten das bei relativ
hohem Volumen (um die 1 Mio.) die CYTO
sich im positivem Bereich aufhält und zulegen kann.
Im Moment wird wieder kräftig gekauft, ich
glaube das Wort heißt akkumuliert.
Ab 6$ ist doch der Weg frei nach oben, oder?
Wie seht ihr denn die Entwicklung.

Gruß DS

[Wunram]

@alle

momentan viel arbeit, aber nachfolgende Meldung beschert uns derzeit -13% an der Nasdaq



Cytogen Reports Fourth Quarter and Year-End 2000 Results

Significant Advances in Mapping the Human Proteome and a Continued Investment
In Oncology and Proteomics Highlight the Company`s Achievements in 2000

Annual Financial Results are Impacted by One-Time
Accounting Charges and Other Non-Operating Items

PRINCETON, N.J., Feb. 7 /PRNewswire/ -- Cytogen Corporation (Nasdaq: CYTO) today announced financial results for the fourth quarter and the year ended December 31, 2000. For the fourth quarter ended December 31, 2000, the Company reported a net loss of $2.4 million or $0.03 per share, compared to net income of $1.3 million or $0.02 per share for the fourth quarter of 1999. For the year ended December 31, 2000, the Company reported a net loss of $27.3 million or $0.37 per share as compared to net income of $729,000 or $0.01 per share for 1999. Excluding the impact of certain one-time charges such as the implementation of the SEC`s Staff Accounting Bulletin No. 101 ("SAB 101"), as discussed below, and the acquisition of certain marketing and technology rights from Advanced Magnetics, Inc., the Company`s reported loss would have been $9.7 million or $0.13 per share for 2000.

"During 2000, we continued to build upon the Company`s core competencies in proteomics and oncology," stated H. Joseph Reiser, Ph.D., Cytogen`s President and Chief Executive Officer. "We significantly accelerated our mapping of the human proteome by investing additional resources in our proteomics subsidiary, AxCell Biosciences. We believe this investment was sound and we eagerly anticipate the launch of our proteomics database product with our marketing partner, InforMax, Inc.

"On the oncology side of the business," Dr. Reiser continued, "we invested heavily in building a well-trained, oncology focused sales force. In order to leverage our investment in the sales force, we in-licensed BrachySeeda, an FDA approved product for use in treating prostate cancer. In order to build a product pipeline, we in-licensed two product candidates, Combidex(R) and Code 7228, two magnetic resonance imaging agents, for oncology applications. I believe the investments made during 2000 will create a more dynamic and valuable Cytogen in the future."

In the fourth quarter of 2000, the Company, in common with other biotechnology companies, implemented SAB 101 which requires certain up-front, non-refundable revenues to be deferred and recognized over future periods. The cumulative effect of the adoption of SAB 101 in the first quarter and year ended 2000 resulted in a one-time, non-cash charge of $4.3 million or $0.06 per share. Following the adoption of SAB 101, the deferred revenues associated with the one-time charge will be recognized in future accounting periods as a component of licensing and contract revenues. The SAB 101 adjustment resulted from the up-front licensing fees, net of associated expenses, received from Berlex Laboratories, Inc. in October 1998 related to the licensing of Quadramet and up-front licensing fees recognized in June 1999 relating to certain applications of the Prostate Specific Membrane Antigen technology which was licensed to a joint venture formed by the Company and Progenics Pharmaceuticals, Inc.

The fourth quarter of 2000 was adversely effected by $1.1 million or $0.01 per share related to the reduced allotment of New Jersey state tax benefits that the Company was able to sell in accordance with the Tax Technology Program (the "Program") sponsored by the State of New Jersey. The amount of state tax benefits available for sale was reduced compared to last year due to decreased overall state funding for the Program as well as an increase in the number of participants in the Program. In the fourth quarter of 1999, the Company recognized $2.7 million from the sale of these benefits versus $1.6 million in 2000.

Revenues for the fourth quarter totaled $2.6 million versus $2.1 million for the comparable prior year period, an increase of 27 percent. The increase in revenues was attributable to continued growth in the sale of ProstaScint, a prostate cancer imaging agent as well as significant growth in royalties derived from the sale of Quadramet, a cancer therapeutic agent, and the recognition of deferred license revenue of $215,000 relating to the adoption of the SAB 101.

Sales of the Company`s products, ProstaScint and OncoScint, increased 25% to $2.0 million in the fourth quarter versus $1.6 million for the comparable prior year period. For the year 2000, product sales grew to $7.4 million from $7.0 million, an increase of 6%. The Company assumed sole responsibility for the marketing and selling of ProstaScint from its former partner, the Urological Division of C.R. Bard Co., at the beginning of the third quarter of 2000. The Company believes that its investment in its sales force will continue to drive the growth of ProstaScint in future quarters. In January 2001, the Company`s oncology sales force began marketing BrachySeed(TM), a prostate cancer therapeutic agent, whose U.S. marketing rights were licensed from Draximage, Inc.

During 2000, sales of Quadramet by Berlex increased 89% compared to the prior year, resulting in a significant increase in royalty revenues by the Company. The sales increase is attributable to increased market penetration and acceptance since Quadramet`s re-launch by Berlex in March 1999. For the fourth quarter and year ended December 31, 2000, royalty revenues were $476,000 and $2.0 million, versus $354,000 and $1.1 million, respectively, for the comparable prior year periods. Berlex has initiated a Phase III clinical trial to evaluate the use of Quadramet earlier in the pain management cycle. If this trial is successful, the Company plans to seek expansion of the FDA approved indication of Quadramet for use in delaying the onset of pain in patients with metastatic bone lesions.

For the year 2000, revenues totaled $10.5 million versus $11.2 million for the prior year, a decrease of $700,000. This decrease was attributable to the phase out of the contract manufacturing business during 1999 which generated $600,000 in revenues and the recognition in 1999 of an up-front license fee of $1.8 million from Progenics Pharmaceuticals, Inc. partially offset by the growth in ProstaScint sales and Quadramet royalties and the recognition of deferred license revenue relating to the adoption of SAB 101 during 2000.

Total on-going operating expenses for the fourth quarter of 2000 were $6.9 million versus $3.8 million in the comparable prior year period. On-going operating expenses for the full year were $22.4 million versus $15.7 million for 1999. The fourth quarter increases were principally due to pre-launch marketing costs associated with the acquisition and January 2001 launch of the BrachySeed(TM) prostate cancer product, continued investment in the proteomics business at AxCell Biosciences as well as increased marketing and sales efforts for the Company`s existing products. For the full year, the increased operating expenditures reflect the Company`s increased research effort related to its proteomics business at AxCell, the investment in its own dedicated oncology sales force, costs associated with the termination of the merger agreement with Advanced Magnetics, Inc., stock based compensation for a key employee as well as additional staffing and related relocation costs.

During 2000, the Company acquired from Advanced Magnetics, Inc. the U.S. marketing rights to two novel, diagnostic pharmaceutical product candidates for use in magnetic resonance imaging. In connection with this acquisition, the Company recorded a one-time charge of $13.2 million, of which $13.1 million was non-cash, since these product candidates are in development. In 1999, the Company recorded a non-cash charge of $1.2 million related to the acquisition of Prostagen, Inc.

At the end of 2000, the Company had $12.0 million of cash, cash equivalents and short-term investments on hand versus $12.4 million at the end of 1999. The Company also recorded a $1.6 million receivable at the end of 2000 relating to the sale of certain New Jersey income tax benefits, which were received in early January. The Company has in place a $70 million equity financing facility from Acqua Wellington North American Equities Fund, Ltd. Pursuant to this facility, the Company received $6.5 million in early February from a direct equity placement and issued 1,276,557 shares of registered common stock at a small discount to the market price.

Attached are the Company`s Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Operations.

Cytogen Corporation is a biopharmaceutical company based in Princeton, NJ. The Company`s two principal lines of business, proteomics and oncology, are built upon its expertise in antibodies and molecular recognition and are directed principally to development of novel products for the diagnosis, imaging, staging and treatment of prostate cancer and a proteomics-driven drug discovery platform. For additional information, visit www.cytogen.com.

AxCell Biosciences, a subsidiary of Cytogen Corporation, is a leader in the effort to chart protein-signaling pathways in the human proteome as a means of discovering new drug targets. AxCell is developing a proprietary protein-pathway database, the Inter-Functional Proteomic Database(TM) (IFP Database), as a discovery and development tool for subscribers in the pharmaceutical, biotechnology and agricultural industries. For additional information on AxCell Biosciences, visit www.axcellbio.com.

This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Information in this press release, which is not historical, is forward-looking and involves a number of risks and uncertainties. Investors are cautioned not to put any undue reliance on any forward-looking statement. The Company`s actual results may differ materially from the Company`s historical results of operations and those discussed in the forward-looking statements for various reasons, including, but not limited to, the Company`s ability to carry out its business plan, successful development and commercial acceptance of its products, ability to fund development necessary for existing products and for the pursuit of new product opportunities, the risk of whether products will result from development activities, protection of its intellectual property portfolio, ability to integrate in-licensed products, ability to establish and successfully complete clinical trials where required for product approval, the risk associated with obtaining the necessary regulatory approvals, dependence on its partners for the development and marketing of certain products, the ability to obtain foreign regulatory approvals for products and to establish marketing arrangements in countries where approval is obtained, and other risk factors discussed in the Company`s 1999 Form 10-K and from time-to-time the Company`s other filings with the Securities and Exchange Commission.

CYTOGEN CORPORATION AND SUBSIDIARIES
(All amounts in thousands except per share data)
(Unaudited)


CONDENSED CONSOLIDATED BALANCE SHEETS
DECEMBER 31, DECEMBER 31,
2000 1999
ASSETS
Cash, Cash Equivalents and Short-Term
Investments $11,993 $12,394
Receivable on New Jersey Income Tax
Benefit Sold 1,625 -
Accounts Receivable, net 1,841 2,150
Inventories 883 685
Property and Equipment, net 2,193 1,997
Other Assets 1,881 1,379
Total Assets $20,416 $18,605
======== =========
LIABILITIES & STOCKHOLDERS` EQUITY
Accounts Payable & Accrued Liabilities $7,218 $5,478
Other Current Liabilities 1,010 162
Long - Term Liabilities 4,970 2,416
Stockholders` Equity 7,218 10,549

Total Liabilities & Stockholders` Equity $20,416 $18,605

========= =========


CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

THREE MONTHS ENDED YEAR ENDED
DECEMBER 31, DECEMBER 31,
____________________ ______________

2000 1999 2000 1999
Revenues
Product Sales $1,950 $1,563 $7,424 $6,971
Royalty Revenue 476 354 2,004 1,060
License and Contract 215 165 1,024 3,171
------ ------ ------ ------
Total Revenues 2,641 2,082 10,452 11,202


On-Going Operating Expenses 6,882 3,790 22,431 15,671
Acquisition of Marketing and
Technology Rights * - - 13,241 1,214
Sale of New Jersey Income Tax
Benefit (1,625) (2,702) (1,625) (2,702)
(Gain) on Sale of Laboratory
and Manufacturing Facilities - - - (3,298)
Interest (Income), net (198) (274) (611) (412)

Net Income (Loss) before
Cumulative Effect of
Accounting Change $(2,418) $1,268 $(22,984) $729
Cumulative Effect of
Accounting Change** - - (4,314) -


Net Income (Loss) $(2,418) $1,268 $(27,298) $729
======== ======== ======= =======

Net Income (Loss) before
Cumulative Effect of
Accounting Change Per Share $(0.03) $0.02 $(0.31) $0.01
Cumulative Effect of
Accounting Change Per Share - - (0.06) -
-------- ------ ------- -------

Basic and Diluted Net
Income (Loss) Per Share $(0.03) $0.02 $(0.37) $0.01
======== ======== ======== =======
Weighted Average Common
Shares Outstanding
Basic 75,593 70,414 73,337 67,179
======== ======== ======== =======
Diluted 75,593 72,307 73,337 68,187
======== ======== ======== =======


*In August 2000, the Company licensed product rights from Advanced Magnetics, Inc. *In June 1999, the Company acquired Prostagen, Inc.

**In 2000, the Company adopted SEC Staff Accounting Bulletin No. 101 and changed its method of accounting for revenue from license agreements.


/CONTACT: Lawrence R. Hoffman, Vice President and CFO of Cytogen Corporation, 609-750-8204/

[Wunram]

mal wieder news die cyto tangieren:

Data on Protein Interactions in Humans to Be Available Through New Product from InforMax and AxCell Biosciences

ROCKVILLE, Md. and PRINCETON, N.J., Feb. 20 /PRNewswire/ -- A broad range of information related to protein-protein interactions in the human body, including data on the WW Domain, the first human protein family to be mapped successfully, will be available through a new product to be launched by InforMax, Inc. (Nasdaq: INMX) and AxCell Biosciences, a subsidiary of Cytogen Corporation (Nasdaq: CYTO). (Photo: http://www.newscom.com/cgi-bin/prnh/20001115/INFORMAXLOGO )

In collaboration with AxCell Biosciences, InforMax has developed a Protein-Protein Interaction (PPI) module for the GenoMax(TM) enterprise bioinformatics system, a modular platform of advanced analysis programs for genomic and proteomic applications, and successfully integrated the Inter-Functional Proteomic Database(TM), AxCell`s growing database of human protein interactions. AxCell has developed technology that provides both qualitative and quantitative information about a wide range of protein-protein interactions. This information is being used to continually update the data available through the Inter-Functional Proteomic (IFP) Database, for which InforMax has exclusive distribution rights.

The integration of GenoMax with the IFP Database will be demonstrated publicly for the first time at the CHI Genome Tri-Conference in San Francisco, CA, from March 3-9, 2001. InforMax and AxCell expect the product to be available for commercial use in the second quarter of this year.

Proteins in the human body interact using signaling pathways that, in turn, regulate cellular activity such as the transmission of nerve impulses, secretion of hormones or the triggering of cell replication. Aberrations in protein interactions play a role in the progress of diseases including cancer, diabetes, cardiovascular and neurological disorders, among many others. Aberrations in the WW protein domain family specifically have been implicated in health problems ranging from hypertension and muscular dystrophy to immunodeficiency.

"At the heart of many diseases are disruptions or alterations in protein-protein interaction networks," said Alex Titomirov, Ph.D., InforMax chief executive officer and chairman. "In order to better identify the complex interacting pathways involved in most cellular processes, scientists need to visualize these protein-protein interactions and correlate them with available sequence, expression, and functional information. The integration of our software with the AxCell database will allow subscribers to use this valuable information to obtain more complete answers to biologically relevant questions."

In January 2001, AxCell announced that company scientists had completed the map of interactions in the WW Protein Domain, representing the first of the body`s 60-80 protein domains to be mapped successfully. AxCell expects to make substantial progress toward complete mapping of two additional protein domains -- the PDZ and SH3 domains -- in 2001. The PDZ and SH3 domains have been implicated in cancer, inflammatory disease, cardiovascular disease and stroke.

The GenoMax Protein-Protein Interaction Module features new visual and analytical tools for the access and enhancement of the IFP data, including:

* a Graphical Affinity Matrix Viewer that clearly identifies the matrix
of protein interactions;

* a Protein Network Viewer that identifies specific protein interaction
pathways;

* the ability to filter, sort, and cluster data to target specific
relationships;

* the ability to save selected protein networks into the Oracle(R)
database for analysis;

* the ability to view sequence information for any molecules in a
pathway; and

* complete integration with all GenoMax modules.


"We are very excited that AxCell`s findings in mapping protein interactions, including the data from the WW Domain, will be available through GenoMax. This collaboration will bring the exciting research information in the IFP database to leaders in the pharmaceutical and biotechnology industries as we move closer to our goal of completing the map of all human protein interactions," said Brian R. Bullard, AxCell vice president and chief information officer. About InforMax

InforMax is a global leader in bioinformatics, the key enabling technology for scientists and research organizations working to understand and extract value from the massive amounts of data generated by genome sequencing. InforMax products are used by more than 1300 research organizations and more than 22,000 individual scientists worldwide (as of December 31, 2000). The Company was founded in 1990 by Alex Titomirov, Ph.D., with the mission to unlock value in the genomic revolution through delivery of bioinformatics software for high-throughput research and discovery. InforMax bioinformatics software solutions enable a full range of gene-to-genome analysis, interpretation and data mining. Its market-leading products include Vector NTI Suite(R), the most comprehensive desktop software suite available for molecular biology, Vector NTI Enterprise(TM), and GenoMax(TM) for enterprise bioinformatics. Additional information about InforMax can be found at the company`s site on the World Wide Web at http://www.informaxinc.com . About AxCell

AxCell Biosciences, a subsidiary of Cytogen Corporation, is a leader in the effort to chart protein signaling pathways in the human proteome as a means of discovering new drug targets. In conjunction with InforMax, AxCell is developing a proprietary protein-pathway database, the Inter-Functional Proteomic Database(TM) (IFP Database), as a discovery and development tool for subscribers in the pharmaceutical, biotechnology and agricultural industries. For additional information on AxCell Biosciences and Cytogen Corporation, visit www.axcellbio.com or www.cytogen.com .

Statements in this press release that are not strictly historical are "forward-looking" statements, which involve a high degree of risk and uncertainty. Such statements are only predictions, and the actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to differences include, but are not limited to, risks associated with the InforMax`s technologies and the need to keep pace with rapid technological change, the Company`s dependence for future revenues on its ability to increase sales of its enterprise platform and successfully establish the GenoMax brand, the Company`s dependence on developing and maintaining strategic alliances, development and availability of competitive products or technologies, the possibility that the Company may not achieve or maintain profitability in the future, the likelihood that the Company`s results may fluctuate from quarter to quarter, dependence on patents and the ability to defend the Company`s intellectual property rights. These factors and others are more fully described in the Company`s Registration Statement on Form S-1, as filed with the Securities and Exchange Commission. The Company specifically disclaims any intention or duty to update any forward-looking statements, and these statements represent the Company`s current outlook only as of the date given.

InforMax and the InforMax logo are registered trademarks and GenoMax is a trademark of InforMax, Inc. All other products or company names are used for identification purposes only, and may be the trademarks of their respective owners.


/CONTACT: Investor Relations, Jerry Parrott of InforMax, 240-747-4010 or [e-mail]; or media, Greta Grass of Ketchum for InforMax, 202-835-9484, or [e-mail]; or Jim Wetmore of Berry & Company for AxCell and Cytogen, 212-279-2060, or [e-mail]/

[Wunram]

Cytogen Reports Successful Launch of BrachySeed(TM); Several Long Term Purchasing Agreements Signed

PRINCETON, N.J., Feb. 22 /PRNewswire/ -- Following the January launch of BrachySeed, a second-generation radioactive iodine implant for the treatment of prostate cancer, Cytogen Corporation (Nasdaq: CYTO) has recently signed long term purchasing agreements with several leading prostate cancer treatment centers in the U.S. for the use of the product. Cytogen completed the agreements soon after initiating extensive pre-marketing activities, including an educational symposium attended by the leading brachytherapy specialists in the country.

"In addition to our extensive pre-marketing activities, our sales force has been actively promoting BrachySeed and their efforts are already paying off. The recent commitments confirm the unique characteristics of BrachySeed`s design and its role as the only second-generation seed on the market," said Terry Novak, Cytogen`s Vice President of Marketing and Sales.

In addition to BrachySeed, the company reports that ProstaScint has also been included in selected purchasing agreements. ProstaScint is the only monoclonal antibody imaging agent available for detecting the spread of prostate cancer. "BrachySeed and ProstaScint together represent better ways to diagnose, stage and treat prostate cancer. The fact that both products have been included in agreements reinforces the synergies that have been created by the addition of BrachySeed to Cytogen`s prostate cancer product portfolio. We expect product sales to continue to grow as we complete negotiations with other centers," said Mr. Novak. Cytogen licensed BrachySeed`s exclusive U.S. marketing rights from Draximage, Inc. in October of 2000.

BrachySeed is a second-generation radioactive pellet that is directly implanted into the prostate to treat localized prostate cancer. Because BrachySeed is robotically manufactured each seed is of the same high quality and accuracy. BrachySeed`s unique central weld provides enhanced visualization and safety and delivers more uniform dimensional characteristics and radiation dose pattern than other currently available seeds.

In one of the recently signed agreements, ProstaScint was selected as the key diagnostic agent in a best practice pathway designed to optimize the treatment of prostate cancer in over 1,500 patients.

"The inclusion of ProstaScint in the best practice pathway validates its clinical utility in detecting the spread of prostate cancer in patients with recurrent disease and in newly diagnosed high risk patients. One of our most important objectives now will be to help more high risk and recurrent disease patients realize the value of having a ProstaScint scan," Mr. Novak added. ProstaScint has also been included in the recently published National Comprehensive Cancer Network (NCCN) Practice Guidelines for Prostate Cancer.

Cytogen Corporation is a biopharmaceutical company based in Princeton, NJ. The company`s two principal lines of business, proteomics and oncology, are built upon its expertise in antibodies and molecular recognition and are directed principally to development of novel products for the diagnosis, imaging, staging and treatment of prostate cancer and a proteomics-driven drug discovery platform. For additional information, visit www.cytogen.com.

AxCell Biosciences, a subsidiary of Cytogen Corporation, is a leader in the effort to chart protein-signaling pathways in the human proteome as a means of discovering new drug targets. In conjunction with InforMax, AxCell is developing a proprietary protein-pathway database, the Inter-Functional Proteomic Database(TM) (IFP Database), as a discovery and development tool for subscribers in the pharmaceutical, biotechnology and agricultural industries. For additional information on AxCell Biosciences, visit www.axcellbio.com.

This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Information in this press release, which is not historical, is forward looking and involves a number of risks and uncertainties. Investors are cautioned not to put any undue reliance on any forward-looking statement. The Company`s actual results may differ materially from the Company`s historical results of operations and those discussed in the forward-looking statements for various reasons, including, but not limited to the Company`s ability to carry out its business plan, successful development and commercial acceptance of its products, ability to fund development necessary for existing products and for the pursuit of new product opportunities, the risk of whether products result from development activities, protection of its intellectual property portfolio, ability to integrate in-licensed products, ability to establish and successfully complete clinical trials where required for product approval, the risk associated with obtaining the necessary regulatory approvals, dependence on its partners for development of certain projects, the ability to obtain foreign regulatory approvals for products and to establish marketing arrangements in countries where approval is obtained, and other factors discussed in the Company`s 1999 Form 10-K and from time-to-time the Company`s other filings with the Securities and Exchange Commission.

/CONTACT: Larry Hoffman, Vice President and CFO of Cytogen, 609-750-8200/

[Wunram]

Cytogen CEO Reiser, Ciphergen VP Verhoef, and Monument Funds` Analyst Mireskandari Preach Proteomics on BioTalk Radio Program

ROSEVILLE, Calif., Feb. 28 /PRNewswire/ -- For some, protein discovery is finding a can of tuna behind the peanut butter in the cupboard. But to the biotech enthusiast, protein discovery and application is called "proteomics," a science that can be interesting and profitable.

BioTalk host Lynn Sutherland will unravel the proteomics universe with guests from Ciphergen (Nasdaq: CIPH), Cytogen (Nasdaq: CYTO) and fund manager Dr. Alidad Mireskandari. To listen to the program click on www.informedinvestors.com or www.broadcast.com/shows/biotech, from 11 a.m.-noon, EST, or tune in on your radio at WMET 1150 AM in Gaithersburg, MD.

Ciphergen VP of Sales/Marketing Martin Verhoef will explain what a "protein chip" is and answer questions about the services Ciphergen provides. Ciphergen enables protein discovery, characterization and assay development to provide researchers with a better understanding of biological functions at the protein level.

Cytogen President and CEO Dr. H. Joseph Reiser will give a historical overview of the company and discuss how Cytogen`s two lines of business, proteomics and oncology, relate. Cytogen has four marketed products, each of which has been approved by the FDA: ProstaScint(R); BrachySeed; OncoScint CR/OV(R) and Quadramet(R).

Dr. Alidad Mireskandari of Monument Funds will offer the perspective of a fund manager. Mireskandari will describe the differences/synergies between proteomics and genomics and tell listeners about emerging trends in the space. Mireskandari will share insights and picks in the sector as the manager of the Monument Genomics Fund and the Monument Medical Sciences Fund.

InformedInvestors.com is the conduit for unfiltered communication between individual investors and the executives of technology and biotechnology companies. Live virtual and onsite Forums, special webcasts, original editorial pieces and weekly radio shows help put individual investors in the analyst`s chair.

Informed Investors will host its next biotechnology conference on March 10 in San Diego. Gene Logic, IDEC Pharmaceuticals and Cell Genesys are among the presenters. Visit www.informedinvestors.com or call 800-992-4683 for information.


/CONTACT: Brian Finnigan or Steve Chanecka, 916-780-6100, or 800-992-4683, both of InformedInvestors.com/

[Wunram]

mal wieder was interessantes - sollte Auftrieb geben


Progenics Pharmaceuticals and Cytogen Create Fully Human Monoclonal Antibodies for Prostate Cancer Therapy through Collaboration With Abgenix

NEW ORLEANS, March 27 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) and Cytogen Corporation (Nasdaq: CYTO) have successfully created human monoclonal antibodies, using XenoMouse(TM) technology from Abgenix, Inc. (Nasdaq: ABGX), that target prostate specific membrane antigen (PSMA), a marker found on prostate cancer cells. The Progenics-Cytogen joint venture, the PSMA Development Company LLC, has entered into a collaboration with Abgenix to use the company`s XenoMouse technology for generating fully human antibodies to PSMA. Terms of the agreement were not disclosed. The scientific findings were announced today by Progenics at the Annual Meeting of the American Association of Cancer Research in New Orleans.

Human monoclonal antibodies are laboratory-produced "clones" of antibodies that are formed by the body in response to specific antigens or "foreign" invaders. Antigens are found on the surface of infectious agents, tumor cells, or foreign tissue cells. The Progenics-Cytogen joint venture plans to develop three approaches to human monoclonal antibodies -- either "naked," linked to toxins or radio-labeled -- capable of selectively targeting and destroying PSMA-expressing cancer cells. Clinical trials in prostate cancer patients of a human monoclonal antibody to PSMA are scheduled to begin next year.

"Because PSMA is abundantly expressed on prostate cancer cells, it is an attractive target for antibody-based immunotherapies," said Warren D. W. Heston, Ph.D., Director of the Research Program in Prostate Cancer at The Cleveland Clinic Foundation, and the discoverer of PSMA. "We believe that the highly specific interaction between these human antibodies and prostate cancer cells may result in potent new therapies for this deadly disease. Compared with mouse or part-mouse monoclonal antibodies, fully human monoclonal antibodies are preferred for therapy, because they persist longer in the body and are less likely to be recognized as foreign, allowing for repeated dosing as needed to complete a successful course of treatment."

"Our new collaboration with Progenics Pharmaceuticals and Cytogen is further evidence of the growing interest of biopharmaceutical companies in generating novel therapeutic antibody product candidates using XenoMouse technology," said R. Scott Greer, Chairman and Chief Executive Officer of Abgenix. "In cancer therapy, such antibodies hold the promise of locating and destroying cancer cells that may go undetected or are inaccessible to surgery or radiation therapy, with minimal side effects compared to conventional chemotherapy."

Prostate cancer is the second leading cause of cancer death among men in the United States, exceeded only by lung cancer. The American Cancer Society estimates that during 2001, approximately 198,100 new cases of prostate cancer will be diagnosed in the U.S., and 31,500 will die of this disease. About 11% of men with prostate cancer are at high risk for metastatic spread of the disease, and nearly 40% have local recurrence of the disease.

In addition to the antibody strategy described above, the joint venture between Progenics and Cytogen is also pursuing a parallel program for the development of therapeutic vaccines which target PSMA and are directed at stimulating a patient`s immune system to eradicate his own cancer. The companies anticipate that a prostate cancer vaccine currently in late stage pre-clinical development could be tested in patients later this year. Company Profiles

Progenics Pharmaceuticals, Inc., Tarrytown, NY, is a biopharmaceutical company focusing on the development and commercialization of products for the treatment and prevention of viral, cancer, and other life-threatening diseases. The Company applies its immunological expertise to develop biopharmaceuticals to fight viral diseases, such as human immunodeficiency virus (HIV) infections, and cancers, such as malignant melanoma and prostate cancer. The Company has initiated Phase II clinical trials of its lead HIV product, PRO 542, a viral entry inhibitor. The Company is developing follow-on product candidates in HIV infection: PRO 367 has completed a Phase I study, PRO 140 is preparing to commence Phase I/II trials, and a lead therapeutic candidate has been selected from a novel class of anti-HIV compounds known as sulfated CCR5 peptides. The Company is also engaged in programs to discover and develop small-molecule HIV therapeutics that target the fusion co-receptors of the virus and other programs focusing on HIV attachment and fusion. The Company is developing cancer immunotherapies based on PSMA (prostate specific membrane antigen) technology. The Company`s most clinically advanced product, GMK, is a cancer vaccine in a pivotal Phase III clinical trial for the treatment of malignant melanoma. Progenics is also prepared to commence Phase II trials with a second cancer vaccine, MGV, with broad application to a variety of cancers. The Company is also developing a novel small-molecule antioxidant, dehydroascorbic acid (DHA), to treat stroke and other disorders.

Cytogen Corporation, Princeton, NJ, is a biopharmaceutical company whose two principal lines of business, proteomics and oncology, are built upon its expertise in antibodies and molecular recognition and are directed principally to development of novel products for the diagnosis, imaging, staging and treatment of prostate cancer and a proteomics-driven drug discovery platform. The Company exclusively licenses the worldwide rights to the PSMA technology from the Memorial Sloan-Kettering Cancer Center. The Company`s in vivo immunotherapy development program is being conducted through its joint venture with Progenics Pharmaceuticals, Inc. AxCell Biosciences, a subsidiary of Cytogen Corporation, is a leader in the effort to chart protein-signaling pathways in the human proteome as a means of discovering new drug targets. In conjunction with InforMax, AxCell is developing a proprietary protein-pathway database, the ProChart Database(TM), as a discovery and development tool for subscribers in the pharmaceutical, biotechnology and agricultural industries.

Abgenix, Inc., Fremont, CA, is a biopharmaceutical company focused on the development and commercialization of fully human monoclonal antibody therapies for a variety of diseases. The company`s antibody technology platform, which includes XenoMouse(TM) technology, enables the rapid generation and selection of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy. Abgenix leverages its leadership position in human antibody technology by building a large and diversified product portfolio through the establishment of licensing arrangements with multiple pharmaceutical, biotechnology and genomics companies and through the development of its own internal proprietary products.

This press release contains forward-looking statements. Any statements contained herein that are not statements of historical fact may be forward-looking statements. When the Companies use the words "anticipates," "plans," "expects" and similar expressions they are identifying forward-looking statements. Such forward-looking statements involve risks and uncertainties which may cause the companies` actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. Such factors include, among others, the uncertainties associated with product development, the risk that clinical trials will not commence when or proceed as planned, the risks and uncertainties associated with dependence upon the actions of the companies` corporate, academic and other collaborators and of government regulatory agencies, the risk that products that appear promising in early clinical trials do not demonstrate efficacy in larger-scale clinical trials, the uncertainty of future profitability and other factors set forth more fully in the companies` Annual Reports on Form 10-K for the fiscal year ended December 31, 1999 and other periodic filings with the Securities and Exchange Commission to which investors are referred for further information. In particular, the companies cannot assure you that any of the their programs will result in a commercial product. The companies do not have a policy of updating or revising forward-looking statements, and thus it should not be assumed that the companies` silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements.

Statements made in this press release about the therapeutic benefit of an anti-PSMA antibody, Abgenix`s XenoMouse technology, product development activities and collaborative arrangements other than statements of historical fact, are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials, the progress of research and product development programs, the regulatory approval process, competitive products, future capital requirements and the extent and breadth of Abgenix`s patent portfolio. Please see Abgenix`s public filings with the Securities and Exchange Commission for information about risks that may affect Abgenix. Editor`s Note:

Additional information on the companies in this press release is available at http://www.progenics.com, http://www.cytogen.com, and http://www.abgenix.com. This release is available on the Internet at http://www.noonanrusso.com


/CONTACT: Richard W. Krawiec, Ph.D., VP, Investor Relations and Corporate Communications of Progenics Pharmaceuticals, Inc., 914-789-2800, [e-mail]; Lawrence R. Hoffman, Chief Financial Officer of Cytogen Corporation, 609-750-8205; Ina Cu-Unjieng, Manager, Investor Relations and Public Relations of Abgenix, Inc., 510-608-4662; Emily Poe of Noonan/

[Wunram]

AxCell Biosciences Previews ProChart(TM), Its Novel Proteomics Database Product

PRINCETON, N.J., April 4 /PRNewswire/ -- AxCell Biosciences Corporation, a subsidiary of Cytogen Corporation (Nasdaq: CYTO), today announced that, in conjunction with InforMax, it successfully completed a seminar series on high- throughput research featuring the Company`s ProChart(TM) database product. ProChart, formerly known as the Inter-Functional Proteomic Database(TM), is a proprietary protein pathway database which measures protein domain-ligand interactions in a high-throughput manner. ProChart will be marketed by InforMax, Inc. within its GenoMax(TM) enterprise bioinformatics platform. During March, the Company displayed ProChart in six cities across the United States using InforMax`s Protein-Protein Interaction module, a new addition to the GenoMax(TM) enterprise software package. This six-city seminar series, which highlighted the technology behind ProChart and detailed the use of the database in pharmaceutical research, was designed by InforMax to showcase their, and partner, products and services and provide an educational forum for pharmaceutical scientists and researchers on commercial advances in bioinformatics, genomics and proteomics.

"With such data, researchers may better pinpoint pathway changes associated with diseases and more accurately select points of intervention for treatment," said John D. Rodwell, Ph.D, President and Chief Technology Officer of AxCell. "We believe that these seminars have helped prepare the market for launch of ProChart this month."

In addition, AxCell has finalized plans for expansion at its Newtown, PA facilities. Construction will begin shortly which, when complete, will add approximately 5500 sq. ft. of workspace, virtually all of which will be used for laboratory space for increased molecular biology, chemistry and screening activities designed to accelerate the acquisition of protein interaction data for use in its ProChart database product and for more effective mining of its data.

As part of its efforts to acquaint the pharmaceutical and biotechnology markets with its ProChart product, AxCell will be presenting at a number of future conferences. The Company is currently scheduled to speak at the 5th Annual Congress on Drug Discovery in Stuttgart, Germany in April, the Proteomics 2001 Conference in Philadelphia in May, the HTT Expo in Philadelphia and the Proteomics Conference in San Francisco which both take place in June. Cytogen Hires Financial Advisor

Cytogen Corporation is currently engaged in two highly competitive lines of business; oncology and proteomics. Cytogen recognizes the need to strengthen each of its businesses in order to enhance shareholder value. Given the challenges of increasing shareholder value and raising capital in today`s marketplace, the Board of directors has engaged UBS Warburg LLC as its financial advisor in order to assist the Company in pursuing various strategic alternatives, including but not limited to marketing arrangements, research and development collaborations, international collaborations, joint ventures and financing opportunities.

About AxCell Biosciences

AxCell Biosciences Corporation is conducting research and development in functional proteomics, the identification of protein interactions and signaling pathways within cells and their relationship to disease processes. Proteomics research efforts can be categorized as structural and functional. Structural proteomics, or protein expression, measures the number and types of proteins present in normal and diseased cells. This approach is useful in defining the structure of proteins in a cell. Some of these proteins may be targets for drug discovery. However, the role of the protein in the disease is still not defined. AxCell`s proteomics business is focused upon functional proteomics, the study of proteins` biological activities. An important function of proteins is the transmission of signals using intricate pathways populated by proteins which interact with one another. Elucidating the role proteins play in these signaling pathways allows a better understanding of their function in cellular behavior and permits identification of potential drug targets. Protein-protein interactions form the core of the Company`s ProChart(TM) Database. AxCell`s plans to offer ProChart(TM) to the pharmaceutical industry as a tool to accelerate the drug discovery process. For additional information on AxCell Biosciences, visit www.axcellbio.com.

About Cytogen Corporation

Cytogen Corporation is a biopharmaceutical company based in Princeton, NJ. The Company`s two principal lines of business, proteomics and oncology, are built upon its expertise in antibodies and molecular recognition and are directed principally to development of novel products for the diagnosis, imaging, staging and treatment of prostate cancer and a proteomics-driven drug discovery platform. For additional information, visit www.cytogen.com.

This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Information in this press release, which is not historical, is forward-looking and involves a number of risks and uncertainties including those discussed in the Company`s 2000 Form 10-K and from time-to-time the Company`s other filings with the Securities and Exchange Commission. Investors are cautioned not to put any undue reliance on any forward-looking statement. The Company`s actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include, but are not limited to, uncertainties associated with the Company`s ability to sustain its intellectual property positions on its proteomics technology, and the successful development and market acceptance of the technology. In particular, the Company cannot assure you that the protein interaction program will result in the commercialization of a successful product or whether any strategic alternative or financing will be available at all on terms that are in the best interests of the Company and its shareholders. The Company specifically disclaims any intention or duty to update any forward-looking statements, and these statements represent the Company`s outlook at this time.


/CONTACT: Lawrence R. Hoffman, Vice President and CFO of Cytogen, 609-750-8200/

[Wunram]

jetzt müssen wir den mist der letzten Tage wieder reinholen!

heute guter start!

CYTO Nasdaq-NM $ 2.8438 +0.3438 +13.75% 16,700

[Wunram]

mein Hoffen der letzten Woche hat sich nicht bestätigt, dafür macht CYTO was fürs image:

Michael D. Becker Appointed VP Investor Relations And Corporate Communications at Cytogen

PRINCETON, N.J., April 9 /PRNewswire/ -- Cytogen Corporation (Nasdaq: CYTO) today announced that Michael D. Becker has joined the company as vice president, investor relations and corporate communications.

For more than a decade, Michael D. Becker has been an influential analyst and commentator for the biotechnology industry. Most recently, he was with Wayne Hummer Investments LLC, a Chicago-based regional brokerage firm, where he held senior positions as a biotechnology analyst, investment executive and portfolio manager. Mr. Becker also served on the board of directors for the Chicago Biotech Network, a nonprofit trade association for the biotechnology industry in Illinois. A nationally recognized spokesperson on issues in biotechnology, Mr. Becker has been featured in many of the nation`s most influential business and healthcare media outlets. He is also the founder and editor of "Beck on Biotech," a highly-regarded monthly biotechnology investment newsletter.

"In products to treat prostate cancer and in researching the human body`s protein interactions to develop new and more effective therapies for many other diseases, Cytogen is already an industry leader with significant potential. I am very excited to be joining such a winning team," Mr. Becker said.

"Michael Becker has an outstanding reputation in our industry, and we are very pleased that he will be joining Cytogen," said H. Joseph Reiser, Ph.D., chief executive officer of Cytogen Corporation. "He is the ideal professional to lead our efforts to communicate the exciting and often complex advances in our work in the years ahead. He will be an important voice in our efforts to inform investors and the medical and patient communities about Cytogen`s products, technology and business strategy."

Cytogen Corporation is a biopharmaceutical company based in Princeton, NJ. The Company has two principal lines of business: a product-based oncology focus and a proteomics drug discovery platform. Cytogen`s expertise in monoclonal antibodies and molecular recognition are directed principally to the development of novel products for the diagnosis, imaging, staging and treatment of prostate cancer and a proteomics-driven drug discovery platform. For information regarding currently marketed products and general corporate information, visit www.cytogen.com.

AxCell Biosciences, a subsidiary of Cytogen Corporation, is a leader in the effort to chart protein-signaling pathways in the human proteome as a means of discovering new drug targets. AxCell is developing a proprietary protein-pathway database, the ProChart(TM) database as a discovery and development tool for subscribers in the pharmaceutical, biotechnology and agricultural industries. For additional information on AxCell Biosciences, visit www.axcellbio.com.

/CONTACT: Media: Jim Wetmore of Berry & Company, 212-279-2060 or [e-mail], for Cytogen; or Investor Relations: Mary Coleman of Cytogen Corporation, 609-750-8224/

[Wunram]

New Proteomics Database Identifying Protein Interactions in the Human Body Introduced in Europe by AxCell Biosciences and InforMax
/FROM PR NEWSWIRE PHILADELPHIA 800-523-4424/ INMX CYTO MTC PDT TO BUSINESS AND MEDICAL EDITORS:

New Proteomics Database Identifying Protein Interactions in the Human Body
Introduced in Europe by AxCell Biosciences and InforMax

ProChart Database(TM) to Make Axcell`s Research in Mapping Interactions In
All of the Body`s 60-80 Protein Domain Families Available for Drug Discovery
And Other Medical Research Using GenoMax(TM) Advanced Bioinformatics Software

Database Includes AxCell`s Map of WW Domain, First Protein Domain Family Ever
To be Mapped, Which is Believed to Affect Health Problems Including
Hypertension, Muscular Dystrophy and Immunodeficiency.


PRINCETON, N.J., April 24 /PRNewswire Interactive News Release/ -- The new ProChart(TM) Database of protein interactions in the human body will be introduced in Europe this week, it was announced today by AxCell Biosciences Corporation, a subsidiary of Cytogen Corporation (Nasdaq: CYTO), and InforMax, Inc. (Nasdaq: INMX).

The database will include the results of AxCell`s successful effort to map all of the interactions of one of the body`s 60-80 protein domain families. In January, 2001, AxCell announced the completion of the map of the WW Protein Domain, which is believed to have an impact on health problems including hypertension, muscular dystrophy and immunodeficiency. AxCell is working to complete the map of all signal transduction protein interactions in the human body within four years.

In March, AxCell introduced ProChart in six cities across the United States using InforMax`s Protein-Protein Interaction Analysis (PPI) module, which will be available in the next release of the GenoMax(TM) enterprise bioinformatics platform, the proprietary advanced bioinformatics software from InforMax.

ProChart is a database of protein-to-protein interactions, created using AxCell`s patented, high-throughput technology, which differs from the most widely used method for studying protein interactions called yeast two-hybrid (Y2H). InforMax is currently marketing the ProChart Database to the pharmaceutical and biotechnology industries through multi-year subscriptions.

Marketing activities for ProChart in Europe begin with presentations at IBC`s Drug Discovery Technology 2001, the multidisciplinary biopharmaceutical conference held April 23-26 in Stuttgart, Germany. AxCell will also again participate in a seminar series with our marketing partner, InforMax. The series is scheduled for May in Europe with further details released by InforMax shortly.

Scientists at AxCell identified more than 69,000 different protein interactions of the WW domain, the name for one of the human body`s specific family of proteins and the initial family offered to ProChart database subscribers. In the future, AxCell anticipates adding PDZ and SH3, two domain families involved with diseases such as stroke, Alzheimer`s, diabetes, cancer, HIV and osteoporosis. The Company will also chart increasingly greater portions of the proteome and add these results to ProChart. Subscription rates will be based on the amount and quality of data available.

"We have been quite pleased with the interest in ProChart in the U.S.," said Brian R. Bullard, vice president and chief information officer of AxCell Biosciences. "Our technology can positively impact numerous steps in research and development, such as target identification and validation, which we believe will offer high value to ProChart customers."

In addition to the high-profile Drug Discovery Technology 2001 conference, AxCell will be presenting at a number of future events, such as the IBC Proteomics 2001 Conference in Philadelphia in May, and Cambridge Healthtech`s HTT Expo in Philadelphia in June and Beyond Genome 2001 Conference in San Francisco, also in June. InforMax is continuing with the U.S. marketing activities for ProChart in the United States, with initial sales contacts and follow-up scheduled for the remainder of 2001. About Cytogen

Cytogen Corporation is a biopharmaceutical company based in Princeton, NJ. The Company has two principal lines of business: a product-based oncology focus and a proteomics drug discovery platform. Cytogen`s expertise in monoclonal antibodies and molecular recognition are directed principally to the development of novel products for the diagnosis, imaging, staging and treatment of prostate cancer and a proteomics-driven drug discovery platform. For information regarding currently marketed oncology products and general corporate information, visit http://www.cytogen.com. About AxCell Biosciences

AxCell Biosciences, a subsidiary of Cytogen Corporation, is a leader in the effort to chart protein-signaling pathways in the human proteome as a means of discovering new drug targets. AxCell is developing a proprietary protein-pathway database, the ProChart(TM) database as a discovery and development tool for subscribers in the pharmaceutical, biotechnology and agricultural industries. For additional information on AxCell Biosciences, visit http://www.axcellbio.com. About InforMax

InforMax is a leading global developer of bioinformatics software for High-Throughput Research(TM). InforMax products are used by more than 1650 research organizations and more than 22,000 individual scientists worldwide (as of December 31, 2000) to understand and extract value from the massive amounts of data being generated by the Genomic Revolution. Among the Company`s customers are 22 of the top 25 pharmaceutical companies. InforMax was founded in 1990 by Alex Titomirov, Ph.D. Its mission is to speed the pace of medical progress by enabling High-Throughput Research(TM), a process for compressing the time it takes to discover and validate the biological targets most likely to result in breakthrough therapeutics, diagnostics or biomolecular interventions to cure or prevent disease. InforMax bioinformatics software solutions enable a full range of gene-to-genome analysis, interpretation and data mining. Its market-leading products include Vector NTI(R) Suite, the most widely used software suite for enhancing laboratory productivity, and GenoMax(TM) for integrated analysis of genomic and proteomic data. Additional information about InforMax can be found at the company`s Web site at http://www.informaxinc.com.

This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Information in this press release, which is not historical, is forward-looking and involves a number of risks and uncertainties including those discussed in the Company`s 2000 Form 10-K and from time-to-time the Company`s other filings with the Securities and Exchange Commission. Investors are cautioned not to put any undue reliance on any forward-looking statement. The Company`s actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include, but are not limited to, uncertainties associated with the Company`s ability to sustain its intellectual property positions on its proteomics technology, and the successful development and market acceptance of the technology. In particular, the Company cannot assure you that the protein interaction program will result in the commercialization of a successful product. The Company specifically disclaims any intention or duty to update any forward-looking statements, and these statements represent the Company`s outlook at this time.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X24534544



/CONTACT: Jim Wetmore of Berry & Company, 212-279-2060, for Cytogen - Axcell; Investor Relations: Michael Becker, VP, Investor Relations & Corporate Communications of Cytogen Corporation, 609-750-8200; or Angela Peacock of InforMax, 240-747-4169

[Wunram]

Cytogen Reports First Quarter 2001 Results; Product Sales Advance 25% Over the Prior Year`s Quarter

PRINCETON, N.J., April 26 /PRNewswire/ -- Cytogen Corporation (Nasdaq: CYTO) today reported its consolidated financial results for the first quarter period ended March 31, 2001. The Company reported a net loss of $2.65 million or $0.03 per share, compared to a net loss of $6.06 million or $0.08 per share for the first quarter of 2000. The loss for the first quarter of 2000 includes a one-time charge related to the adoption of the SEC`s Staff Accounting Bulletin No. 101 ("SAB 101") of $4.31 million or $0.06 per share.

Product sales increased from $1.87 million in the first quarter of 2000 to $2.34 million in the first quarter of 2001, an increase of 25%. Quadramet(R) royalty revenue for the first quarter of 2001 was $441,000, slightly below the $498,000 achieved in the first quarter of 2000. This decrease was partially due to a temporary, weather-related disruption in the supply of Quadramet from the manufacturer of the product during 2001, which has been resolved.

Commenting on the results, H. Joseph Reiser, Ph.D., Cytogen`s president and chief executive officer, said, "We continue to be encouraged by the growth in product sales over the prior year`s quarter, reflecting our evolution into a biopharmaceutical company with multiple product opportunities and the establishment of an in-house oncology sales force to promote our products to urologists, radiation oncologists and nuclear medicine physicians.

"ProstaScint(R), our prostate cancer imaging agent, recorded its highest level of quarterly unit sales since the product was launched in 1997. We are building on this momentum by capitalizing on the synergies inherent between ProstaScint and BrachySeed(TM), a second-generation radioactive seed implant used to treat prostate cancer that is currently in its launch phase. In addition, we are working to expand the applications and markets for ProstaScint, such as performing image-guided therapy and obtaining more accurate prostate biopsies.

"Our marketing partner, Berlex Laboratories, Inc., continues to explore expanded uses for Quadramet in combination with other therapies commonly used to treat bone metastases, including chemotherapies, bisphosphonates and external beam radiation therapy. Future clinical trials, if successful, may significantly expand the market for Quadramet.

"As communicated previously, the market for OncoScint CR/OV(R) as a colorectal cancer diagnostic has been negatively affected by positron emission tomography or `PET` scans, which may produce the same or higher sensitivity than OncoScint. The decline in OncoScint revenue, however, was partially offset by early sales of BrachySeed from its initial launch phase.

"During the quarter, our proteomics subsidiary AxCell Biosciences, announced that it has successfully mapped the first protein domain family, the WW domain, believed to affect health problems including hypertension, muscular dystrophy and immunodeficiency. In addition, AxCell introduced the ProChart(TM) database of protein interactions in the human body using InforMax`s Protein-Protein Interaction Analysis (PPI) module, which will be available in the next release of the GenoMax(TM) enterprise bioinformatics platform, the proprietary advanced bioinformatics software from InforMax, Inc.

"Finally, during the quarter we strengthened our cash resources through a draw down on an Equity Financing Facility with Acqua Wellington North American Equities Fund, Ltd., for aggregate proceeds of $6.5 million," Dr. Reiser concluded.

Cytogen`s cash and cash equivalents at the end of the first quarter 2001 were $14.27 million compared to $11.99 million as of December 31, 2000.

Operating expenses in the first quarter of 2001 increased 29% to $5.82 million compared to $4.50 million in the first quarter of 2000, reflecting research and development efforts for AxCell`s proteomics program and increased selling and marketing expenses due to the Company`s efforts to expand its in-house sales force including costs associated with the January 2001 launch of BrachySeeds, radioactive implants used to treat prostate cancer.

Effective January 1, 2000, Cytogen adopted SAB 101, which requires up-front, non-refundable license fees to be deferred and recognized over future periods. As a result of the adoption of SAB 101, certain up-front, non-refundable license fees recognized in prior periods have been deferred and are being recognized over the terms of the relevant agreements. In the first quarter of 2000, Cytogen recorded a one-time, non-cash charge of $4.31 million representing the cumulative effect of this accounting change. Previously reported results for the first quarter of 2000 have been restated to reflect the adoption of SAB 101. About Cytogen

Cytogen Corporation is a biopharmaceutical company based in Princeton, NJ. The Company has two principal lines of business: a product-based oncology focus and a proteomics drug discovery platform. Cytogen`s expertise in monoclonal antibodies and molecular recognition are directed principally to the development of novel products for the diagnosis, imaging, staging and treatment of prostate cancer and a proteomics-driven drug discovery platform. The Company`s cancer management franchise currently comprises four FDA- approved products: ProstaScint(R), used to image the extent and spread of prostate cancer; BrachySeed(TM) implants for prostate cancer therapy, OncoScint CR/OV(R), a diagnostic imaging agent for colorectal and ovarian cancer; and Quadramet(R), for the relief of cancer-related bone pain. The Company has established a pipeline of product candidates based on its proprietary antibody and prostate specific membrane antigen, or PSMA, technologies, and holds a worldwide exclusive license to PSMA. Cytogen and its joint venture partner, Progenics Pharmaceuticals, are developing in-vivo immunotherapies for prostate cancer based on PSMA. The Company also has U.S. marketing rights to the late-stage product candidate Combidex(R), a magnetic resonance imaging agent being developed by Advanced Magnetics for the detection of lymph node metastases. About AxCell Biosciences

AxCell Biosciences, a subsidiary of Cytogen Corporation, is a leader in the effort to chart protein-signaling pathways in the human proteome as a means of discovering new drug targets. AxCell is developing a proprietary protein-pathway database, the ProChart(TM) database as a discovery and development tool for subscribers in the pharmaceutical, biotechnology and agricultural industries. For additional information on Cytogen, visit the Company`s web sites at http://www.cytogen.com and http://www.axcellbio.com.

This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Information in this press release, which is not historical, is forward looking and involves a number of risks and uncertainties. Investors are cautioned not to put any undue reliance on any forward-looking statement. The Company`s actual results may differ materially from the Company`s historical results of operations and those discussed in the forward-looking statements for various reasons, including, but not limited to the Company`s ability to carry out its business plan, to successfully develop and commercialize acceptance of its products such as ProChart(TM), ability to fund development necessary for existing products and for the pursuit of new product opportunities, the risk of whether products result from development activities, protection of its intellectual property portfolio, ability to integrate in-licensed products such as BrachySeed(TM), ability to establish and successfully complete clinical trials where required for product approval, the risk associated with obtaining the necessary regulatory approvals, dependence on its partners for development of certain projects, the ability to obtain foreign regulatory approvals for products and to establish marketing arrangements in countries where approval is obtained, and other factors discussed in the Company`s 2000 Form 10-K and from time-to-time the Company`s other filings with the Securities and Exchange Commission.


CYTOGEN CORPORATION AND SUBSIDIARIES
(All amounts in thousands except per share data)
(Unaudited)

CONDENSED CONSOLIDATED BALANCE SHEETS

MARCH 31, DECEMBER 31,
2001 2000
___________ ____________
Assets
Cash and Cash Equivalents $14,271 $11,993
Receivable on Income Tax Benefit Sold - 1,625
Accounts Receivable, net 2,155 1,841
Inventories 997 883
Property and Equipment, net 1,986 2,193
Other Assets 2,709 1,881
------ ------
Total Assets $22,118 $20,416
========= =========

Liabilities & Stockholders` Equity
Accounts Payable & Accrued Liabilities $5,167 $7,218
Other Current Liabilities 993 1,010
Long - Term Liabilities 4,762 4,970
Stockholders` Equity 11,196 7,218
------ ------
Total Liabilities & Stockholders` Equity $22,118 $20,416
========= =========


CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

THREE MONTHS ENDED
MARCH 31
2001 2000
________ ________
Revenues
Product Sales $2,335 $1,872
Royalty Revenue 441 498
License and Contract 215 273
-------- --------
Total Revenues 2,991 2,643
-------- --------

Operating Expenses 5,817 4,500
Interest Income, net (172) (111)
-------- --------

Loss before cumulative Effect of
Accounting Change (2,654) (1,746)
Cumulative Effect of Accounting Change* - (4,314)
-------- --------

Net Loss $(2,654) $(6,060)
========= =========


Net Loss Per Share:
Basic and Diluted Net Loss before Cumulative
Effect of Accounting Change $(0.03) $(0.02)
Cumulative Effect of Accounting Change* - (0.06)
-------- --------

Basic and Diluted Net Loss $(0.03) $(0.08)
========= =========

Weighted Average Common Shares Outstanding 76,244 71,630
========= =========

* In 2000, the Company recorded a non-cash charge for the cumulative
effect related to the adoption of SEC Staff Accounting Bulletin No.
101.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X39605712



/CONTACT: Investor Relations: Michael Becker, VP, investor relations & corporate communications of Cytogen, 609-750-8289/

[Dummschwaezer]

Seit ihr noch da!?

was ist da nur Los,welche News gibt es?
RT 4,31 +20% und in der 1 Stunde über 300T Aktien.
Das ist nicht Normal.

Gruß
DS

[Kanzler-neu]

Das lange Warten hat sich gelohnt!
www.cytogen.com/investors.html

Progenics ist in vorklinischen Tests der Durchbruch mit einer neuartigen Behandlung von Prostata-Krebs gelungen. Der Vertrieb für das Medikament liegt bei Cytogen, der Profit wird geteilt.

Gruß, Kanzler

[börsenfüxlein]

hier die newsSOURCE: Progenics Pharmaceuticals, Inc. and Cytogen Corporation
Progenics Pharmaceuticals and Cytogen Report Positive Immune System Responses From Prostate Cancer Vaccine
- Body`s own defenses mobilized to kill cancer cells -
SAN FRANCISCO, May 16 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX - news) and Cytogen Corporation (Nasdaq: CYTO - news) today announced that in preclinical studies their experimental prostate cancer vaccine generated a potent dual-immune response against PSMA (prostate specific membrane antigen), a well-recognized marker found on prostate cancer cells. The new PSMA-based therapeutic vaccine, which employs the body`s own defense mechanisms to identify and destroy prostate cancer cells, yielded both antibodies and killer T cells, the two principal mechanisms used by the immune system to eliminate harmful cells. The findings were presented yesterday by Progenics at the 37th Annual Meeting of The American Society of Clinical Oncology in San Francisco.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010410/PROGENICS )
``T cell- and antibody-based immunity represent two major arms of the human immune system,`` said William C. Olson, Ph.D., Progenics` Vice President, Research & Development. ``PSMA is an attractive target for vaccine therapy, because it is abundantly expressed on prostate cancer cells. This vaccine may provide a powerful way to train the body`s natural defenses to protect against the recurrence of this deadly disease. Importantly, PSMA-based immunotherapy is designed to destroy cancer cells while sparing healthy tissue.``

In the study, mice were immunized with a non-replicating virus that was genetically engineered to contain the human DNA sequence which encodes a form of PSMA protein. Each of the vaccinated animals generated high levels of both antibodies and CD8+ killer T cells that recognized PSMA-expressing target cells but not control cells that do not express PSMA. Unvaccinated animals exhibited no immunity to PSMA.

The PSMA gene was first discovered by scientists at Memorial Sloan- Kettering Cancer Center. PSMA is a cell-surface protein that is abundantly expressed on prostate cancer cells at all stages of disease, including advanced or metastatic disease. Further work has demonstrated that PSMA is also present at high levels on the newly formed blood vessels (neovasculature) needed for the growth and survival of many types of solid tumors. If PSMA- targeted therapies can destroy or prevent formation of these new blood vessels, the therapies may prove valuable in treating a broad range of cancers. The Progenics-Cytogen joint venture, the PSMA Development Company LLC, holds worldwide exclusive rights to PSMA technology for in vivo immunotherapy and is developing a portfolio of therapeutic product candidates designed to target this cancer marker.

Progenics Pharmaceuticals, Inc., of Tarrytown, NY, is a biopharmaceutical company focusing on the development and commercialization of products for the treatment and prevention of viral, cancer, and other life-threatening diseases. The Company applies its immunological expertise to develop biopharmaceuticals to fight viral diseases, such as human immunodeficiency virus (HIV) infections, and cancers, such as malignant melanoma and prostate cancer. The Company has initiated Phase II clinical trials of its lead HIV product, PRO 542, a viral-entry inhibitor. The Company is developing follow- on product candidates in HIV infection: PRO 367 has completed a Phase I study, PRO 140 is preparing to commence Phase I/II trials, and a lead therapeutic candidate has been selected from a novel class of anti-HIV compounds known as sulfated CCR5 peptides. The Company is also engaged in programs to discover and develop small-molecule HIV therapeutics that target the fusion co- receptors of the virus and other programs focusing on HIV attachment and fusion. The Company is developing cancer immunotherapies based on PSMA (prostate specific membrane antigen) technology. The Company`s most clinically advanced product, GMK, is a cancer vaccine in Phase III clinical trials for the treatment of malignant melanoma. Progenics is also developing a second cancer vaccine, MGV, with broad application to a variety of cancers. The Company is also developing a novel small-molecule antioxidant, dehydroascorbic acid (DHA), to treat stroke and other disorders.

Cytogen Corporation, of Princeton, NJ, is a biopharmaceutical company with an established and growing product line in prostate cancer and other areas of oncology, and a leadership position in proteomics research designed to accelerate drug discovery and development. In oncology, products include ProstaScint® (a monoclonal antibody-based imaging agent used to image the extent and spread of prostate cancer); BrachySeed(TM) (a second-generation radioactive seed implant for the treatment of localized prostate cancer), OncoScint CR/OV(TM) (a monoclonal antibody-based imaging agent for colorectal and ovarian cancer), and Quadramet(TM) (a therapeutic agent marketed for the relief of bone pain in prostate and other types of cancer). Cytogen is evolving a pipeline of oncology product candidates by exploiting its prostate specific membrane antigen, or PSMA, technologies which are exclusively licensed from Memorial Sloan-Kettering Cancer Center. AxCell Biosciences, a subsidiary of Cytogen Corporation, is a leader in the effort to chart protein-signaling pathways for use in accelerating drug discovery and development. In conjunction with InforMax, Inc., AxCell markets the ProChart(TM) database of protein interactions as a discovery and development tool for subscribers in the pharmaceutical, biotechnology and agricultural industries. Cytogen plans to use AxCell`s findings to develop novel drug targets independently or via collaborative ventures. For more information, visit http://www.cytogen.com.

This press release contains forward-looking statements. Any statements contained herein that are not statements of historical fact may be forward-looking statements. When the Companies use the words ``anticipates,`` ``plans,`` ``expects`` and similar expressions they are identifying forward-looking statements. Such forward-looking statements involve risks and uncertainties which may cause the companies` actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. Such factors include, among others, the uncertainties associated with product development, the risk that clinical trials will not commence when or proceed as planned, the risks and uncertainties associated with dependence upon the actions of the companies` corporate, academic and other collaborators and of government regulatory agencies, the risk that products that appear promising in early clinical trials do not demonstrate efficacy in larger-scale clinical trials, the uncertainty of future profitability and other factors set forth more fully in the companies` Annual Reports on Form 10-K for the fiscal year ended December 31, 2000 and other periodic filings with the Securities and Exchange Commission to which investors are referred for further information. In particular, the companies cannot assure you that any of the their programs will result in a commercial product. The companies do not have a policy of updating or revising forward-looking statements, and thus it should not be assumed that the companies` silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements.

cyto wurde heute außerdem 2mal auf cnbs erwähnt. derzeit + 35%. wird aber auch zeit.

füxlein

[CaptainChaos]

16.05. 22:10
Cytogen: Test erfolgreich, +43%
--------------------------------------------------------------------------------
(©BörseGo - http://www.boerse-go.de)

Cytogen steigt auf Schlusskursbasis um 42.86% auf $5.10. Das biopharmazeutische Unternehmen und Progenics Pharmaceuticals gaben bekannt, dass positive Resultate hinsichtlich einer experimentellen Prostata-Krebs-Behandlungsmethode erzielt werden konnten. Die Resultate wurden gestern von Progenics auf der 37th Annual Meeting of The American Society of Clinical Oncology in San Francisco präsentiert.

[Dummschwaezer]

Könnte die Behandlungsmethode auch auf
andere Krebsformen ausgeweitet werden?
Ich denke da z.B. an Brustkrebs....
Vieleicht mehr dazu am 23.Mai. bei
der UBS Warburg Global Specialty
Pharmaceuticat Conference in NY.

[Forum]

Nun sollten wir bald zweistellige Kurse sehen, oder ??

[CaptainChaos]

New Study Finds Innovative Prostate Cancer Imaging Agent Identifies Recurrence And Spread of Cancer Earlier

Study Suggests That ProstaScint(R) Diagnostic Scan, Developed and Marketed By
Cytogen Corporation, May Also Help Determine the Most Appropriate Treatment
For Recurrent Prostate Cancer
ANAHEIM, Calif., June 5 /PRNewswire/ -- According to a new study conducted by scientists at Duke University and Johns Hopkins medical centers, the use of an innovative prostate cancer diagnostic imaging agent may significantly improve a doctor`s ability to detect the location and extent of recurrent cancer in patients who have previously had their prostates removed. The findings were announced today at the annual meeting of the American Urological Association in Anaheim, California.

For patients who have had a radical prostatectomy, a procedure in which the entire prostate gland and some surrounding tissue is surgically removed, researchers found that the use of the radiolabeled imaging agent ProstaScint(R) (Capromab Pendetide) makes it possible to identify the existence and location of recurrent prostate cancer earlier than with previously available imaging methods. A radical prostatectomy is most often used to treat localized disease (prostate cancer confined to the gland). According to the American Cancer Society, nearly 40 of men with prostate cancer have local recurrence of the disease after surgery, and approximately 11 are at high risk for metastatic spread of the disease.

This multicenter study involved 255 men, who, after undergoing a radical prostatectomy, received no additional therapy and subsequently had an increase in the level of PSA (prostate-specific antigen) in their blood as the only indication that their cancer had recurred. These patients, whose PSA levels ranged from 0.1-4.0 ng/mL, were then given a ProstaScint scan to localize their disease. The ProstaScint scan identified recurrent disease in 72 of patients with serum PSA less than or equal to 4.0 ng/mL. Of 151 patients who also underwent additional imaging studies, bone and/or CT (computed tomography) scans identified recurrence in 12 (16/139) and 16 (15/92) of patients, respectively.

"In order for conventional imaging modalities such as a CT scan to detect a site of recurrence, a significant volume of prostate cancer must effect changes to normal anatomic structures. Often the recurrent disease is advanced prior to detection on a bone or CT scan. This study suggests that a ProstaScint scan may detect and localize recurrent prostate cancer earlier than previously thought possible for patients with a low serum PSA after radical prostatectomy," said Ganesh V. Raj, M.D., Ph.D., the lead author on the study from the Division of Urology, Duke University Medical Center.

ProstaScint(R) is a radiolabeled monoclonal antibody that specifically targets PSMA (prostate specific membrane antigen), a highly expressed marker found on prostate cancer cells. During a ProstaScint imaging procedure, the radiolabeled monoclonal antibody is administered intravenously into the patient, travels through the bloodstream and binds to prostate cancer cells. A gamma camera detects the radioactive isotope that has been attached to the antibody, identifying the specific sites of cancer.

"A better understanding of the location and extent of disease may help to determine the most appropriate course of therapy for recurrent prostate cancer and could potentially spare certain patients from the side effects associated with unnecessary treatments," added Thomas J. Polascik, M.D., Division of Urology at Duke University Medical Center.

Because PSMA is abundantly expressed on prostate cancer cells, Cytogen (Nasdaq: CYTO) is pursuing the development of a full range of prostate cancer management products and services throughout the progression of the disease, including therapeutic vaccines directed at stimulating a patient`s immune system to eradicate his own cancer, antibody-delivered therapeutic compounds and novel assays for detection of primary and recurrent prostate cancer. Cytogen`s in vivo immunotherapeutic development program is being conducted in collaboration with Progenics Pharmaceuticals, Inc.

Approximately one in every six men will develop prostate cancer. It is the second leading cause of cancer death among men in the United States, exceeded only by lung cancer. The American Cancer Society estimates that approximately 198,100 new cases of prostate cancer will be diagnosed this year in the U.S., and that 31,500 men will die of this disease.

Cytogen Corporation (Nasdaq: CYTO) of Princeton, NJ, is a biopharmaceutical company with an established and growing product line in prostate cancer and other areas of oncology, and a leadership position in proteomics research designed to accelerate drug discovery and development. In oncology, products include ProstaScint(R) (a monoclonal antibody-based imaging agent used to image the extent and spread of prostate cancer) BrachySeed(TM) (a second-generation radioactive seed implant for the treatment of localized prostate cancer), Quadramet(TM) (a therapeutic agent marketed for the relief of bone pain in prostate and other types of cancer), and OncoScint CR/OV(TM) (a monoclonal antibody-based imaging agent for colorectal and ovarian cancer). Cytogen is evolving a pipeline of oncology product candidates by exploiting its prostate specific membrane antigen, or PSMA, technologies, which are exclusively licensed from Memorial Sloan-Kettering Cancer Center. AxCell Biosciences, a subsidiary of Cytogen Corporation, is a leader in the effort to chart protein-signaling pathways for use in accelerating drug discovery and development. In conjunction with InforMax, Inc., AxCell intends to market the ProChart(TM) database of protein interactions as a discovery and development tool for subscribers in the pharmaceutical, biotechnology and agricultural industries. Cytogen plans to use AxCell`s findings to develop novel drug targets independently or via collaborative ventures. For more information, visit http://www.cytogen.com.

This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Information in this press release, which is not historical, is forward-looking and involves a number of risks and uncertainties. Investors are cautioned not to put any undue reliance on any forward-looking statement. The Company`s actual results may differ materially from the Company`s historical results of operations and those discussed in the forward-looking statements for various reasons, including, but not limited to the Company`s ability to carry out its business plan, to successfully develop and commercialize acceptance of its products such as ProChart(TM), ability to fund development necessary for existing products and for the pursuit of new product opportunities, the risk of whether products result from development activities, protection of its intellectual property portfolio, ability to integrate in-licensed products such as BrachySeed(TM), ability to establish and successfully complete clinical trials where required for product approval, the risk associated with obtaining the necessary regulatory approvals, dependence on its partners for development of certain projects, the ability to obtain foreign regulatory approvals for products and to establish marketing arrangements in countries where approval is obtained, and other factors discussed in the Company`s 2000 Form 10-K and from time-to-time the Company`s other filings with the Securities and Exchange Commission. The Company specifically disclaims any intention or duty to update any forward-looking statements, and these statements represent the Company`s current outlook only as of the date given.

MAKE YOUR OPINION COUNT - Click Here

http://tbutton.prnewswire.com/prn/11690X59314367


--------------------------------------------------------------------------------
Contact:

[Wunram]

New Studies Show Advanced Imaging Agent Identifies Prostate Cancer With Greater Accuracy

TORONTO, June 26 /PRNewswire/ -- A new study by doctors at New York University (NYU) School of Medicine found that it is possible to identify recurrent prostate cancer with greater precision by using the radiolabeled imaging agent ProstaScint(R) (Capromab Pendetide) in combination with other diagnostic imaging techniques. The results of this and two related studies were announced today at the 48th Society of Nuclear Medicine Annual Meeting in Toronto.

The study by researchers at NYU found that ProstaScint imaging, when combined or fused with MRI (magnetic resonance imaging) or CT (computed tomography) scans in a digital overlay, offers a more specific evaluation of prostate cancer than was possible using any of these imaging agents alone. The use of ProstaScint with other diagnostic tools reduced the rate of false positives by nearly 50%. In addition, fusion imaging helped to show that 17 patients thought to have had a spread of prostate cancer to lymph nodes may have only had a local recurrence of the disease.

"This study suggests that the fusion of ProstaScint with CT or MRI offers increased confidence in accurately staging the disease," said Elissa Kramer, M.D., co-author of the study and professor of clinical radiology with the NYU School of Medicine.

In related studies, Bruce Sodee, M.D., associate professor of radiology, Case Western Reserve University in Cleveland, OH, extended the work that led to last year`s Society of Nuclear Medicine "image of the year" by comparing the results of PET (positron emission tomography) imaging of fluorodeoxyglucose and CT- or MRI-fused ProstaScint imaging in patients newly diagnosed with prostate cancer. Following radical prostatectomy, a procedure in which the entire prostate gland and some surrounding tissue is surgically removed, the "gold standard" of histological confirmation from tissue samples established that fused ProstaScint imaging better identifies cancerous regions within the prostate than PET imaging.

"Last year we provided the first 3-D fusion images of ProstaScint uptake within the prostate. These further studies confirm our ability to specifically identify areas of cancer in the prostate gland, which may assist in targeting treatment directly to these sites," said Dr. Sodee.

Approximately one in every six men will develop prostate cancer. It is the second leading cause of cancer death among men in the United States, exceeded only by lung cancer. The American Cancer Society estimates that approximately 198,100 new cases of prostate cancer will be diagnosed this year in the U.S., and that 31,500 men will die of the disease.

"This information is really a call to action for many patients who should explore the full range of prostate cancer imaging capabilities as they evaluate their treatment options. Improved staging could lead to more appropriate treatments and improved quality of life," said John Page, executive director of Us Too! International, the world`s largest independent education and support network for men with prostate cancer and their families (www.ustoo.com).

ProstaScint(R), developed and marketed by Cytogen Corporation (Nasdaq: CYTO), is a radiolabeled monoclonal antibody that specifically targets PSMA (prostate specific membrane antigen), a highly expressed marker found on prostate cancer cells. During a ProstaScint imaging procedure, the radiolabeled monoclonal antibody is administered intravenously to the patient, travels through the bloodstream and binds to prostate cancer cells. A gamma camera detects the radioactive isotope that has been attached to the antibody, identifying the specific sites of cancer. Cytogen has initiatives underway at numerous partners in excellence (PIE) sites to provide coregistration (image fusion) capabilities to a broader audience.

Because PSMA is abundantly expressed on prostate cancer cells, Cytogen is pursuing the development of a full range of prostate cancer management products and services throughout the progression of the disease, including therapeutic vaccines directed at stimulating a patient`s own immune system to eradicate his cancer, antibody-delivered therapeutic compounds and novel assays for detection of primary and recurrent prostate cancer. Cytogen`s in vivo immunotherapeutic development program is being conducted in collaboration with Progenics Pharmaceuticals, Inc.

Cytogen Corporation of Princeton, NJ, is a biopharmaceutical company with an established and growing product line in prostate cancer and other areas of oncology, and a leadership position in proteomics research designed to accelerate drug discovery and development. In oncology, FDA-approved products include ProstaScint(R) (a monoclonal antibody-based imaging agent used to image the extent and spread of prostate cancer); BrachySeed(TM) (a uniquely designed next-generation radioactive seed implant for the treatment of localized prostate cancer), Quadramet(R) (a therapeutic agent marketed for the relief of bone pain in prostate and other types of cancer), and OncoScint CR/OV(R) (a monoclonal antibody-based imaging agent for colorectal and ovarian cancer). Cytogen is evolving a pipeline of oncology product candidates by exploiting its prostate specific membrane antigen, or PSMA, technologies, which are exclusively licensed from Memorial Sloan-Kettering Cancer Center. AxCell Biosciences, a subsidiary of Cytogen Corporation, is a leader in the effort to chart protein-signaling pathways for use in accelerating drug discovery and development. In conjunction with InforMax, Inc., AxCell intends to market the ProChart(TM) database of protein interactions as a discovery and development tool for subscribers in the pharmaceutical, biotechnology and agricultural industries. In addition, Cytogen plans to use AxCell`s proteomics technology to research and develop novel drug targets independently or via collaborative ventures. For more information, visit http://www.cytogen.com.

This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Information in this press release, which is not historical, is forward looking and involves a number of risks and uncertainties. Investors are cautioned not to put any undue reliance on any forward-looking statement. The Company`s actual results may differ materially from the Company`s historical results of operations and those discussed in the forward-looking statements for various reasons, including, but not limited to the Company`s ability to carry out its business plan, to successfully develop and commercialize acceptance of its products such as ProChart(TM), ability to fund development necessary for existing products and for the pursuit of new product opportunities, the risk of whether products result from development activities, protection of its intellectual property portfolio, ability to integrate in-licensed products such as BrachySeed(TM), ability to establish and successfully complete clinical trials where required for product approval, the risk associated with obtaining the necessary regulatory approvals, dependence on its partners for development of certain projects, the ability to obtain foreign regulatory approvals for products and to establish marketing arrangements in countries where approval is obtained, and other factors discussed in the Company`s 2000 Form 10-K and from time-to-time the Company`s other filings with the Securities and Exchange Commission. The Company specifically disclaims any intention or duty to update any forward-looking statements, and these statements represent the Company`s current outlook only as of the date given.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X18271258


/CONTACT: Jim Wetmore of Berry & Company, 212-279-2060, or Michael Becker of Cytogen Corporation, 609-750-8289/

[Der Pharmer]

Hey, warum sind die wieder soooo abgeschmiert ??

Waren die Zahlen so schlecht ??

[Wunram]

naja, eigentlich nicht, aber 1Cent mehr Verlust als erwartet!

Cytogen Reports Second Quarter 2001 Results; Product Sales Advance 22% Over the Prior Year`s Quarter; Quadramet Royalty Revenue Achieves a New Quarterly Record

PRINCETON, N.J., Aug. 7 /PRNewswire/ -- Cytogen Corporation (Nasdaq: CYTO), a biopharmaceutical company with an established and growing product line in prostate cancer and a leadership position in proteomics research, today reported its consolidated financial results for the three and six month periods ended June 30, 2001.

The Company reported a net loss of $3.09 million or $0.04 per share for the second quarter of 2001, compared to a net loss of $2.37 million or $0.03 per share for the second quarter of 2000. For the six months ended June 30, 2001, the Company reported a net loss of $5.74 million or $0.07 per share, compared to a net loss of $8.43 million or $0.12 per share for the same period in 2000. The loss for the six months ended June 30, 2000 includes a one-time, non-cash charge related to the adoption of the SEC`s Staff Accounting Bulletin No. 101 ("SAB 101") of $4.31 million or $0.06 per share.

Product sales, reflecting OncoScint(R), ProstaScint(R), and BrachySeed(TM), increased from $1.62 million in the second quarter of 2000 to $1.98 million in the second quarter of 2001, an increase of 22%. Royalty revenue from the sale of Quadramet(R) by Berlex Laboratories achieved a new quarterly record, growing from $508,000 in the second quarter of 2000 to $595,000 in the second quarter of 2001, an increase of 17%. Combined revenue derived from the sale of these four products increased from $2.13 million in the second quarter of 2000 to $2.58 million in the second quarter of 2001, an increase of 21% and the fourth consecutive quarter of double-digit comparable growth. Total revenues, which include licensing and contract fees, increased from $2.44 million in the second quarter of 2000 to $2.83 million in the second quarter of 2001.

Product related revenues for the six months ended June 30, 2001 were $5.35 million, compared to $4.50 million for the same period in 2000, representing an increase of 19%. Total revenues for the six months ended June 30, 2001 were $5.83 million, compared to $5.08 million for the same period in 2000.

Operating expenses in the second quarter of 2001 increased 22% to $6.03 million compared to $4.95 million in the second quarter of 2000. For the six months ended June 30, 2001, total operating expenses were $11.85 million, compared to $9.45 million for the same period in 2000. The increase in expenses was primarily due to research and development efforts to further AxCell`s proteomics program.

Cytogen`s cash and cash equivalents as of June 30, 2001 were $18.71 million compared to $11.99 million as of December 31, 2000.

Effective January 1, 2000, Cytogen adopted SAB 101, which requires up-front, non-refundable license fees to be deferred and recognized over future periods. As a result of the adoption of SAB 101, certain up-front, non-refundable license fees recognized in prior periods have been deferred and are being recognized over the terms of the relevant agreements. In the first quarter of 2000, Cytogen recorded a one-time, non-cash charge of $4.31 million representing the cumulative effect of this accounting change. Previously reported results for the six months ended June 30, 2000 have been restated to reflect the adoption of SAB 101.

"This quarter demonstrates that Cytogen continues to make significant strides in building shareholder value," said H. Joseph Reiser, Ph.D., Cytogen`s president and chief executive officer. "The increase in product sales over the prior period results from our evolution into a biopharmaceutical company with multiple product opportunities. The strategic decision to establish an in-house oncology sales force to promote our products is positively impacting our business. Importantly, the introduction of two additional products during this period -- the iodine version of BrachySeed and AxCell`s ProChart(TM) database -- provide substantial new revenue opportunities going forward."

Second Quarter Highlights:

-- Revenue derived from the sale of the Company`s four products increased
21%, representing the fourth consecutive quarter of double-digit
comparable growth.
-- Cytogen executed an agreement with its largest current shareholder,
the State of Wisconsin Investment Board (SWIB), to sell $8.19 million
of common stock. The Company sold a total of 1,820,000 registered
shares to SWIB at $4.50 per share.
-- Doctors at Duke and Johns Hopkins Universities reported that for
patients who have previously had a radical prostatectomy, a procedure
in which the entire prostate gland and some surrounding tissue is
surgically removed, the use of the radiolabeled imaging agent
ProstaScint makes it possible to identify the existence and location
of recurrent prostate cancer earlier than with previously available
imaging methods. The findings were reported at the annual meeting of
the American Urological Association.
-- Doctors at the New York University School of Medicine found that
ProstaScint images, when combined or fused with MRI (magnetic
resonance imaging) or CT (computed tomography) scans in a digital
overlay, offers a more specific evaluation of prostate cancer than
was possible using any of these imaging agents alone. The results of
this and two similar studies were reported at the 48th Society of
Nuclear Medicine Annual Meeting.
-- InforMax, Inc., a leading global provider of bioinformatics software
solutions, announced the release of GenoMax(TM) 3.1, which contains
the new GenoMax Protein-Protein Interaction Analysis (PPI) module, a
leading-edge proteomic application developed in conjunction with
AxCell Biosciences, a subsidiary of Cytogen Corporation. The PPI
module allows research scientists to quickly access and correlate the
protein pathway information in AxCell`s ProChart database with the
sequence, expression, distribution, structural and bibliographical
information that exists for the protein or pathway in question.
-- Progenics Pharmaceuticals, Inc. and Cytogen announced that in
preclinical studies their experimental prostate cancer vaccine
generated a potent antibody and killer T cell response against PSMA
(prostate specific membrane antigen), a well-recognized marker that
is highly expressed on prostate cancer cells. The findings were
presented by Progenics at the 37th Annual Meeting of The American
Society of Clinical Oncology.


"During the second half of 2001, we plan to launch a palladium version of BrachySeed, which represents our third new product introduction of the year. BrachySeed is a uniquely designed next-generation radioactive seed implant for the treatment of localized prostate cancer. In addition, AxCell Biosciences will seek to develop a broad range of alliances for additional applications of its proprietary Genetic Diversity Library(TM), Cloning of Ligand Targets(TM), and affinity screening technologies. Collectively, these platform technologies are used to generate data for the ProChart database, but they can also be deployed independently to extract additional value from AxCell`s technology," Dr. Reiser added.

The Company also announced today that S. Leslie Misrock resigned as a member of the board of directors due to health reasons. "We express our deep thanks and appreciation to Leslie for his hard work and leadership. He will be missed and we wish him a speedy recovery to full health," Dr. Reiser concluded. About Cytogen Corporation

Cytogen Corporation of Princeton, NJ, is a biopharmaceutical company with an established and growing product line in prostate cancer and other areas of oncology, and a leadership position in proteomics research designed to accelerate drug discovery and development. In oncology, FDA-approved products include ProstaScint(R) (a monoclonal antibody-based imaging agent used to image the extent and spread of prostate cancer); BrachySeed(TM) (a uniquely designed next-generation radioactive seed implant for the treatment of localized prostate cancer), Quadramet(R) (a therapeutic agent marketed for the relief of bone pain in prostate and other types of cancer), and OncoScint CR/OV(R) (a monoclonal antibody-based imaging agent for colorectal and ovarian cancer). Cytogen is evolving a pipeline of oncology product candidates by exploiting its prostate specific membrane antigen, or PSMA, technologies, which are exclusively licensed from Memorial Sloan-Kettering Cancer Center. In addition, Cytogen plans to use AxCell`s proteomics technology to research and develop novel drug targets independently or via collaborative ventures. For more information, visit www.cytogen.com. About AxCell Biosciences

AxCell Biosciences, a subsidiary of Cytogen Corporation, is a leader in the effort to chart protein signaling pathways in the human proteome as a means of discovering new drug targets. In conjunction with InforMax, AxCell is developing a proprietary protein pathway database, ProChart(TM), as a discovery and development tool for subscribers in the pharmaceutical, biotechnology and agricultural industries. AxCell is also seeking to develop alliances for the development of custom protein pathway information utilizing its proprietary Genetic Diversity Library(TM), Cloning of Ligand Targets(TM), and affinity screening technologies. For additional information on AxCell Biosciences, visit www.axcellbio.com.

This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Information in this press release, which is not historical, is forward looking and involves a number of risks and uncertainties. Investors are cautioned not to put any undue reliance on any forward-looking statement. The Company`s actual results may differ materially from the Company`s historical results of operations and those discussed in the forward-looking statements for various reasons, including, but not limited to the Company`s ability to carry out its business plan, to successfully develop and commercialize acceptance of its products such as ProChart(TM), ability to fund development necessary for existing products and for the pursuit of new product opportunities, the risk of whether products result from development activities, protection of its intellectual property portfolio, ability to integrate in-licensed products such as BrachySeed(TM), ability to establish and successfully complete clinical trials where required for product approval, the risk associated with obtaining the necessary regulatory approvals, shifts in the regulatory environment affecting sale of the Company`s products, dependence on its partners for development of certain projects, the ability to obtain foreign regulatory approvals for products and to establish marketing arrangements in countries where approval is obtained, and other factors discussed in Form 10-K for the year ended December 31, 2000 and from time-to-time in the Company`s other filings with the Securities and Exchange Commission. The Company specifically disclaims any intention or duty to update any forward-looking statements, and these statements represent the Company`s current outlook only as of the date given.


CYTOGEN CORPORATION AND SUBSIDIARIES
(All amounts in thousands except per share data)
(Unaudited)

CONDENSED CONSOLIDATED BALANCE SHEETS

JUNE 30, DECEMBER 31,
2001 2000
_________ _________
ASSETS
Cash, and Cash Equivalents $18,713 $11,993
Receivable on Income Tax Benefit Sold - 1,625
Accounts Receivable, net 2,211 1,841
Inventories 1,862 883
Property and Equipment, net 1,916 2,193
Other Assets 2,677 1,881
_________ _________

Total Assets $27,379 $20,416
========= =========

LIABILITIES & STOCKHOLDERS` EQUITY
Accounts Payable & Accrued Liabilities $5,809 $7,218
Other Current Liabilities 939 1,010
Long - Term Liabilities 4,504 4,970
Stockholders` Equity 16,127 7,218
_________ _________

Total Liabilities & Stockholders` Equity $27,379 $20,416
========= =========


CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

THREE MONTHS ENDED SIX MONTHS ENDED
JUNE 30, JUNE 30,
__________________ __________________

2001 2000 2001 2000
______ ______ ______ ______
Revenues
Product Sales $1,982 $1,622 $4,317 $3,494
Royalty Revenue 595 508 1,036 1,006
License and Contract 257 305 472 578
______ ______ ______ ______
Total Revenues 2,834 2,435 5,825 5,078


Operating Expenses 6,031 4,951 11,849 9,451
Interest Income, net (112) (143) (285) (254)
_____ ______ ______ ______

Loss before Cumulative
Effect of Accounting
Change (3,085) (2,373) (5,739) (4,119)
Cumulative Effect of
Accounting Change* - - - (4,314)
______ ______ ______ ______

Net Loss $(3,085) $(2,373) $(5,739) $(8,433)
======== ======== ======== =======
Net Loss Per Share:
Basic and Diluted Net
Loss before Cumulative
Effect of Accounting
Change $(0.04) $(0.03) $(0.07) $(0.06)
Cumulative Effect
of Accounting Change* - - - (0.06)
______ ______ ______ ______
Basic and Diluted
Net Loss $(0.04) $(0.03) $(0.07) $(0.12)
======== ======== ======== =======
Weighted Average
Common Shares
Outstanding 77,444 72,779 76,836 72,130
======== ======== ======== =======

*In 2000, the Company recorded a non-cash charge for the cumulative effect
related to the adoption of SEC Staff Accounting Bulletin No. 101.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X73382136



/CONTACT: Michael Becker, VP, investor relations & corporate communications of Cytogen, [phone]/

[Der Pharmer]

Und, seid ihr noch überzeugt von dem Wert ??

[MrBurns2001]

Ich habe immer noch einige Cytogen Aktien in meinem Depot und bin bei der derzeitigen Situation sogar am Überlegen,ob ich nicht nocheinmal aufstocke,was denkt Ihr über die Aktie???

[Wunram]

Zahlen
Cytogen Reports Third Quarter 2001 Results

BrachySeed Sales Advance 244% Over the Second Quarter 2001

Quadramet Royalty Revenue Advances 11% Over Prior Year`s Quarter

PRINCETON, N.J., Nov. 7 /PRNewswire/ -- Cytogen Corporation (Nasdaq: CYTO), a biopharmaceutical company with an established and growing product line in prostate cancer and proteomics research, today reported its consolidated financial results for the three and nine-month periods ended September 30, 2001.

The Company reported a net loss of $3.78 million or $0.05 per share for the third quarter of 2001, compared to a net loss of $16.45 million or $0.22 per share for the third quarter of 2000. The loss for the three months ended September 30, 2000 includes a one-time charge for marketing and technology rights to product candidates from Advanced Magnetics, Inc. of $13.24 million or $0.18 per share. For the nine months ended September 30, 2001, the Company reported a net loss of $9.52 million or $0.12 per share, compared to a net loss of $24.88 million or $0.34 per share for the same period in 2000. The loss for the nine months ended September 30, 2000 includes a one-time, non- cash charge related to the adoption of the SEC`s Staff Accounting Bulletin No. 101 ("SAB 101") of $4.31 million or $0.06 per share.

"Our third quarter performance reflects the continuation of our evolution into a biopharmaceutical company with multiple product opportunities," said H. Joseph Reiser, Ph.D., Cytogen`s president and chief executive officer. "The tragic events of September 11th were especially challenging for Cytogen, since our radiopharmaceutical products are largely elective procedures, require overnight air transportation, and may be subject to special shipping requirements. Despite the negative impact of these events, however, both BrachySeed and Quadramet(R) exhibited solid sales performances, which helped partially offset weakness in ProstaScint(R) during the quarter. We are at a critical and unique stage of implementing our business plans, both in oncology and proteomics. In this regard, we are successfully transitioning through major milestones in terms of new product introductions, transfer of manufacturing for ProstaScint and strengthening sales and marketing, which represent the growth foundation for Cytogen`s future." Product Sales

Marketed products sales, reflecting ProstaScint, BrachySeed I-125 (iodine version), and OncoScint(R), increased from $1.98 million in the third quarter of 2000 to $2.00 million in the third quarter of 2001.

ProstaScint sales in the third quarter of 2001 decreased 9% to $1.68 million from $1.85 million in the third quarter of 2000. Future growth in ProstaScint is expected to result from an expansion of the Company`s prostate cancer product franchise, increased marketing and sales initiatives by its in-house sales force, entry into additional markets and the exploration of new product applications, such as using ProstaScint scans to guide the placement of brachytherapy seeds and/or external beam radiation.

BrachySeed I-125 sales in the third quarter of 2001 increased 244% to $244,000 from $71,000 in the second quarter 2001. Since the market introduction of this product in the first half of 2001, an increased market penetration for the treatment of prostate cancer confined to the gland and our focused marketing message on the leading product attributes of BrachySeed has contributed to a positive sales trend and consistent quarter-over-quarter growth.

OncoScint sales in the third quarter of 2001 decreased 44% to $73,000 from $130,000 in the third quarter of 2000. As previously indicated, the market for OncoScint for colorectal cancer diagnosis has been negatively impacted by positron emission tomography, or PET, scans. Accordingly, Cytogen is emphasizing marketing of OncoScint for the recurrent ovarian cancer setting.

Building on the record royalty revenue achieved during the second quarter 2001, royalty revenue from the sale of Quadramet by Berlex Laboratories advanced from $523,000 in the third quarter of 2000 to $579,000 in the third quarter of 2001, representing an increase of 11%.

Combined revenue derived from the sale of these four products increased from $2.50 million in the third quarter of 2000 to $2.58 million in the third quarter of 2001. Total revenues, which include licensing and contract fees, increased from $2.73 million in the third quarter of 2000 to $2.80 million in the third quarter of 2001.

Product related revenues for the nine months ended September 30, 2001 were $7.93 million, compared to $7.00 million for the same period in 2000, representing an increase of 13%. Total revenues for the nine months ended September 30, 2001 were $8.63 million, compared to $7.81 million for the same period in 2000. Costs and Expenses

Ongoing operating expenses in the third quarter of 2001 increased 10% to $6.70 million compared to $6.10 million in the third quarter of 2000. For the nine months ended September 30, 2001, total ongoing operating expenses were $18.55 million, compared to $15.55 million for the same period in 2000. The increase in expenses was primarily due to research and development efforts to further AxCell`s proteomics program, the transfer of certain product manufacturing to DSM Biologics, and increased sales and marketing expenses.

Cytogen`s cash and cash equivalents as of September 30, 2001 were $14.55 million compared to $11.99 million as of December 31, 2000.

Effective January 1, 2000, Cytogen adopted SAB 101, which requires up- front, non-refundable license fees to be deferred and recognized over future periods. As a result of the adoption of SAB 101, certain up-front, non- refundable license fees recognized in prior periods have been deferred and are being recognized over the terms of the relevant agreements. In the first quarter of 2000, Cytogen recorded a one-time, non-cash charge of $4.31 million representing the cumulative effect of this accounting change. Previously reported results for the three and nine months ended September 30, 2000 have been restated to reflect the adoption of SAB 101.

Cytogen Business and Product Development Highlights
Third Quarter, 2001

Products
-- Launch of "Screen, Stage and Support" national prostate cancer
awareness campaign to promote prostate cancer education and
awareness. The campaign was launched during Prostate Cancer Month in
a special event at the Nasdaq Stock Market(SM)
-- Introduction of a new educational brochure outlining the vital role
that proper screening, staging and support can play for patients with
prostate cancer and the launch of a free patient video with important
information about the risk of recurrent disease following treatment

Pipeline
-- The completion of a worldwide exclusive licensing agreement between
our PSMA Development Company LLC and AlphaVax Human Vaccines, Inc. to
use the AlphaVax Replicon Vector(TM) system to create therapeutic
cancer vaccines incorporating prostate specific membrane antigen
(PSMA)

AxCell Biosciences
-- AxCell Biosciences and National Cancer Institute signed a Letter of
Intent to enter into a cooperative research and development agreement
to study two major signal transduction families, tyrosine kinases and
serine-threonine kinases, and how they impact signaling pathways
within cells
-- Expansion into additional 5,400 square foot laboratory space in
Newtown, PA completed

Corporate Activities
-- Cytogen participated in UBS Warburg`s Global Life Sciences Conference
in New York


"During the fourth quarter of 2001, we plan to introduce BrachySeed Pd-103 (palladium version), which represents our third new product introduction of the year. Both BrachySeed I-125 and BrachySeed Pd-103 are uniquely designed next-generation radioactive seed implants for the treatment of localized prostate cancer. While we are focused on sales and marketing initiatives, Cytogen continues to make progress in advancing its pipeline, such as the novel prostate cancer vaccine being developed through our PSMA Development Company LLC. Additionally, our AxCell Biosciences subsidiary continues to seek and develop a broad range of alliances for additional applications of its proprietary proteomics technologies, such as the recent Letter of Intent with the National Cancer Institute," Dr. Reiser concluded. About Cytogen Corporation

Cytogen Corporation of Princeton, NJ, is a biopharmaceutical company with an established and growing product line in prostate cancer and other areas of oncology, and a pioneer in proteomics research designed to accelerate drug discovery and development. In oncology, FDA-approved products include ProstaScint(R) (a monoclonal antibody-based imaging agent used to image the extent and spread of prostate cancer); BrachySeed(TM) (a uniquely designed next-generation radioactive seed implant for the treatment of localized prostate cancer), Quadramet(R) (a therapeutic agent marketed for the relief of bone pain in prostate and other types of cancer), and OncoScint CR/OV(R) (a monoclonal antibody-based imaging agent for colorectal and ovarian cancer). Cytogen is evolving a pipeline of oncology product candidates by exploiting its prostate specific membrane antigen, or PSMA, technologies, which are exclusively licensed from Memorial Sloan-Kettering Cancer Center. In addition, Cytogen plans to use AxCell`s proteomics technology to research and develop novel drug targets independently or via collaborative ventures. For more information, visit www.cytogen.com. About AxCell Biosciences

AxCell Biosciences, a subsidiary of Cytogen Corporation, is a pioneer in the effort to chart protein signaling pathways in the human proteome to accelerate the discovery of new drug targets and facilitate efficient pharmaceutical and biotechnology research and development. Through the systematic and industrialized application of proteomics, AxCell provides a growing portfolio of protein pathway solutions based on its proprietary Genetic Diversity Library(TM), Cloning of Ligand Targets(TM), and affinity screening technologies. In conjunction with InforMax, Inc., AxCell is developing a proprietary protein pathway database, called ProChart(TM), which is commercially available as a discovery and development tool for subscribers in the pharmaceutical, biotechnology and agricultural industries. AxCell is also seeking to develop alliances for the development of custom protein pathway information and intends to leverage its proteomic capabilities to identify novel drug targets for internal use. For additional information on AxCell Biosciences, visit www.axcellbio.com.

This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Information in this press release, which is not historical, is forward-looking and involves a number of risks and uncertainties. Investors are cautioned not to put any undue reliance on any forward-looking statement. The Company`s actual results may differ materially from the Company`s historical results of operations and those discussed in the forward-looking statements for various reasons, including, but not limited to the Company`s ability to carry out its business plan, to successfully develop and commercialize acceptance of its products such as ProChart(TM), ability to fund development necessary for existing products and for the pursuit of new product opportunities, the risk of whether products result from development activities, protection of its intellectual property portfolio, ability to integrate in-licensed products such as BrachySeed(TM), ability to establish and successfully complete clinical trials where required for product approval, the risk associated with obtaining the necessary regulatory approvals, shifts in the regulatory environment affecting sale of the Company`s products, dependence on its partners for development of certain projects, the ability to obtain foreign regulatory approvals for products and to establish marketing arrangements in countries where approval is obtained, and other factors discussed in Form 10-K for the year ended December 31, 2000 and from time-to-time in the Company`s other filings with the Securities and Exchange Commission. The Company specifically disclaims any intention or duty to update any forward-looking statements, and these statements represent the Company`s current outlook only as of the date given.


Cytogen Corporation and Subsidiaries
(All amounts in thousands except per share data)
(Unaudited)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

THREE MONTHS ENDED NINE MONTHS ENDED
SEPTEMBER 30, SEPTEMBER 30,
2001 2000 2001 2000

Revenues: --------- --------- --------- ---------
Product Sales $1,996 $1,979 $6,313 $5,473
Royalty Revenue 579 523 1,615 1,529
License and Contract 225 231 697 809
Total Revenues 2,800 2,733 8,625 7,811

Ongoing Operating Expenses:
Research and
Development 2,661 2,005 6,882 5,037
Selling and Marketing 1,489 1,242 4,820 3,695
Other Expenses* 2,547 2,852 6,844 6,817
Total Ongoing
Operating
Expenses 6,697 6,099 18,546 15,549

Acquisition of Marketing
and Technology Rights** 0 13,241 0 13,241
Interest Income, net (118) (158) (402) (412)
Loss Before Cumulative
Effect of Accounting
Change $(3,779) $(16,449) $(9,519) $(20,567)
Cumulative Effect
of Accounting
Change*** - - - (4,314)
Net Loss $(3,779) $(16,449) $(9,519) $(24,881)
========= ========= ========= =========
Net Loss Per Share:
Basic and Diluted
Net Loss before
Cumulative Effect
of Accounting
Change $(0.05) $(0.22) $(0.12) $(0.28)
Cumulative Effect
of Accounting
Change*** - - - (0.06)
Basic and Diluted
Net Loss $(0.05) $(0.22) $(0.12) $(0.34)
========= ========= ========= =========
Weighted Average
Common Shares
Outstanding 78,866 73,632 77,446 72,660

========= ========= ========= =========

* Other expenses include general and administrative and cost of goods
sold.
** In August 2000, the Company licensed marketing and technology rights
to product candidates from Advanced Magnetics, Inc.
*** In 2000, the Company recorded a non-cash charge for the cumulative
effect related to the adoption of SEC Staff Accounting Bulletin No.
101.


CONDENSED CONSOLIDATED BALANCE SHEETS
SEPTEMBER 30, DECEMBER 31,
2001 2000
Assets ------------ ------------
Cash and Cash Equivalents $14,548 $11,993
Receivable on Income Tax Benefit Sold - 1,625
Accounts Receivable, net 2,198 1,841
Inventories 1,712 883
Property and Equipment, net 1,794 2,193
Other Assets 2,430 1,881
Total Assets $22,682 $20,416
============ ============
Liabilities & Stockholders` Equity
Accounts Payable & Accrued Liabilities $4,890 $7,218
Other Current Liabilities 774 1,010
Long-Term Liabilities 4,461 4,970
Stockholders` Equity 12,557 7,218
Total Liabilities & Stockholders`
Equity $22,682 $20,416
============ ============

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X24865389



/CONTACT: Investor Relations: Michael Becker, VP, Investor Relations Officer of Cytogen, [phone]/

[Erlenzeisig]

Kann mir jemand sagen, warum der Kurs der Aktie immer tiefer
in den Keller geht? Droht da bald der Totalverlust?

[Wunram]

mal wieder wirklich was neues


Cytogen Receives Regulatory Approval In Canada for ProstaScint(R) Prostate Cancer Imaging Agent


ProstaScint(R) diagnostic scan, which helps to determine the extent and location of prostate cancer, is approved with an expanded label to help identify patients likely to benefit from salvage therapy.

PRINCETON, N.J., Mar 18, 2002 (Canada NewsWire via COMTEX) -- Cytogen Corporation (Nasdaq: CYTO) announced today that Health Canada has issued a "Notice of Compliance" for ProstaScint(R), the company`s radio-labeled monoclonal antibody prostate cancer imaging agent. In both Canada and the United States, ProstaScint is indicated for use in patients newly diagnosed with prostate cancer who are at high risk for lymph node metastases and for patients with recurrent prostate cancer following a radical prostatectomy who are suspected of having occult metastatic disease. In Canada, ProstaScint is also indicated for use in identifying those patients with recurrent prostate cancer who are likely to benefit from receiving local salvage radiation therapy.
"We are very pleased that ProstaScint will be available in Canada," said H. Joseph Reiser, Ph.D., president and chief executive officer of Cytogen Corporation. "The expanded product label further validates the value of the information obtained from ProstaScint imaging in helping physicians and prostate cancer patients make more appropriate and informed treatment decisions," added Dr. Reiser.

Following a radical prostatectomy (a procedure in which the entire prostate gland and some surrounding tissue is surgically removed) for the treatment of primary prostate cancer, a rising level of prostate specific antigen (PSA) in the blood is an indication that the disease has recurred. Studies in patients with this stage of disease have shown that those having a ProstaScint scan that is positive for disease only in the pelvic region are more likely to benefit from salvage radiation therapy than are patients in whom the ProstaScint scan indicates the presence of disease beyond the pelvis.

ProstaScint(R) (Capromab Pendetide), developed and marketed by Cytogen Corporation, is a radiolabeled monoclonal antibody that specifically targets PSMA (prostate specific membrane antigen), a highly expressed marker found on prostate cancer cells. During a ProstaScint imaging procedure, the radiolabeled monoclonal antibody is administered intravenously to the patient, traveling through the bloodstream and binding to prostate cancer cells. A gamma camera is then used to detect the radioactive isotope that has been attached to the antibody, identifying the specific sites of cancer. ProstaScint has been marketed in the U.S. since 1997.

In 1998, Cytogen received approval from Health Canada to market Quadramet(R), a radiopharmaceutical agent marketed for the relief of bone pain in prostate and other types of cancer in patients with multiple osteoblastic skeletal metastases confirmed by positive radionuclide bone scan. With the recent approval of ProstaScint in Canada, Cytogen expects to initiate a multi- phased marketing and medical education campaign to support the launch of these two products in Canada, alone or with a partner.

Prostate cancer is the most frequently diagnosed cancer in Canadian men. The Canadian Cancer Society estimates that approximately 17,800 new cases of prostate cancer will be diagnosed this year, and that 4,300 men will die of the disease. About one in every nine Canadian men will develop prostate cancer during his lifetime.

About Cytogen Corporation

Cytogen Corporation of Princeton, NJ, is a biopharmaceutical company with an established and growing product line in prostate cancer and other areas of oncology. FDA-approved products include ProstaScint(R) (a monoclonal antibody-based imaging agent used to image the extent and spread of prostate cancer); BrachySeed(TM) I-125 and Pd-103 (uniquely designed, next-generation radioactive seed implants for the treatment of localized prostate cancer); and Quadramet(R) (a therapeutic agent marketed for the relief of bone pain in prostate and other types of cancer). Cytogen is evolving a pipeline of oncology product candidates by developing its prostate specific membrane antigen, or PSMA, technologies, which are exclusively licensed from Memorial Sloan-Kettering Cancer Center. For more information, visit www.cytogen.com.

About AxCell Biosciences

AxCell Biosciences of Newtown, PA, a subsidiary of Cytogen Corporation, is engaged in the research and development of novel biopharmaceutical products using its growing portfolio of functional proteomics solutions and collection of proprietary signal transduction pathway information. Through the systematic and industrialized measurement of protein-to-protein interactions, AxCell is assembling ProChart(TM), a proprietary database of signal transduction pathway information that is relevant in a number of therapeutically important classes of molecules including growth factors, receptors and other potential protein therapeutics or drug targets. AxCell`s database content and functional proteomics tools are available on a non- exclusive basis to biotechnology, pharmaceutical and academic researchers. AxCell is expanding and accelerating its research activities to further elucidate the role of novel proteins and pathways in ProChart(TM), through both external collaborations and internal data mining. For additional information on AxCell Biosciences, visit www.axcellbio.com.

This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Information in this press release, which is not historical, is forward-looking and involves a number of risks and uncertainties. Investors are cautioned not to put any undue reliance on any forward-looking statement. The Company`s actual results may differ materially from the Company`s historical results of operations and those discussed in the forward-looking statements for various reasons, including, but not limited to the Company`s ability to carry out its business plan, to successfully develop and commercialize acceptance of its products such as ProChart(TM), ability to fund development necessary for existing products and for the pursuit of new product opportunities, the risk of whether products result from development activities, protection of its intellectual property portfolio, ability to integrate in-licensed products such as BrachySeed(TM), ability to establish and successfully complete clinical trials where required for product approval, the risk associated with obtaining the necessary regulatory approvals, shifts in the regulatory environment affecting sale of the Company`s products such as third-party payor reimbursement issues, dependence on its partners for development of certain projects, the ability to obtain foreign regulatory approvals for products and to establish marketing arrangements in countries where approval is obtained, and other factors discussed in Form 10-K for the year ended December 31, 2000 and from time-to-time in the Company`s other filings with the Securities and Exchange Commission. The Company specifically disclaims any intention or duty to update any forward-looking statements, and these statements represent the Company`s current outlook only as of the date given.

/Web site: http://www.axcellbio.com /

/Web site: http://www.cytogen.com/

VIEW ADDITIONAL COMPANY-SPECIFIC INFORMATION: http://www.newswire.ca/cgi-bin/inquiry.cgi?OKEY=20041



CONTACT: For further information: Media: Jim Wetmore of Berry & Co. Public
Relations, [phone], jwetmore(at)berrypr.com; or Investor Relations:
Mary Coleman of Cytogen Corporation, [phone],
mcoleman(at)cytogen.com

[Dummschwaezer]

Würde gerne wissen wer ausser mir noch Investiert ist?
Gruss DS

[Wunram]

@DS

na ich

Wunram

[Dummschwaezer]

@wunram, @und alle verbliebenen CYTO`s
Ich beobachte CYTO schon eine ganze weile! Nachdem ich bei ca.5$ letztes Jahr aussteigen musste, bin ich jetzt wieder drin. Ein 52 Wochen Tief, hat sie aber mit Sicherheit nicht verdient. CYTO wird, so denke ich bis Ende nächsten Jahres zu den wenigen BioTech Unternehmen zählen die Gewinne erwirtschaften. Und dies trotz einer Tochter, die im Moment noch eine menge Geld kostet. Na ja, Forschung und Marktführerschaft gibt’s nun mal nicht umsonst. Die Wachstumsraten sind außerdem demografisch garantiert. Ich sehe bis auf das Börsenumfeld keine negativen Faktoren. Ach ja, die Klage von IMMU stört mit Sicherlich einige. Was kann da im schlimmsten Fall passieren? PS. Würde ich auch gerne wissen! Eure Meinigen, bitte. Gruss DS

[Dummschwaezer]

Good News, meine Freunde!!!
Posting#57 nimmt bei CYTO anscheinend Formen an.
Quadramet, scheint positiv auf die Behandlung von
Brustkrebspatientinnen bei Knochenmetastase zu wirken.
Gruss DS

[Dummschwaezer]

Cytogen Reports 29 Percent Increase in Marketed Product Sales for Second Quarter 2002
Marketed Product Sales Achieve a New Quarterly Record
Company Reaffirms Previous Revenue Guidance of $12.5 Million to $14.5 Million For 2002

Die guten Ergebnisse scheinen im Moment niemanden zu interessieren.
Aber eines sollte jeder bedenken.
Lange kann sich CYTO ein Kurs an der NASDAQ unter <1$ nicht leisten.
Außerdem sind sie, ein günstiger Übernahmekandidat für Firmen, wie z.B. Schering,
die sich billig die Marktführerschaft, inkl. der vier Produkte (Habe Combidex bereits
hinzu gezählt!) einverleiben könnten. Ich bin guten Mutes, gerade und erst recht mit AxCell, und nicht so pessimistisch wie einige vom YahooBoard Gruss..DS

[Wunram]

news

delisting droht in ferner zukunft:

Cytogen Receives Notification By Nasdaq Regarding Marketplace Rule 4450(a)(5)

PRINCETON, NJ, Aug 14, 2002 (INTERNET WIRE via COMTEX) -- Cytogen Corporation (Nasdaq: CYTO), a biopharmaceutical company with an established and growing product line in oncology, today announced that it has been notified by The Nasdaq Stock Market, Inc. that the Company`s common stock has closed for more than 30 consecutive trading days below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq National Market.
In accordance with Nasdaq rules, the Company has been afforded 90 calendar days, or until November 12, 2002, to regain compliance with the minimum bid price requirements. If, at anytime before November 12, 2002, the bid price of the Company`s common stock closes at $1.00 per share or more for a minimum of 10 consecutive trading days, The Nasdaq Stock Market, Inc. staff will provide written notification that the Company complies with Marketplace Rule 4450(a)(5). If the Company cannot demonstrate compliance by that date, the Company`s common stock is subject to being delisted from the Nasdaq National Market pending other options the company may enact at that time.

"Management will consider all available options in order to regain full compliance with the Nasdaq listing requirements," said H. Joseph Reiser, Ph.D., Cytogen`s president and chief executive officer.

About Cytogen Corporation

.....

@Dummschwaezer

wie ist deine Einschätzung dazu??

cashburning ist kleiner geworden, auf 6-monatsbasis Umsatz um 10% gestiegen Verluste um 42% ausgeweitet.

wie gehts weiter???

Gruss wunram

[Dummschwaezer]

Hallo Wunram,ich habe keine Ahnung wie`s weiter gehen soll. Werde mich heute Nacht, bei unseren Koleggen vom Yahoo Board ein wenig Informieren. Melde mich in kürze! Gruss..DS

[Wunram]

@DS

im RB hab ich folgendes gefunden - aber sonst nirgends ein Hinweis auf ein neues Patent:

--------------------------------------------------------
By: NeoCyClone
13 Aug 2002, 10:33 PM EDT Msg. 7183 of 7189

NEW patent to CYTO today...

I cannot post on Yahoo. My pc is messed. I see that Cyto did not announce this good event.

The patent pertains to the SH3 peptides...

dano
--------------------------------------------------------
Gruss Wunram

[Dummschwaezer]

@Wunram
Schau doch mal unter Msg. 174343 und 174380 im Yahoo Board!
Mein erster Eindruck, hier verkaufen einige die auf Pump Fett im Geschäft waren und sich kurzfristig höhere Kurse erhoft haben. Auf die schnelle sehe ich nicht`s, was ein derartigen Kurseinbruch rechtfertigen könnte. Gruss..DS

[Wunram]

@DS

danke - sehr interessant;
normalerweise lese ich nicht bei yahoo (Affenstall ) bei cyto sind aber offensichtlich ein paar "Wissende" zwischendrin vorhanden. Zumindest klingt es so; man kann sich schliesslich nicht in jede Materie voll hineinknien.

N8
Wunram

[Dummschwaezer]

Umsatz gesteigert! Gewinn erhöht! Ausgaben ausgeweitet! Ja, schön aber warum
sind die Ausgaben übermäßig angestiegen? Liegt doch auf der Hand, die Entwicklungs-
kosten am PSMA- Projekt mit Progenix an der man zu 50% beteiligt ist, erfordern
mehr Kapital als CYTO wahrscheinlich hierfür hat. Combidex kurz vor der FDA
Zulassung. Code 7228 „Phase I/II“ und eigene PSMA Projekte strapazieren die Ausgaben. Und zu allem Überfluss
Frist das eigene Kind „AxCell“ die Barreserven auf um seine Vormachtstellung zu
behaupten und auszubauen. Und es ist wichtig zu Investieren den ein richtiger
„Block Buster“ fehlt in der CYTO Familie, oder? Wie wir sehen alles schlechte Nachrichten.
Und schon Interessiert es niemanden, dass hier eigentlich in die Zukunft Investiert wird
und das man trotz der hohen Belastungen Ende 2003 den „Break Even“ mit den eigene
zurzeit vorhanden Produkten erreichen kann. Soviel ich weis, werden die Präparate z.Z. lediglich in den USA und in Kanada vermarktet. Mehr sag ich hierzu nicht, möge sich
jeder selbst Gedanken machen. Zwar quälen mich auch noch andere Fragen, aber vorerst genug von mir. Bis die Tage! Gruss..DS

[Dummschwaezer]

@Wunram
Die Jung`s vom YahooBoard sind nicht so schlecht wie ihr Ruf!
Der Inhalt zu CYTO, in nachfolgender URL entspricht im großem und ganzem auch meiner Ansicht.
Gruss..DS
http://www.prohostonline.com/ImpactingNews/News%20of%209%201…

[Wunram]

@alle

viele behaupten ja ein reverse stock split ist der Anfang vom Ende...

Cytogen to Hold Special Meeting of Stockholders to Approve a Reverse Stock Split
26 Sep 2002, 08:02am ET
/FROM PR NEWSWIRE NEW YORK 800-776-8090/
[STK] CYTO
[IN] FIN MTC
[SU]
TO BUSINESS AND MEDICAL EDITORS:

Cytogen to Hold Special Meeting of Stockholders to Approve a Reverse Stock Split

PRINCETON, N.J., Sept. 26 /PRNewswire-FirstCall/ -- The Board of Directors of Cytogen Corporation (NASDAQ:CYTO) today unanimously approved and recommended to stockholders a proposal that would give the Board of Directors
authority to effect a reverse stock split of Cytogen`s common stock. A special meeting of Cytogen`s stockholders will be held on October 25, 2002 to consider the following proposals:

* An amendment to the Company`s Restated Certificate of Incorporation, as
amended, to effect a reverse stock split of the Company`s Common Stock,
$.01 par value per share (the "Common Stock"), and to grant the
Company`s Board of Directors the authority, in its sole discretion, to
(i) set the ratio for the reverse stock split at up to one-for-ten, or
(ii) not to complete the reverse stock split; and

* An amendment to the Company`s Restated Certificate of Incorporation, as
amended, to decrease the number of authorized shares of Common Stock
from 250,000,000 shares to a reduced number of shares that is
proportionate to the reduction in outstanding shares of common stock as
a result of the reverse stock split.

Stockholders of record on August 27, 2002 will be entitled to vote at this special meeting. The affirmative vote of a majority of shares of common stock will permit the Cytogen Board of Directors to effect a reverse stock split at a ratio of up to one-for-ten at any time prior to December 31, 2002.
Cytogen believes the ability to effect a reverse stock split is in the best interests of the Company and its stockholders and will help increase the market price of its common stock above the minimum bid requirement of $1.00
per share required by The Nasdaq Stock Market, Inc. ("Nasdaq"). Cytogen`s common stock is currently quoted on the Nasdaq National Market. In order for Cytogen`s common stock to continue to be quoted thereon, the Company is
required to continue to comply with various listing maintenance standards established by Nasdaq.
"Nasdaq requires the Company to maintain, among other things, a minimum share price and the reverse stock split is intended to help us meet this requirement," said H. Joseph Reiser, Cytogen`s president and chief executive
officer.
If Cytogen`s common stock is not listed on the Nasdaq National Market and the trading price of its common stock were to remain below $1.00 per share,trading in Cytogen`s common stock could also be subject to the requirements of
certain rules promulgated under the Securities Exchange Act of 1934, as amended, which require additional disclosures by broker-dealers in connection with any trades involving a stock defined as a "penny stock" (generally, a non-Nasdaq equity security that has a market price of less than $5.00 per share, subject to certain exceptions). In such event, the additional burdens imposed upon broker-dealers to effect transactions in Cytogen`s common stock could inhibit brokers from trading in its common stock and further limit the market liquidity of its common stock and the ability of our investors to trade in our common stock.
Cytogen further believes that the reverse stock split and anticipated increase in the price of its common stock should also enhance the acceptability and marketability of its common stock to the financial community and investing public, while a delisting could greatly impair the Company`s
ability to access the capital markets. Many institutional investors have policies prohibiting them from holding lower-priced stocks in their portfolios, which reduces the number of potential buyers of Cytogen`s common stock. Additionally, analysts at many brokerage firms are reluctant to recommend lower-priced stocks to their clients or monitor the activity of lower-priced stocks. Brokerage houses also frequently have internal practices and policies that discourage individual brokers from dealing in lower-priced stocks. Further, because brokers` commissions on lower-priced stock generally represent a higher percentage of the stock price than commissions on higher priced stock, investors in lower-priced stocks pay transaction costs which are a higher percentage of their total share value, which may limit the willingness of individual investors and institutions to purchase its common stock.
As of August 27, 2002, Cytogen had approximately 87.1 million shares of common stock outstanding.

Additional Information and Where to Find It
Cytogen intends to file a preliminary proxy statement regarding the reverse stock split proposals with the Securities and Exchange Commission, and it intends to mail a definitive proxy statement to its stockholders regarding
the proposals. Investors and stockholders of Cytogen are urged to read the definitive proxy statement when it becomes available because it will contain important information about Cytogen and the reverse stock split proposals.
Investors and stockholders may obtain a free copy of the definitive proxy statement (when it is available) and all of Cytogen`s annual, quarterly and special reports at the SEC`s web site at http://www.sec.gov. A free copy of
the definitive proxy statement and all of Cytogen`s annual, quarterly and special reports may also be obtained from Cytogen by directing a request to Investor Relations at [phone]. Cytogen and its executive officers and
directors may be deemed to be participants in the solicitation of proxies from Cytogen`s stockholders in favor of the reverse stock split proposals.
Information regarding the security ownership and other interests of Cytogen`s executive officers and directors will be included in the definitive proxy statement.

About Cytogen Corporation
...

For more information, visit http://www.cytogen.com and
http://www.axcellbio.com.

This press release contains certain "forward-looking" statements .....


SOURCE Cytogen Corporation
-0- 09/26/2002
/CONTACT: Michael Becker of Cytogen Corporation, [phone],
[e-mail] /
/Web site: http://www.cytogen.com
http://www.axcellbio.com /

die Begründungen sind echt witzig; für mich bedeutet es, dass Cyto keine Möglichkeit sieht bis zum 12. November den Kurs für 10 aufeinanderfolgende Tage über 1$ zu bringen!

Gruss Wunram

[Wunram]

da ist auch schon das "Preliminary Proxy Statement"

http://www.edgar-online.com/bin/cobrand/finSys_main.asp?form…

Wunram

[Wunram]

mit 13 Mio Aktien größter Anteilseigner ist das State of Wisconsin Investment Board wohl einverstanden mit den Plänen von Cytogen - es geht ja wohl um einiges in der Pensionskasse

State of Wisconsin Investment Board Supports Cytogen`s Announcement Regarding a Reverse Stock Split

PRINCETON, N.J., Sept. 26 /PRNewswire-FirstCall/ --
Cytogen Corporation (NASDAQ:CYTO), a biopharmaceutical company with an established and growing product line in prostate cancer and other areas of oncology, today announced that the State of Wisconsin Investment Board,
Cytogen`s largest institutional investor that holds approximately 15% of Cytogen`s outstanding shares of common stock, supports the Company`s announcement regarding a reverse stock split and has verbally agreed to vote
in favor of the announced proposals.

"At this point in time, we believe that a reverse stock split represents the most attractive solution for Cytogen to maintain its listing on the Nasdaq National Market," said John Nelson, Investment Director for the State of
Wisconsin Investment Board.

The State of Wisconsin Investment Board manages investments of over $60 billion on behalf of 450,000 government employees and retirees.

Additional Information and Where to Find It
.....
About Cytogen Corporation
.......


For more information, visit www.cytogen.com and
www.axcellbio.com.

This press release contains certain "forward-looking" statements .....

SOURCE Cytogen Corporation
-0- 09/26/2002
/CONTACT: Michael Becker of Cytogen Corporation, [phone],
[e-mail]/
/Web site: http://www.cytogen.com/

[Dummschwaezer]

Hallo Wunram,
warum im Minus heute! Die Nachrichten sind doch gut, oder?
Ein Aktienrückkauf hat doch noch nie geschadet.
Der Verbleib an der NASDAQ ist vorerst auch gesichert.
Fundamental hat sich doch nichts geändert, dis auf die Tatsache das die Aktie in diesen Marktsegment für`n Appel un Ei zu kriegen ist. Gruß..DS

[Wunram]

@Dummschwaezer

nix Rückkauf - reverse split: aus deinen, sgen wir mal 10.000 Cyto werden 1000!

Wie schin gesagt,mich bedeutet es, dass Cyto keine Möglichkeit sieht bis zum 12. November den Kurs für 10 aufeinanderfolgende Tage über 1$ zu bringen! Und dann ist deadline - vgl. #73

Gruss Wunram

[Wunram]

nachtrag:

kaufe ein a
tausche i gegen o
kaufe ein für


Wunram

[Dummschwaezer]

Sorry Wunram, hätte mal besser übersetzen sollen!
Ja nun und wo ist bitte schön das Problem?
Ob Delisting oder Reserve Split, mir ist es sch... egal ob CYTO an der NASDAQ oder am OTC-BB gehandelt wird!
Was hat sich Fundamental geändert? Sind die Aussichten zukünftiger Projekte schlechter geworden? Hätte Cyto durch ein Delisting oder ein Reserve Split weniger Cash im Säckel bzw. finazielle einbussen?

[Wunram]

news

National Cancer Institute to Study use of Advanced Magnetics` MRI Contrast Agents, Combidex(R) and Code 7228, in Detection of Metastatic Lymph Node Disease

30 Sep 2002, 1:42pm ET

/FROM PR NEWSWIRE BOSTON 617-482-5355/
[STK] AVM CYTO
[IN] MTC
[SU]
TO BUSINESS AND MEDICAL EDITORS:

National Cancer Institute to Study use of Advanced Magnetics` MRI Contrast Agents, Combidex(R) and Code 7228, in Detection of Metastatic Lymph Node Disease

CAMBRIDGE, Mass., and PRINCETON, N.J., Sept. 30 /PRNewswire-FirstCall/ --

Advanced Magnetics, Inc. (AMEX:AVM) and Cytogen Corporation (NASDAQ:CYTO) announced today that Advanced Magnetics has entered into two clinical trial agreements with the Biomedical Imaging Program (BIP) of the National Cancer
Institute to study the use of Combidex(R) and Code 7228 Magnetic Resonance Imaging (MRI) contrast agents in the detection of metastatic disease in lymph nodes. Combidex and Code 7228 modify the MR signal of normal lymph nodes while those of metastatic nodes remains unchanged. The BIP will sponsor these clinical trials in cooperation with Advanced Magnetics.
"We are very excited by the Biomedical Imaging Program`s interest in both Combidex and Code 7228," stated Jerome Goldstein, Chairman and CEO of Advanced Magnetics. "We believe that both of these imaging agents can play an
important role in the staging of metastatic disease, especially through accurate assessment of lymph node status. We look forward to working with the BIP in helping to improve the manner in which cancer is diagnosed in medical practice today."
Combidex, the lead product in Advanced Magnetics` development pipeline, received an approvable letter, subject to certain conditions, from the U.S. Food and Drug Administration in June 2000 for use in lymph node imaging. Code 7228 is in Phase II clinical studies for use in Magnetic Resonance Angiography and for use in iron replacement therapy. Cytogen Corporation has exclusive
U.S. rights to Combidex and Code 7228 for the detection of lymph node metastases and oncology applications.
"We are very pleased that the National Cancer Institute has decided to study the use of Combidex and Code 7228 in detecting metastatic lymph node disease," said H. Joseph Reiser, Ph.D., president and CEO of Cytogen Corporation. "Before Combidex and Code 7228, there were no MRI contrast agents available to help distinguish malignant from normal lymph nodes. Such a determination is key to allowing cancer patients and their physicians to make
more appropriate treatment decisions."
The signing of these clinical trial agreements by the Biomedical Imaging Program of the National Cancer Institute does not claim, infer or imply an endorsement or recommendation of the products by the NCI or the Department of Health and Human Services.

Advanced Magnetics, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutic iron compounds for treating anemia as well as novel imaging agents to aid in the diagnosis of cancer and
cardiovascular disease. For more information, please visit the Company`s web site at www.advancedmagnetics.com.

Cytogen Corporation of Princeton, NJ, is a biopharmaceutical company with an established and growing product line in prostate cancer and other areas of
oncology. AxCell Biosciences of Newtown, PA, a subsidiary of Cytogen Corporation, is engaged in the research and development of novel biopharmaceutical products using its portfolio of functional proteomics solutions and collection of proprietary signal transduction pathway information. For more information, visit www.cytogen.com and www.axcellbio.com.

For Advanced Magnetics:
This document contains forward-looking statements.....

For Cytogen Corporation:
This press release contains certain "forward-looking" ....

Advanced Magnetics Contacts:
Paula Jacobs, VP - Development
or Lisa Gordon, Investor Relations
Advanced Magnetics, Inc.
[phone]

Cytogen Contact:
Jim Wetmore
Berry & Co. Public Relations
[phone]
[e-mail]


SOURCE Advanced Magnetics, Inc.
-0- 09/30/2002
/CONTACT: Paula Jacobs, VP of Development, or Lisa Gordon, Investor
Relations of Advanced Magnetics, Inc., [phone] or Jim Wetmore of Berry
& Co. Public Relations for Cytogen, [phone], [e-mail]/
/Web site: http://www.advancedmagnetics.com/

@DS

was die finanzierung angeht ändert sich schon was: "....while a delisting could greatly impair the Company`s
ability to access the capital markets. Many institutional investors have policies prohibiting them from holding lower-priced stocks in their portfolios, which reduces the number of potential buyers of Cytogen`s common stock...."

Aber CYTO ist ja weiter aktiv wie man sieht

Gruss Wunram

[Dummschwaezer]

Es wird in kürze ein 10:1 Reserve Split geben!

[Wunram]

na ja ist ja trotz reverse split ganz schön abgegangen. Der Vollständigkeithalber meldet CYTO, dass sie jetzt die 1$ Anforderung der Nasdaq wieder erfüllen

Cytogen Announces Compliance With Nasdaq Listing Requirements
12 Nov 2002, 08:45am ET

PRINCETON, N.J., Nov. 12 /PRNewswire-FirstCall/ --
Cytogen Corporation (NASDAQ:CYTOD), a product-driven, oncology-focused biopharmaceutical company, today announced that the Nasdaq Stock Market, Inc. notified the Company that it had regained compliance with the Nasdaq National
Market`s listing standard regarding minimum bid price.
"As anticipated, following last month`s stockholder-approved reverse stock split, Cytogen has regained compliance with Nasdaq listing standards," said H.
Joseph Reiser, Ph.D., Cytogen`s president and chief executive officer. "We believe that continued listing on the Nasdaq National Market clearly benefits our stockholders."
In August 2002, Cytogen was notified that it was not in compliance with the Nasdaq National Market`s listing standard regarding minimum bid price. In accordance with that requirement, Cytogen had 90 days to regain compliance by having its stock close at a trading price above $1 for ten consecutive days.
In late October 2002, Cytogen`s board of directors approved a 1-for-10 reverse stock split of its outstanding shares. This action followed a vote held on October 25, 2002 at a special meeting of the Company`s stockholders, at which more than 87% of stockholders eligible to vote at the special meeting authorized the board of directors to effect a reverse stock split. Cytogen`s shares began trading on a post-split basis at market opening on October 28, 2002.

About Cytogen Corporation
.....
For more information, please visit the Company`s website at www.cytogen.com.

This press release contains certain "forward-looking" statements .....

http://tbutton.prnewswire.com/prn/11690X67066107

SOURCE Cytogen Corporation
-0- 11/12/2002
/CONTACT: Michael Becker, Vice President, Business Development & Industry
Relations of Cytogen Corporation, [phone]/
/Web site: http://www.cytogen.com /